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ABSTRACT 
 
Glioblastoma multiforme is the most frequently occurring primary brain tumour and it carries a 
dismal prognosis. Despite surgical intervention and aggressive chemo-radiotherapy the median 
survival of patients is just under 15 months. Very little progress has been made with regards to 
improving patient survival therefore novel therapeutic interventions are required. 
Vaccination offers an attractive option for the therapeutic treatment of GBM, with activated T-cells 
previously being shown to access tumours located within the brain resulting in improved survival 
in pre-clinical murine models of GBM. Several vaccine platforms have been developed and tested 
in GBM patients, however many of these therapies fail during clinical trials and as of 2019 no 
immunotherapeutic treatments have been approved for use in the GBM setting. One major 
obstacle to overcome when using the immune system to treat GBMs is the highly 
immunosuppressive phenotype these cancers have. GBMs frequently express immunosuppressive 
checkpoints that prevent anti-tumour T-cell activity. Immune checkpoint blockade has recently 
gained approval for the treatment of malignant melanoma, lung cancer, head and neck cancer, 
lymphoma, bladder cancer and kidney cancer. The utilisation of immune checkpoint blockade as a 
monotherapy improves survival in small subsets of patients however it is not a completely curative 
treatment modality. Therefore it is of great interest to see if combining immune checkpoint 
blockade with vaccine therapy can boost anti-tumour immunity by stimulating T-cells and 
preventing the inhibitory signals from tumour cells that prevent T-cell killing. 
Examination of GBM tumour tissues and cell lines revealed that a large proportion of GBMs express 
the immunogenic antigens Tyrosinase-related protein-2 (TRP-2) and Wilms’ tumour 1 (WT-1). It was 
also revealed that these tumours expressed several immunosuppressive proteins with PD-L1, HLA-
E and HLA-G expression being observed in tissues and cell lines studied. It was also revealed that 
when GBM cell lines were treated with the immune stimulating cytokine IFNγ they up-regulated 
the immunosuppressive proteins PD-L1 and IDO. 
The ImmunoBody® DNA plasmid vaccination encodes an IgG antibody molecule that acts as a carrier 
protein for the peptide targets of interest, these peptides are engrafted into the complementarity 
determining regions of the antibody. This method of vaccination generates a strong-immune 
response via direct and cross-presentation. Pre-clinical testing using the humanised HHDII/DR1 
C57BL/6 mouse model revealed that a HLA-A2 specific TRP-2 and a HLA-A2 specific WT-1 directed 
ImmunoBody® vaccine generated a strong peptide specific immune response. When both 
vaccinations were given simultaneously this strong TRP-2 and WT-1 directed immune response was 
3 
 
equivalent to when each vaccine was given alone meaning that epitope dominance is not a factor 
when targeting these two antigens.  
Using the HHDII/DR1 humanised mouse the effects of this dual ImmunoBody® vaccination regime 
was tested both prophylactically and therapeutically. In these proof of concept experiments the 
B16 HHDII/DR1 Luc2 cell line was utilised. This cell line expresses both TRP-2 and WT-1 antigens 
and it has the chimeric HLA-A2 HHDII/DR1 MHC molecule meaning it presents HLA-A2 specific 
peptides. When the dual ImmunoBody® vaccination regime was used prophylactically it 
significantly improved the survival of mice intracranially implanted with B16 HHDII/DR1 Luc2 cells 
compared to sham vaccinated mice. In the therapeutic setting the addition of an anti-PD-1 blocking 
antibody to the dual vaccination regime improved survival of B16 HHDII/DR1 Luc1 tumour bearing 
mice when compared to dual vaccinated mice receiving PD-1 isotype control antibody and control 
sham vaccinated mice that received PD-1 isotype antibody. Analysis of tumour infiltrating 
lymphocyte populations revealed that dual vaccination increases CD8+ T-cell infiltrate into these 
intracranial tumours with these cells showing increased cell surface expression of the activation 
markers CD25 and CD69. 
The dipeptide carnosine was also used to treat GBM cells in vitro, this molecule has previously been 
shown to have anti-tumour activity. When carnosine was used to treat GBM cells it led to reduced 
mitochondrial metabolism and migration of these cells. These properties make carnosine an 
attractive adjunct to immunotherapy. 
Overall these results provide promise for the use of ImmunoBody® vaccination with immune 
checkpoint blockade for the treatment of GBM. Whilst immune cells can actively access tumours 
systemically administered checkpoint antibodies don't cross the blood-brain-barrier freely, 
therefore in order for these therapies to be further developed methods for improving brain 
penetrance of checkpoint inhibitors needs to be explored. 
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CHAPTER 1: INTRODUCTION 
1.1. Cancer 
Cancer is characterised by several hallmarks; these are the sustaining of proliferative signalling, 
evasion of growth suppression, resistance of cell death which enables replicative immortality, 
induction of angiogenesis and activation of invasion and metastasis. There are also several other 
hallmarks that have been identified as being indicative of cancer these are: genome instability and 
mutation, tumour promoting inflammation, reprogramming of energy metabolism and evasion of 
immune destruction (Hanahan, Weinberg 2011). This uncontrolled cellular growth can be 
problematic, especially if these cells are expanding in a major organ such as the brain. 
 
1.2. Glioblastoma multiforme 
Glioblastoma multiforme (GBM, WHO grade 4) is the most commonly occurring malignant central 
nervous system tumour accounting for 47.1 % of all malignant CNS tumours. It is more common in 
older adults, with incidence increasing with age. Glioblastoma was found to be 1.58 times more 
common in men than women. Only around 5 % of patients survive five years post diagnosis (Ostrom, 
Gittleman et al. 2017). Glioblastoma multiforme are mainly primary and occur de novo however 
secondary glioblastoma multiforme can also arise from lower grade gliomas (Bleeker, Molenaar et 
al. 2012). Glioblastoma histopathology reveals GBM tumours are highly cellular comprised of poorly 
differentiated and pleomorphic astrocytic cells with nuclear atypia and high mitotic activity. 
Vascular proliferation is also evident, and necrosis is also observed in some sections of the tumour 
(Young, Jamshidi et al. 2015).  
Glioblastoma multiforme has been divided into four main subtypes, the classical, mesenchymal, 
proneural and neural subtypes. These subtypes are divided by their gene expression profiles and 
occur at slightly differing rates with roughly 32 % of cases being proneuronal, 14 % neural, 22 % 
classical and 32 % mesenchymal (Verhaak, Hoadley et al. 2010). The classical subtype is 
characterised by chromosome 7 loss and Epidermal growth factor receptor (EGFR) amplification. 
Homozygous 9p21.3 deletion is also associated with the classical subclass. The mesenchymal 
subtype is characterised by focal hemizygous deletion of a region at 17q11.2 containing the 
neurofibromatosis 1 (NF1) gene. This subtype also expresses the mesenchymal markers Chitinase-
3-like protein 1 (YKL40) and Hepatocyte growth factor receptor (MET). Several genes in the tumour 
necrosis factor super family and nucelar factor kappa-light-chain-enhancer of activated B cells (NF-
κB) pathways are also highly expressed in this subtype. The proneural class is defined by 
amplification of Platelet derived growth factor receptor A (PDGFRA) and point mutations in 
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isocitrate dehydrogenase 1 (IDH1). Tumour protein 53 (TP53) mutations and loss of heterozygosity 
are frequently observed in this subtype. High expression of homeobox protein Nkx-2.2 (NKX2-2) and 
oligodendrocyte transcription factor 2 (OLIG2) are also typical of this subtype. The neural subtype 
is characterised by the expression of neuron markers such as Neurofilament light polypeptide 
(NEFL), Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1), synaptotagmin 1 (SYT1) and 
potassium-chloride transporter member 5 (SLC12A5) (Verhaak, Hoadley et al. 2010). 
Referring to Hanah and Weinberg’s hallmarks of cancer (Hanahan, Weinberg 2011) GBM tumours 
have a wide array of alterations in gene expression that contribute to their malignant phenotype. 
Activating mutations have been observed in around 70 % of the receptor tyrosine kinases (RTKs), 
inactivating mutations of the phosphate and tensin homolog (PTEN) gene are also observed in 36 % 
of cases preventing the inhibition of proliferation. Mutations in the p53 and RB pathways also 
contribute to the sustained proliferative signalling observed in GBM tumours. With regards to 
evading growth suppression; loss of function mutations are seen in several tumour suppressor 
genes such as NF2, LKB1, RB and TP53. Metastasis is rarely seen in GBM; however, invasion is a 
hallmark of this type of cancer. The protein connexin 43 (cnx43/GJA1) is a key component of the 
gap junctions formed between cells; GBM cells have been shown to downregulate this protein 
reducing their adherence and as a result increasing their invasiveness (Verhaak, Hoadley et al. 2010). 
Pro-inflammatory proteins have also been shown to contribute to the invasiveness of GBM cells. 
These tumours are often hypoxic, and this hypoxia also contributes to the pro-inflammatory 
environment. Epithelial-to-mesenchymal transition (EMT) can also contribute to these tumours’ 
invasiveness with down regulation of the junction protein E-cadherin, enabling cell invasion. These 
cells can then subsequently undergo epigenetic changes enabling them to develop a mesenchymal 
(stem-cell like) phenotype. The telomerase reverse transcriptase (TERT) gene has been found to be 
mutated in 51 % of GBMs, this gene encodes the telomerase protein which lengthens the telomeres, 
immortalising cells. The gene alpha thalassaemia mental retardation (ATRX) is responsible for the 
deposition of histones at the telomeres, mutations in this gene have also been seen in GBM and 
this is linked to telomere lengthening. Due to the hypoxic nature of GBM tumours vascular 
endothelial growth factor (VEGF) is often upregulated, inducing increased angiogenesis. Mutations 
in several of the intracellular signalling proteins such as PI3K, AKT and mTOR prevent apoptosis and 
autophagy. GBM tumours employ many mechanisms to avoid immune destruction such as 
expression of immune inhibitory checkpoint proteins and recruitment of immunosuppressive 
myeloid derived suppressor cells (MDSCs). The isocitrate dehydrogenase (IDH) gene codes for three 
IDH enzymes, these enzymes are responsible for the production of nicotinamide adenine 
dinucleotide phosphate (NADPH) via oxidative carboxylation of isocitrate. IDH1 and IDH2 are the 
only two IDH genes found to be mutated in GBM, these mutations decrease IDH activity leading to 
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increased production of 2-hydroxyglutarate (2-HG) from NADPH, decreasing NADPH levels. 2-HG 
inhibits α-ketoglutarate-dependent dioxygenases, resulting in further epigenetic changes (Noroxe, 
Poulsen et al. 2017).  
1.3. Glioblastoma multiforme therapy 
The current course of treatment involves surgical reduction of the tumour (where possible) 
followed by concomitant radiotherapy and temozolomide chemotherapy. Despite aggressive 
multimodal therapy the median survival for patients on this treatment regime is 14.6 months (Stupp, 
Mason et al. 2005).  
The corticosteroid dexamethasone is given preoperatively to help reduce peritumoural swelling. 
Surgery can be performed in a variety of ways; craniotomy is the preferred surgical method; these 
can be performed as asleep-awake craniotomies where the patient is still conscious. This is 
particularly useful for tumours located within areas of the brain associated with certain functions 
(e.g. speech or hearing), this allows for monitoring of the patient’s faculties whilst resection takes 
place (Holland 2000). The asleep-awake craniotomy is associated with increased extent of resection 
and reduced neurologic deficits. An asleep craniotomy may also be performed with the patient 
being completely unconscious. Intraoperative electrical stimulation can also be used to map brain 
function during awake surgery. Another method for resecting GBM tumours is stereotactic ablation; 
this involves the use of a stereotactic frame to insert an optic cable into the tumour; low powered 
laser light can then be used to destroy tumour tissue (laser-induced thermal therapy) (Bigner, 
Friedman et al. 2016). Glioblastoma multiforme is highly resistant to therapy and due to the 
tumours’ highly infiltrative and diffuse nature recurrence is frequently observed. The diffuse nature 
of these tumours makes complete surgical resection difficult to achieve (Holland 2000).  
Temozolomide (TMZ) is a pro-drug that can be administered orally. The drug is stable at acidic pH 
but breaks down at a pH of 7 and above (Zhang, J., Stevens, and Bradshaw 2012).  TMZ is absorbed 
and rapidly broken down to monomethyl triazene 5-(3-methyltriazen-1-yl)-imidazole-4-
carboxamide (MTIC). This MTIC then reacts with water to produce 5-aminoimidazole-4-
carboxamide (AIC) and the active component methyldiazonium. This methyldiazonium cation 
methylates DNA at 3 positions; the N7 position of guanine, the N3 position of adenine and the O6 
position of guanine. The methylation at the O6 position of guanine is responsible for the cytotoxic 
effects of TMZ on cancer cells. The temozolomide pro-drug is preferentially processed in brain 
tumours due to their higher pH. When left unchecked O6 methyl guanine mismatches with thymine 
during replication, this triggers DNA mismatch repair (MMR). This results in excision of the thymine 
base. After several rounds of futile MMR, DNA double strand breaks occur resulting in cell cycle 
arrest and eventual apoptosis. Unfortunately, the lethal O6 guanine adducts induced by TMZ may 
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be repaired by an enzyme known as methylguanine-DNA methyltransferase (MGMT). The methyl 
group on the guanine is transferred to a cysteine residue within the active site of MGMT in a single 
step suicide reaction (Zhang, J., Stevens, and Bradshaw 2012). Not only is the protein MGMT also 
involved in resistance to TMZ but several micro RNAs are implicated in acquired resistance to TMZ 
chemotherapy (Ujifuku, Mitsutake et al. 2010). 
Bevacizumab and tumour treating fields are the only other Federal Drug Administration (FDA) 
approved treatments available for GBM patients. In 2009 the humanised anti-vascular endothelial 
growth factor (VEGF) IgG antibody bevacizumab was approved for GBM therapy (Cohen, Shen et al. 
2009). Unfortunately, it was found that bevacizumab had little benefit for patient survival when 
used in newly diagnosed patients with standard of care therapy (Gilbert, Dignam et al. 2014). 
However, bevacizumab may provide an alternative to corticosteroids for reduction of cerebral 
oedema. This is of particular interest for immunotherapeutic approaches since the corticosteroids 
commonly used in GBM; such as dexamethasone are highly immunosuppressive. Tumour treating 
fields are administered via a device known as Optune and these were approved by the FDA in 2011. 
This involves users wearing scalp electrodes that apply alternating electric fields that affect mitosis 
of tumour cells and this method of treatment has been shown to improve progression free survival 
and overall survival of patients, however this method of treatment is still far from curative 
(Hottinger, Pacheco et al. 2016, Mittal, Klinger et al. 2018). 
 
1.4. Immunotherapy 
In the early 19th century William B. Coley unwittingly utilised the immune systems of patients to 
cause cancer remission by treating them with erysipelas (an infection caused by Streptococcus 
bacteria), this treatment involved the injection of these bacteria into patients tumours locally 
activating the immune system (Coley 1891). 
Immunotherapy is the utilisation of the body’s own defences to target and attack tumours within 
the body, breaking the ‘tolerance’ that tumours have developed. This involves engaging the 
immune system and alerting it to the presence of tumours within the body. Immunotherapy can 
take many forms, there are two main branches of immunotherapy; passive immunotherapy and 
active immunotherapy.  
Immunotherapy as a mode of cancer therapy has become very popular due to its tumour specificity 
and reduced side effects (when compared to chemotherapy and radiotherapy). 
Immunotherapeutic treatments for cancer have gained traction with several therapies being 
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approved for use and well over 2,000 clinical trials currently ongoing involve immunotherapeutic 
treatments. 
Sipuleucel-T was the first FDA approved therapeutic cancer vaccine, an active form of 
immunotherapy. Sipuleucel-T is used to treat metastatic castration-resistant prostate cancer, it 
works by targeting the prostate acid phosphatase (PAP) antigen expressed by prostate cancer cells. 
To generate the vaccine autologous peripheral blood mononuclear cells (PBMC) from the patient 
are stimulated with a PAP-GM-CSF fusion protein comprised of the prostate cancer specific antigen 
prostatic acid phosphatase (PAP) and the immune stimulating granulocyte macrophage-colony 
stimulating factor (GM-CSF). These ex vivo stimulated cells are then infused into the patient where 
activated immune cells target the PAP expressing prostate cancer cells (Cheever, Higano 2011). 
A plethora of therapeutic antibodies have also been approved in the cancer setting (Postow, 
Callahan et al. 2015). The most relevant antibodies in the immunotherapy setting are the 
checkpoint blockade antibodies that target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), 
programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1).  
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Figure 1. A diagram of how the immune checkpoints PD-1/PD-L1 and CTLA-4 dampen the immune 
response. PD-L1 expressed on tumour cells binds to PD-1 on T-cells resulting in the death of the PD-
1 expressing T-cells. CTLA-4 on T-cells outcompetes CD28 when binding to B7 molecules preventing 
the activation of the T-cell, the CTLA-4 binding to the B7 molecules can also transendocytose the B7 
molecules and lead to their degradation. Adapted from (Reardon, Freeman et al. 2014) 
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PD-1 is a member of the CD28 family and it shares over 20 % homology with CTLA-4. CTLA-4 is 
expressed exclusively on T-cells however PD-1 is expressed on B cells and myeloid cells as well as 
T-cells. PD-1 is expressed on activated T-cells and binds to its ligands PD-L1 (B7-H1) and PD-L2 (B7-
DC). PD-L1 is classically expressed on immune cells and specific tissues such as β cells in the 
pancreas and the placenta, however cancers have been shown to co-opt the PD-L1 antigen to evade 
the anti-tumour immune response. PD-L2 is expressed on activated macrophages and dendritic 
cells; tumours also utilise PD-L2 to evade immune detection (Okazaki, Honjo 2006). PD-L2 
expression is far less common in tumours compared to PD-L1 (Chen, D. S., Irving et al. 2012). PD-L1 
expression has been well documented in the GBM setting with expression of PD-L1 being found in 
25-88 % of GBM cases (Vlahovic, Fecci et al. 2015, Berghoff, Kiesel et al. 2015a). PD-L1 expression 
in GBM has been examined as a prognostic factor; Nduom et al. (2016) revealed that expression of 
PD-1 and PD-L1 were found to be predictors of negative patient outcome (Nduom, Wei et al. 2016). 
Interestingly it was also found that PD-L1 expression by neurons close to tumours conveyed a better 
prognosis in GBM patients. It was found that when PD-L1 wasn't expressed in surrounding neurons 
the tumour expressed high levels of PD-L1. This research highlights an active interaction between 
the tumour and its surrounding tissues however the mechanisms by which the PD-L1 expression in 
surrounding neurons induces/increases glioma cell death is still not fully understood (Liu, Y., 
Carlsson et al. 2013). Currently there are five FDA approved antibodies that target the PD-1/PD-L1 
axis; Nivolumab and Pembrolizumab inhibit PD-1 whereas Atezolizumab, Avelumab and 
Durvalumab target PD-L1. Whilst there are several approved PD-1/PD-L1 inhibitors many more are 
being clinically trialled. Unfortunately these antibodies have not been approved for use in the GBM 
setting, however these antibodies are being tested in over 40 clinical trials for GBM (either alone 
or in combination with other therapies) (, clinicaltrials.gov - PubMed - NCBI). 
To generate activation of T-cells the T-Cell Receptor (TCR) needs to engage antigenic peptide 
presented on a major histocompatibility complex (MHC) molecule. After this TCR engagement a 
secondary signal also occurs from T-cell CD28 binding to the ligands B7-1 (CD80) and B7-2 (CD86) 
on the surface of antigen presenting cells. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4/CD152) binds to both B7-1 and B7-2 with much higher affinity than CD28, outcompeting it. The 
binding of CTLA-4 to the B7 ligands results in the inhibition of T-cell proliferation (Leach, Krummel 
et al. 1996). CTLA-4 not only outcompetes CD28 for ligation with CD80/CD86 it can also occupy 
CD80/86 preventing CD28 on neighbouring cells from interacting with CD80/86 (Walker, Sansom 
2015). The binding of CTLA-4 to CD80/86 has also been shown to lead to the transfer of CD80 and 
CD86 to CTLA-4 expressing cells, these CTLA-4 expressing cells then degrade these CD80 and CD86 
molecules. This results in decreased immune cell activity and stunts the immune cell activation 
capabilities of dendritic cells (Qureshi, Zheng et al. 2011). Ipilimumab is the only FDA approved anti-
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CTLA-4 antibody and much like the PD-1 and PD-L1 checkpoint inhibitors CTLA-4 use has not 
received approval for GBM therapy. Whilst Ipilimumab has not been approved for GBM therapy 
there are currently 10 ongoing clinical trials examining its efficacy in this setting (either alone or in 
combination with other therapies). Early stage clinical trials using combinatorial Ipilimumab and the 
anti-VEGF antibody Bevacizumab have shown that this regime is well tolerated in patients. 31 % of 
the 20 patients studied had a partial response to this combined therapy and 31 % had stable disease 
with the remaining 38 % showing disease progression. Some adverse immune effects such as 
pulmonary embolism and arthritis were observed however these were controlled with the use of 
corticosteroids (Carter, Shaw et al. 2016). 
Trastuzumab (Herceptin) is an antibody that targets the epidermal growth factor HER2 and its use 
has been approved for Her2 positive breast cancer. Trastuzumab is a humanised monoclonal 
antibody that binds the extracellular domain of HER2. This results in a reduction of HER2 signalling 
resulting in apoptosis of Her2 expressing cells. Trastuzumab may also induce an anti-tumour 
immune response, this is thought to be due to NK immune cells binding to the Fc region of the 
Trastuzumab via their Fc receptors stimulating NK cell lysis of Her2 expressing tumours (Nahta, 
Esteva 2006). The Her2 antigen is found to be expressed in GBM tissues and the Trastuzumab 
antibody is found to induce death of GBM cells, however this antibody is yet to be approved for use 
in the treatment of GBM (Mineo, Bordron et al. 2004). Whilst in vitro activity was demonstrated 
Trastuzumab never underwent clinical trials for GBM as a monotherapy. 
Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene Ciloleucel) are chimeric antigen receptor 
(CAR)-T-cell therapies that have been approved for use in leukaemia. Both therapies are CD19-
specific meaning that they target B-cell lymphomas and leukaemias (Zheng, Kros et al. 2018). CAR 
T-cells are genetically engineered T-cells that are engineered so that they have an antigen specific 
domain fused with an intracellular signalling domain, this enables these cells to specifically target 
cells and activate the T-cell. Some interesting pre-clinical data is being amassed for the use of CAR 
T-cells in the GBM setting however the use of CAR T-cells in the clinic is still in its relative infancy 
with primarily phase I/II clinical trials ongoing (Bagley, Desai et al. 2018). In the GBM setting CAR T-
cells have been engineered to target the truncated EGFRviii receptor (O'Rourke, Nasrallah et al. 
2017), the stem cell marker CD133 (Zhu, X., Prasad et al. 2015) and the GBM associated antigen 
IL13Rα2 (Brown, C. E., Alizadeh et al. 2016) to name a few. 
 
1.5. The immune system in glioblastoma multiforme 
The brain has been traditionally thought of as being an immunoprivileged organ, however there is 
mounting evidence of an interaction between the brain and the immune system. An early indicator 
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of the effects of the peripherally activated immune system at targeting antigens within the brain 
was evidenced in skin graft experiments performed on rabbits (MEDAWAR 1948). When 
heterotypic skin grafts are implanted directly into the brain, they do not elicit an immune response, 
however when these skin grafts are engrafted on a raw area of the skin the cerebral grafts were 
rejected due to an immune response (MEDAWAR 1948). Regression of brain tumours has also been 
linked to perisurgical bacterial infection, it was hypothesised that bacteria acted as an immune 
adjuvant that boosted the anti-tumour response as evidenced by increased granulocyte and 
lymphocyte infiltration (Bowles, Perkins 1999). Prins et al. (2008) revealed that antigen specific 
CD8+ T-cells penetrated the brain parenchyma and penetrated tumours within the brains of a pre-
clinical mouse model of GBM (Prins, Shu et al. 2008). Immunohistochemical analysis of glioblastoma 
multiforme tumours taken from patients has also revealed evidence of immune cell infiltration and 
this immune cell infiltrate can be a predictor of clinical outcome, with high CD4+ and low CD8+ 
tumour infiltration being correlated with poorer prognosis (Han, Zhang et al. 2014). Glioblastoma 
patients have also been shown to have circulating CD8+ T-cells specific for GBM cells indicating that 
there is an active interaction between the immune system and GBM tumours located within the 
brain (Tang, Flomenberg et al. 2005). The recent discovery of a brain specific lymphatic system has 
also helped to highlight the fact that there is an active interaction between the brain and the 
immune system (Louveau, Smirnov et al. 2015, Aspelund, Antila et al. 2015). Studies have found 
that implantation of allografts near the ventricles or within the subarachnoid space were rejected 
without prior peripheral exposure, indicating that these meningeal spaces containing cerebrospinal 
fluid have increased immune cell infiltration (Louveau, Plog et al. 2017). Under normal conditions 
immune cells are present within the meningeal compartment, the endothelial cells surrounding the 
cerebrospinal fluid filled areas is more permissive to immune cell crossing than the blood brain 
barrier. Tracers injected into the brain parenchyma and the subarachnoid spaces were both seen 
to drain to the cervical lymph nodes within the neck. Immune cells injected into the subarachnoid 
spaces were also seen to drain to these cervical lymph nodes. The data for immune cells injected 
into the parenchyma is far more varied with some studies witnessing drainage to the cervical lymph 
nodes and others failing to observe this phenomenon. These findings indicate that antigens located 
within the brain can be drained into the cervical lymph nodes and these can in turn educate 
extracranial immune cells. It may also be possible that intracranial immune cells drain to these 
lymph nodes and lead to further immune cell education/activation (Louveau, Plog et al. 2017). 
Whilst the brain is not immunoprivileged it is however a unique immune environment. 
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1.6. Vaccination and the immune response 
Numerous approaches have been used to generate an immune response, one of the most frequent 
methods is to inject an antigenic peptide specific for the bacteria/virus/cancer, and this antigen is 
then up-taken and processed by the immune system generating antigen specific immune cells and 
a peptide-specific immune response. There are several classes of antigens utilised for targeting 
cancers: Cancer-testis antigens, these are expressed in germ cells but are also aberrantly expressed 
in tumour cells, differentiation antigens of melanocyte lineage, mutational antigens, overexpressed 
self-antigens and viral antigens (such as human cytomegalovirus antigens) (Jager, Gnjatic et al. 
2000). 
To develop a peptide vaccine specific immunodominant epitopes need to be selected that provide 
protection against the disease of interest. The epitopes chosen should induce both effector T- 
and/or B-cell responses as well as T-helper cell responses. This ensures efficient protection against 
the chosen epitopes and helps develop memory cell responses (Li, W., Joshi et al. 2014). CD8 
cytotoxic T-cell epitopes are very specific and a single amino acid change within the epitope can 
render it non-immunogenic. Traditional vaccines are usually used in a protective manner, 
preventing future infection. In the cancer settings peptide vaccines are usually therapeutic, acting 
upon established disease. In the cancer setting, peptides longer than the standard 9-11 amino acid 
epitope size are used. These large peptides usually contain both MHC class 1 (CD8) and MHC class 
2 (CD4) epitopes. These larger peptides are usually processed by the immunoproteasome and 
presented via MHC I and MHC II molecules by antigen presenting cells. These longer peptides have 
been shown to induce a stronger immune response than shorter 9-11 amino acid long peptides. 
This was thought to be due to CD4 T-cell help. This theory was proven using MHCII knockout mice, 
where these mice failed to elicit a strong anti-peptide CD8 T-cell response when vaccinated with a 
long peptide (Li, W., Joshi et al. 2014). A key factor to consider is the method of delivery and use of 
potential adjuvant, in some cases these two things can be combined. Adjuvants are used to boost 
the immunogenicity of peptide vaccinations and increase the efficacy of the vaccine, this can be 
achieved in a variety of ways. Some adjuvants may work to modify the cytokine network enhancing 
immune cell activation. Some adjuvants work by increasing the uptake of peptide by antigen 
presenting cells, allowing the peptide to remain in its native state and be processed as desired (Cox, 
Coulter 1997, Khong, Overwijk 2016).  
B cells can also contribute to the vaccine induced immune response by present antigens to CD8 and 
CD4 T-cells enhancing the anti-tumour immune response (Yuen, Demissie et al. 2016). Depending 
upon the signals B cells receive they can become effector B cells or antibody secreting plasma cells. 
Tumour infiltrating B cells can secrete antibodies that induce antibody-dependent cell-mediated 
toxicity or activation of the complement system resulting in the death of tumour cells. Activated B 
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cells can present antigen to T-cells and they secrete costimulatory cytokines that help maintain T 
cell activation. Regulatory B cells may also be present within the tumour infiltrating B cell 
population, these cells may promote tumour growth by secreting immunosuppressive cytokines 
such as IL-10 and TGF-β (Guo, F. F., Cui 2019). In a pre-clinical brain tumour model the recruitment 
of B cells to brain tumours was found to be necessary for the anti-tumour immune effects of Ad-
TK+AdFLT3l gene therapy. When B-cells were blocked with an anti-CD20 antibody, or B cell deficient 
mice were treated with this Ad-TK+AdFLT3l gene therapy it was less efficacious than mice with 
functioning B cells (Candolfi, Curtin et al. 2011). Interestingly a DNA vaccine targeting the cancer 
associated antigen HER-2/neu was found to be efficacious in mice lacking B cells. B cell deficient 
mice were shown to reject HER-2 expressing tumours just as well as mice who still had an intact B 
cell compartment indicating that in the case of HER-2 expressing tumours, the T-cell compartment 
is necessary for anti-tumour immunity and the subsequent tumour rejection (Lindencrona, Preiss 
et al. 2004). As mentioned previously B cells can also contribute to tumour immune escape, anti-
tumour CD8 T-cell cytotoxicity was shown to be improved in B cell knockout mice (Inoue, Leitner et 
al. 2006). Murine studies have revealed that the presence of B cells limits the repertoire of CD4 T 
cells, resulting in a lesser anti-tumour immune response. Immunoglobulins secreted by plasma cells 
have been shown to act as a carrier for immunosuppressive TGF-β highlighting the 
immunosuppressive potential of B cells. B-cells have been shown to act as antigen presenting cells 
when they are activated by CD40, these CD40 activated B cells can lead to the expansion of antigen 
specific CD4 and CD8 T cells (Fremd, Schuetz et al. 2013). Increased B cell infiltrate in GBM tumours 
has been shown to predict a significant survival advantage (Li, B., Severson et al. 2016). B cells much 
like many of the other immune cell types can act in both in a pro-tumourigenic and anti-
tumourigenic manner. Antibodies secreted by plasma cells can induce antibody-dependent cell-
mediated cytotoxicity (ADCC) resulting in antibody mediated tumour cell death. Antigen specific 
antibodies bind to antigens expressed on tumour cells, and the Fc regions on these antibodies are 
recognised by Fc receptors on effector cells. This crosslinking results in activation of immune 
effector cells resulting in tumour cell death (Iannello, Ahmad 2005). Whilst antibodies can 
contribute to immune cell killing of cancer cells, these immunoglobulins can form immune 
complexes, these complexes can support tumour growth and their presence is associated with 
increased tumour burden. These immune complexes have also been shown to interact with 
immune suppressive TGF-β, reducing the anti-tumour response within the tumour 
microenvironment (Tan, Coussens 2007).  
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1.7. Human leukocyte antigen (HLA) haplotypes 
MHC antigen presentation is dependent upon the HLA haplotypes expressed by the patient. The 
HLA complexes are grouped into three main classes: MHC class 1, 2 and 3. MHC class I is comprised 
of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G. MHC class II is comprised of HLA-DP, HLA-DR, 
HLA-DQ, HLA-DO and HLA-DM (Maenaka, Jones 1999). Less is known about the MHC class III 
complexes and they will not be detailed here since the interest is focussed on the MHC class I and 
II genes. Structurally MHC class I and II genes differ. MHC class I consists of two heterodimeric 
polypeptide chains linked non-covalently. The beta 2 microglobulin (β2M) is also non-covalently 
linked to the alpha 3 chain which contains a transmembrane domain. The alpha 1 and 2 domains 
form a peptide binding groove that can hold peptides 8-10 amino acids long for presentation to T-
cells. MHC class II is also a heterodimer formed with one alpha and one beta polypeptide chains. 
The alpha 1 and beta 1 domains form a peptide binding groove that can present peptides 15-24 
amino acids long to T-cells. The alpha 3 region on the MHC class I receptor binds to CD8 on cytotoxic 
T-cells leading to presentation of the bound peptides to the TCR of these types of cells (Maenaka, 
Jones 1999). CD4 on helper T-cells binds to the beta 2 domain on MHC class II molecules, this 
domain is structurally analogous to the CD8 binding domain on the alpha 3 domain on MHC class I. 
This binding of CD4 to the MHC class II allows bound peptides to be presented to the TCRs on these 
CD4 positive cells (Konig, Huang et al. 1992). 
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Figure 2. A schematic representation of the structure of MHC class I and II molecules. Alpha subunits 
are represented by green shading whilst the beta sub-units and beta 2 m molecules are shaded 
yellow. Adapted from (Janeway, Capra et al. 2001). 
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Each MHC molecule binds a different range of peptides, therefore possessing several genes for each 
MHC class is advantageous; enabling an individual to present a broad range of peptides. Most 
humans are heterozygous at MHC loci, the combination of genes at this MHC loci is known as the 
MHC/HLA haplotype. MHC alleles are codominant so both haplotypes are expressed within cells, 
this makes the antigen presenting capabilities of cells highly diverse. Each MHC variant is unique, 
and these differences lead to differing peptide-binding grooves on the MHC molecules making the 
peptide binding properties of MHC molecules unique. Antigen recognition of antigens by T-cells is 
dependent upon the presence of specific MHC molecules present on the surface of antigen 
presenting cells. The MHC molecule is also necessary for specific TCR engagement; when the same 
peptide is presented by different MHC molecules T-cells will distinguish between the two MHC 
receptors, despite the same peptide being presented. This reveals the importance of the MHC 
molecule in not only dictating peptide binding but also T-cell recognition of the peptide (Janeway, 
Capra et al. 2001).  
 
1.8. GBM tumour immune escape 
GBM tumours are known to be poorly immunogenic, this is mainly due to their highly 
immunosuppressive nature; with tumours employing a wide array of immune inhibitory escape 
mechanisms. Programmed death ligand 1 (PD-L1) is an immune inhibitory check point ligand that 
binds to its cognate receptor programmed death 1 (PD-1), the binding of PD-1 on activated T-cells 
to PD-L1 leads to apoptosis of T-cells, preventing immune response directed towards the PD-L1 
expressing cells (Reardon, Freeman et al. 2014). GBM tumours have been shown to express PD-L1 
with as many as 88 % of patients expressing this immunosuppressive marker (Berghoff, Kiesel et al. 
2015b). As expected, patients expressing high levels of PD-L1 have also been shown to have a worse 
overall survival (Xue, S., Song et al. 2017). Due to the high levels of PD-L1 expression within these 
tumours the use of antibodies that block the PD-1/PD-L1 interaction have been tested to try and 
treat GBM, unfortunately GBM patients take the immunosuppressive anti-inflammatory drug 
dexamethasone. Dexamethasone is taken to control cerebral oedema in these patients however at 
the dosages taken it can dampen the response to immune checkpoint blockade (McGranahan, 
Therkelsen et al. 2019). Regulatory T-cells (T-regs) are a subset of immune cell that act to dampen 
the immune response and prevent auto-immunity. These regulatory T-cells are immunoinhibitory 
and as a result their recruitment to the tumour microenvironment is undesirable for an efficient 
anti-tumour immune response. Unfortunately, in the case of GBM these tumours secrete soluble 
factors which increase the presence and expansion of regulatory T-cells. Increased levels of T-regs 
are found within GBM tumours when compared with circulating peripheral blood mononuclear cells. 
This increased recruitment of T-regs to the tumours was shown to be due to secretion of the 
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chemokine CCL22 by the tumours (Crane, Ahn et al. 2012). Glioblastoma multiforme tumours have 
also been shown to secrete numerous other immunosuppressive cytokines, one such example 
being transforming growth factor beta (TGF-β). TGF-β has been shown to be secreted by GBM 
tumours and its secretion has been shown to reduce T-cell infiltration in high grade gliomas (Lohr, 
Ratliff et al. 2011, Bodmer, Strommer et al. 1989). TGF-β interacts with a plethora of other growth 
factors in the GBM setting, such as basal fibroblast growth factor (bFGF), epidermal growth factor 
(EGF), platelet derived growth factor (PDGF) and plasmin activator inhibitor-1 (PAI-1). TGFB-β1 
leads to increased collagen synthesis by GBM cells. PAI-1 expression by GBM cell lines can be 
reversed using an anti TGF-β blocking antibody. GBM cells unlike other cancer cell lines release TGF-
β in its bioactive form (Platten, Wick et al. 2001). This TGF-β has been shown to lead to increased 
matrix metalloproteinase 2 and 9 (MMP2 and MMP9) activity on the surface of GBM cells. This in 
turn results in increased cell motility and invasion of surrounding brain (Platten, Wick et al. 2001). 
MMP9 interacts with intracellular adhesion molecule-1 (ICAM-1) resulting in its cleavage resulting 
in a tumour cell resistance to natural killer cell mediated cytotoxicity (Fiore, Fusco et al. 2002).  
Interleukin-10 (IL-10) is an immunoinhibitory cytokine that inhibits synthesis of other cytokines, 
reducing the immune response. IL-10 mRNA was found to be highly expressed in recurrent and 
high-grade gliomas (Huettner, Paulus et al. 1995). Further research revealed that IL-10 not only has 
immunosuppressive effects but it also increases proliferation and migration of glioblastoma 
multiforme cell lines in culture. This IL-10 was shown to be produced by cells of 
microglia/macrophage origin (Wagner, Czub et al. 1999). Not only do tumour associated 
macrophages produce IL-10 they have also been shown to have immunoinhibitory effects by 
becoming M2-type macrophages. There are two main types of macrophage, the classically 
activated M1 pro-inflammatory macrophage and the alternatively activated M2-type macrophages 
which exert anti-immune effects. Glioblastoma multiforme tumour mass is largely composed of 
these M2 macrophages which promote growth of tumour cells (Kennedy, Showers et al. 2013). 
Human cytomegalovirus (hCMV) is a herpes virus that persistently infects 50-90 % of the adult 
human population. Immunohistochemical analysis of GBM tumours revealed that 100 % of GBM 
tumours expressed the hCMV encoded protein IE1-72; these results were further corroborated by 
polymerase chain reaction (PCR) of GBM tissues (Cobbs, Harkins et al. 2002). Another study by Lucas 
et al. (2011) found that 51 % of GBM tumours studied express the pp65 CMV protein and only 16 % 
expressed the IE1 protein (Lucas, Bao et al. 2011). Human cytomegalovirus has been shown to 
secrete IL-10, enabling persistent viral infection, seeing that GBM tissue appears to be commonly 
infected with CMV, and this attenuation of the immune response prevents eradication of the 
tumour along with the virus. CMV IL-10 was shown to lead to the differentiation of CD14+ 
monocytes to macrophages, which was shown to support hCMV infection. Dendritic cell maturation 
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and life span is also affected by CMV IL-10, with in vitro studies revealing that the dendritic cells 
have delayed maturation and less longevity. Monocytic dendritic cells exposed to CMV IL-10 can 
reach maturation, however their cytokine production is impaired in a non-reversible manner. CMV 
IL-10 was shown to result in a decrease in antiviral IgG, this results in less efficient control of virus 
spreading and as a result more aggressive tumour growth (Chang, Barry 2010). 
Immune cell populations have been shown to contribute to glioma pathology as well as regression. 
The presence of tumour infiltrating lymphocytes (TILs) correlates with glioma grade but this 
increase in TILs is also correlated to preferential prognosis (Han, Zhang et al. 2014). Lymphocytes 
entering the central nervous system/tumour compartment have been shown to down regulate 
costimulatory CD28 and CD62L ligands. Elevated regulatory T-cell presence in tumours has been 
correlated with shorter recurrence free survival. CD8+ T cell infiltration into GBM tumours has been 
correlated with survival. Radiotherapy has been shown to increase cytotoxic T-cell infiltrate and 
deplete regulatory T-cells providing a good adjunct to immunotherapy. Microglia and macrophages 
that transport to glioma tumours are altered into the protumorigenic M2 phenotype, promoting 
immune suppression and tumour cell suppression. These tumour associated 
microglia/macrophages have been shown to comprise up to 30 % of GBM tumour bulk. These 
microglia/macrophages express high levels of PD-L1 contributing to the local immunosuppressive 
phenotype. M1 macrophages induce anti-tumorigenic immune responses by leading to a decrease 
in regulatory T cells and an increase in CD8+ T cells. Soluble factors produced by GBM cells induce 
CCL22 secretion by M2 macrophages/microglia resulting in T Reg and MDSC cell recruitment to the 
tumour (D. Caponegro, Tetsuo Miyauchi et al. 2018).  
VEGF secretion can inhibit the maturation and function of dendritic cells. Extracellular matrix 
components are found at high levels in the glioma tumour micro-environment. The presence of 
these extracellular matrix components leads to a retention of growth factors such as FGF and VEGF, 
which promotes tumour progression  (Brown, N. F., Carter et al. 2018). These factors increase 
angiogenesis increasing the tumour vasculature resulting in upregulation of the macromolecules 
periostin and tenascin C (TNC). TNC blocks the migration of T cells across blood vessels preventing 
them penetrating the parenchyma. Periostin has also been shown to recruit circulating M2 
macrophages into the tumour. GBM cells have been shown to down regulate MHC expression, 
proteins essential for antigen presentation. The presence of the immunosuppressive cytokines IL-
10 and TGF-β are thought to cause the down regulation of MHC molecules in the tumour micro 
environment (Brown, N. F., Carter et al. 2018). TNF-α is responsible of dendritic cell maturation 
within the brain, it can also stimulate the growth of T-cells. TNF-α can have both pro-tumourigenic 
and anti-tumourigenic effects in the GBM setting. Exposure of GBM cells to TNF-α leads to increased 
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neovascularisation via the upregulation of pro angiogenic cytokines such as IL-8 and VEGF (Zhu, V. 
F., Yang et al. 2012). 
IL-1β is a pro-inflammatory cytokine that has been shown to be upregulated in the U373 
glioblastoma multiforme cell line and radiation has been shown to lead to upregulation of IL-1β in 
GBM tumours (Kore, Abraham 2014). IL-1β leads to increased intracellular signalling through 
mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase 2 (JNK2) resulting in 
increased GBM cell proliferation and invasion. IL-1β exposure also leads to increased VEGF 
secretion which as mentioned previously contributes to the immune evasion of GBM (Yeung, 
McDonald et al. 2013). 
Intracellular adhesion molecule 1 (ICAM-1/CD54) is key for regulating the cellular 
microenvironment and mediating cell-cell interactions. ICAM-1 is commonly upregulated in the 
GBM setting with GBM tumours being shown to express higher levels of ICAM-1 when compared 
to normal brain when studied immunohistochemically (Gingras, Roussel et al. 1995). ICAM-1 is a 
ligand for lymphocyte function-associated antigen 1 (LFA-1/CD11a/CD18) this results in increased 
myeloid cell migration into the tumours and increased numbers of macrophages enhancing 
immune suppression within the tumours (Piao, Henry et al. 2017).  
Expression of galectin-1 (Gal-1) by glioblastoma cells has been shown to promote proliferation and 
migration of these cells, not only does this Gal-1 expression promote migration and proliferation it 
also leads to the death of T-cells when they are co-cultured with Gal-1 expressing cells, further 
highlighting the ability of GBM to evade immune attack (Kovacs-Solyom, Blasko et al. 2010). 
Macrophage migration inhibitory factor (MIF) expression in GBM has been shown to be linked to 
immune escape. This antigen was found to be expressed in GBM tumours, and when MIF is knocked 
down in GBM tumour cells they become more susceptible to natural killer (NK) cell mediated killing 
(Mittelbronn, Platten et al. 2011). 
HLA-G is a non-classical MHC class I molecule that plays a role in tolerance; it is often expressed on 
trophoblasts to prevent immune reactions to the developing foetus. HLA-G is also expressed in 
adult thymic epithelial cells, nail matrix and cornea. It is rarely expressed elsewhere in the body; 
however, GBM cells have been shown to express this protein (Wastowski, Simoes et al. 2013). HLA-
G also has a soluble form that has been found in plasma, cerebrospinal fluid and sperm. High levels 
of HLA-G have also been correlated with cytomegalovirus, a virus commonly found present in GBM 
tumour tissues. HLA-G has several receptors, these are the inhibitory receptors ILT-2, ILT-4 and the 
non-inhibitory receptors CD8, CD160 and KIR2DL4. ILT-2 and ILT-4 are expressed on immune cells, 
they recognise MHC class I molecules via their α3 and β2m domains however they bind 
preferentially to HLA-G. Binding of soluble HLA-G to CD8 on T cells results in Fas-FasL mediated 
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CD8+ T cell apoptosis. HLA-G binding to ILT-2 inhibits NK cell cytolysis by inhibiting polarisation of 
lytic granules and the microtubule-organising centre at the contact zone (Carosella, Rouas-Freiss et 
al. 2015). HLA-E is another non-classical MHC class I molecule; it is a ligand for both NKG2A and 
NKG2C expressed on NK, CD8 αβ and γδ T cells. HLA-E can either lead to immune cell activation by 
binding with C-type lectin -like receptor NKG2C and it can also lead to immune cell inhibition by 
binding to C-type lectin -like receptor NKG2A. HLA-E has been shown to be expressed in 
glioblastoma tumour tissues and cell lines. HLA-E much like HLA-G is thought to play a role in 
maternal tolerance of a foetus (Wischhusen, Friese et al. 2005). GBM has been shown to express 
FasL (CD95L), this ligand binds to Fas (CD95/APO-1) on T-cells leading to their apoptosis. GBM tissue 
staining revealed that this expression of FasL by GBM cells induced cell death of CD3 T-cells 
expressing Fas (Didenko, Ngo et al. 2002).  
Stat3 is a cytoplasmic transcription factor that is activated by upstream events such as growth factor 
and cytokine signalling. When Stat3 is activated it is phosphorylated and persistent Stat3 
phosphorylation is seen in numerous cancers including GBM. Stat3 phosphorylation has been found 
to varying degrees in GBM and the amount of Stat3 phosphorylation has been directly correlated 
to brain tumour grade with GBM (grade IV) showing the highest level of Stat3 phosphorylation 
(Birner, Toumangelova-Uzeir et al. 2010). Stat3 regulatory proteins have also been shown to be 
downregulated in GBM patients. One such example is protein inhibitor of Stat3 (PIAS3), and this 
protein was only detected in 11 % of GBM samples compared to 100 % control non-neoplastic brain 
samples from epileptic patients. IL-6 is a key activator of Stat3, IL-6 and its receptor are often 
upregulated in GBM tumours further highlighting the importance of Stat3 activation in GBM tumour 
malignancy. Knockdown of Stat3 in GBM cell lines results in slower in vitro and in vivo growth (Luwor, 
Stylli et al. 2013). 
Indoleamine 2, 3-dioxygenase (IDO) is an enzyme involved in the catabolism of the amino acid 
tryptophan into immune-regulatory kynurenines. IDO much like many other immune inhibitory 
proteins is involved in prevention of maternal foetal rejection. Activation of several receptors leads 
to downstream signalling events that induce IDO expression. Toll like receptors (TLRs), tumour 
necrosis factor receptor superfamily members (TNFRs), interferon gamma receptors (IFNGR), 
interferon beta receptors (IFNBR), transforming growth factor beta receptors (TGFBRs) and aryl 
hydrocarbon receptors (AhRs) have all been shown to induce IDO expression upon activation. The 
depletion of tryptophan by IDO has been shown to inhibit immune cells and prevent dendritic cell 
maturation (Mbongue, Nicholas et al. 2015). IDO has been identified as a significant 
immunosuppressive factor in glioblastoma multiforme. IDO is upregulated in recurrent GBMs, with 
Mitsuka et al. (2013) finding that 100 % of patients studied expressed IDO upon second surgery 
(Mitsuka, Kawataki et al. 2013).  
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Research has also shown that GBM promotes T-cell death via CD70 and ganglioside expression 
(Chahlavi, Rayman et al. 2005). Activated T-cells were shown to be more susceptible to GBM-cell 
induced death. CD70 expressed by GBM binds to CD27 a TNFR family member that modulates 
apoptosis upon binding of CD70. Blockade of CD70 on GBM cell lines partially protected T cells from 
apoptosis. The contribution of gangliosides to T cell death was also studied using DL-thre-phenyl-2-
hexadecanoylamino-3-pyrrolidino-1-propanol (PPPP) an inhibitor of glucosylceramide synthesis. 
PPPP was proven to induce a reduction in ganglioside expression when PPPP cells were assessed by 
HPLC. This reduction in gangliosides resulted in reduced T-cell apoptosis by GBM cell lines (Chahlavi, 
Rayman et al. 2005). 
Unfortunately, standard therapies have also been shown to increase glioblastoma multiforme 
immunosuppression. In vitro studies have revealed that GBM cell lines exposed to doxorubicin and 
radiation therapy release the immunosuppressive cytokine prostaglandin E2 (PGE2). Cells exposed 
to TMZ were also shown to suppress the proliferation of T-cells via the release of PGE2 (Authier, 
Farrand et al. 2015). Furthermore, the current treatment strategies have also been shown to 
hamper immunotherapeutic approaches. Steroids are often given to patients to counteract 
cerebral oedema, dexamethasone is frequently used in this context. Dexamethasone has been 
shown to result in upregulation of the immunosuppressive checkpoint CTLA-4 on T-cells, reducing 
their anti-tumour activity. Dexamethasone was also shown to reduce the proliferation of T-cells 
(Giles, Hutchinson et al. 2018). To alleviate the potential deleterious effects of dexamethasone 
alternative treatments need to be considered. One such alternative for the relief of oedema is the 
previously mentioned FDA approved anti-VEGF antibody Bevacizumab.  
Tumours establish a somewhat immunopriveleged environment via their altered physiology and 
co-opting of stromal cells. The brain is a unique organ with an extracellular matrix composed of 
proteoglycans, glycosaminoglycans and glycoproteins. In the brain tumour microenvironment 
significant increases in heparan sulphate proteoglycans (HSPG) have been observed. These HSPGs 
can trap growth factors such as FGF and VEGF in the tumour microenvironment. As mentioned 
previously this VEGF secretion leads to upregulation of TNC and periostin promoting cancer cell 
survival and increased trapping of T-cells within blood vessels preventing their penetration of the 
tumour bulk (Quail, Joyce 2017). Hypoxia is one of the hallmarks of GBM tumours, this hypoxia 
potentiates the immune suppression exerted by these tumours. Hypoxia can lead to increased 
secretion of angiogenic factors such as VEGF by tumour cells, which as mentioned previously 
generates an immunosuppressive microenvironment. Another factor that enables GBMs to 
suppress the immune system and evade immune surveillance is their high heterogeneity as 
indicated in their name ‘multiforme’. The presence of stem-like/cancer initiating GBM cells has 
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been shown to contribute to the immunosuppressive nature of GBM (Wei, Barr et al. 2010, Wu, 
Wei et al. 2010). 
 
1.9. Immune checkpoint blockade for GBM 
As mentioned previously tumours upregulate immune inhibitory checkpoints such as PD-L1. 
Research has found a plethora of immune inhibitory proteins that can be targeted to boost the 
resident anti-tumour immune response. Many of these immune checkpoints are being targeted in 
the cancer setting with several checkpoint blockade antibodies being approved for therapy and 
many more being tested in clinical trials. Ipilimumab (anti-CTLA4) and Pembrolizumab (anti-PD-1) 
have been approved for the treatment of melanoma and renal cell carcinoma. Pembrolizumab has 
also been approved for non-small cell lung cancer and Hodgkin lymphoma. These checkpoint 
blockade modalities are gaining traction in the field of cancer therapy. Checkpoint blockade has 
been tested in the GBM setting and researchers have tried to identify molecular patterns linked 
with immune checkpoint blockade responsiveness. In recurrent GBM non-response to anti-PD-1 
therapy was linked to PTEN mutations, whereas mutations in the MAPK pathway were linked with 
a response to anti-PD-1 therapy. These PTEN mutations were linked with immunosuppressive gene 
signatures meaning that despite PD-1 blockade the immune system is still being suppressed via 
other mechanisms within the tumour microenvironment (Zhao, Chen et al. 2019). When used in a 
neoadjuvant manner (prior to surgical resection) PD-1 therapy was not linked to an increase 
infiltration of immune cells and no significant changes in T-cell function were observed when 
compared to the immune microenvironment prior to treatment. When comparing neoadjuvant 
Pembrolizumab with adjuvant Pembrolizumab therapy in the GBM setting it was found that 
neoadjuvant therapy was linked to an increase in IFN-γ related genes and a repression of cell cycle 
gene expression in tumour cells. These findings seem to suggest that pembrolizumab checkpoint 
blockade is more efficacious in the neoadjuvant setting as opposed to the adjuvant setting (Ito, 
Nakashima et al. 2019). What is even more exciting about these immune checkpoint blockade 
therapies is that they can also be combined with other treatment modalities, most interestingly is 
the potential of combining checkpoint blockade with active immunotherapy with the purpose of 
boosting the anti-tumour immune response generated by vaccination. 
 
1.10. ImmunoBody® vaccination 
As previously mentioned immunotherapy has been tested in the GBM setting however there 
appear to be several challenges involved in treating these types of tumours with immunotherapy 
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and several clinical trials have fallen at the last hurdle, as a result of these failures there is a great 
need to find novel ways of generating an active immune response in GBM patients. 
ImmunoBody® (Scancell) is a DNA plasmid vaccine that encodes a human IgG1 antibody with CD8+ 
and CD4+ T-cell epitopes engrafted into the complementarity determining regions (CDRs) of the 
antibody. This method of vaccinations generates an immune response via direct presentation 
(transfection of the antigen presenting cells (APCs)) and by cross presentation (transfection of non-
APCs resulting in secretion of the IgG1 protein and its uptake by APCs (Pudney, Metheringham et 
al. 2010). The ImmunoBody® vector generates a 100-fold higher avidity response than an identical 
peptide vaccination (Brentville, Metheringham et al. 2012).  
SCIB1 is an ImmunoBody® vaccine that encodes three immunogenic epitopes, two for the 
melanoma antigen gp100 (glycoprotein 100/PMEL/melanocyte protein) and one for the antigen 
TRP-2 (tyrosine-related protein 2/dopachrome tautomerase (DCT)/dopachrome delta-isomerase) 
(Xue, W., Brentville, Symonds, Cook, Yagita, Metheringham, and Durrant 2016). These two antigens 
are abundant in the melanoma setting. SCIB1 encodes a CD8+ T-cell 9-mer epitope for TRP-2 and a 
16-mer and 18-mer gp100 sequences containing both CD4+ and CD8+ T-cell epitopes (See Figure 
3). Pre-clinical results with a TRP-2 directed ImmunoBody® have shown that this mode of 
vaccination generates a high avidity T-cell response that resulted in a significant decrease in B16F10 
murine melanoma tumour size (Metheringham, Pudney et al. 2009, Pudney, Metheringham et al. 
2010). These promising pre-clinical results have led to the initiation of ImmunoBody® clinical trials 
in the melanoma setting. Phase I results showed that SCIB1 ImmunoBody® vaccination was well 
tolerated with no adverse events seen in patients. Even more impressive was that 23/25 patients 
showed a detectable immune response and one patient’s tumour lesions were seen to decrease in 
size (Patel, Poulam M., Durrant et al. 2014, Patel, P. M., Ottensmeier et al. 2018). The promising 
early results for SCIB1 have led to some pre-clinical work looking at combining SCIB1 vaccination 
with anti-PD-1 checkpoint blockade. SCIB1 and anti-PD-1 were used in combination to treat B16F1-
DR4 melanoma tumours in transgenic HLA-DR4 mice. This combination was shown to increase 
survival and reduce tumour volume. Even when mice were challenged with a high number of 
tumour cells the combined SCIB1 anti-PD-1 therapy still led to improved survival in these animals 
when compared to SCIB1 or anti-PD-1 monotherapy (Xue, W., Brentville, Symonds, Cook, Yagita, 
Metheringham, and Durrant 2016). The ImmunoBody® plasmid can be engineered to target cancer 
related antigens other than TRP-2 and gp100; SCIB2 is an ImmunoBody® plasmid that has epitopes 
for New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) engrafted into its 
complementarity determining regions (CDRs) as opposed to TRP-2 and gp100. Combining PD-1 
blockade with SCIB2 ImmunoBody® vaccination was shown to result in 100 % long term survival in 
mice harbouring NY-ESO-1 expressing B16 tumours (Xue, W., Metheringham et al. 2016). The 
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advantage of ImmunoBody® vaccination is that it generates high avidity T-cell responses which have 
been shown to be enough for eradication of antigen expressing tumours. Another advantage of the 
ImmunoBody® plasmid is that it can easily be engineered to target other tumour specific epitopes 
and this method of vaccination does not require administration of an adjuvant to generate a strong 
anti-tumour response.   
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Figure 3. A schematic representation of the SCIB1 ImmunoBody® plasmid with the gp100 and TRP-
2 peptide sequences detailed, and their insertion sites outlined. Diagram provided in a 
correspondence from Scancell Ltd. 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
1.11. Carnosine as a first line non-toxic therapeutic 
In order to treat GBM a multitude of treatment modalities will most likely need to be combined. 
Previous research has found that single therapies are not as effective as combinatorial therapies 
(Stupp, Mason et al. 2005). Whilst combining therapeutic modalities can help improve patient 
survival one key factor to consider is the increased potential for deleterious side effects, for 
example the combination of anti-PD-1 and anti-CTLA-4 immune checkpoint blockade has been 
linked to increased incidences of adverse immune events in the melanoma setting (Hassel, 
Heinzerling et al. 2017). As a result combining standard therapy with treatments that have little to 
no side effects represents an exciting avenue for GBM therapy. In GBM the use of a ketogenic diet 
(low carbohydrate high fat) has been explored in combination with the current standard therapy 
(TMZ and radiotherapy (RT)). Early studies using a ketogenic diet in combination with standard 
therapy have revealed that this method of treating GBM holds promise and indicate that altering 
metabolism may hold the key to tackling GBM (Champ, Palmer et al. 2014, Zuccoli, Marcello et al. 
2010).  
Carnosine is a dipeptide composed of the amino acids beta alanine and L-histidine. Carnosine is 
abundant within the brain and skeletal muscle. Carnosine is a relatively enigmatic compound which 
has been shown to have many functions in numerous settings. It has been suggested that carnosine 
can act as a free radical scavenger, metal ion chelator, neurotransmitter, immunomodulatory, anti-
oxidant and pH buffer to name a few (Hipkiss, Preston et al. 1998). Carnosine has been shown to 
have anti-tumour effects in numerous cancers, however the mechanism by which carnosine affects 
tumour cells has not been fully elucidated, and carnosine has been shown to induce various changes 
within tumour cells. Previous research has shown that carnosine can inhibit human GBM cell growth 
(Oppermann, Dietterle et al. 2018). The activity of carnosine has been examined in numerous 
cancers and the proposed mechanism of action seems to be varied depending on the cancer studied.  
In the cancer setting carnosine has been shown to reduce the acidification of growth media when 
HeLa cervical cancer cells were grown under hypoxia in vitro. This reduced acidification was 
attributed to a reduction in the amount of carbonic anhydrase IX (CAIX) enzyme activity within 
these cells, and carnosine was shown to directly interact with CAIX tumours (Ditte, Ditte et al. 2014). 
Carnosine was also shown to lead to increased HIF-1α expression in HeLa cells cultured under 
hypoxic conditions. In vivo carnosine treatment led to a lower rate of tumour growth in a HeLa 
xenograft model with a reduction in the size of carnosine treated tumours even observed. The 
carnosine treated tumours were also shown to express higher levels of HIF-1α compared to control 
tumours (Ditte, Ditte et al. 2014). The reduction of extracellular acidification has been explored as 
potential treatment strategy for cancer and as a result the pH buffering effects of carnosine 
represent an attractive therapeutic modality. Combination of carnosine with the chemotherapeutic 
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agent 5-fluorouracil (5-FU) has also shown therapeutic potential against HT29 colon cancer cells in 
vitro. Carnosine did not directly induce apoptosis of 5-FU resistant HT29 cells, but it did however 
reduce the proliferation of these cells. Carnosine was shown to increase the sensitivity of these cells 
by reducing HIF-1α expression and its downstream targets (Iovine, Guardia et al. 2016). These 
results contradict those findings found using HeLa cervical cancer cells highlighting the enigmatic 
nature of the carnosine dipeptide. Carnosine also seemed to be cytotoxic for the human renal 
carcinoma cell line Caki-2, leading to increased activity of the apoptotic protein caspase-3. 
Computer modelling revealed that carnosine binds to a specific drug binding pocket on caspase-3 
(Pandurangan, Mistry et al. 2016). Carnosine appeared not to induce apoptosis or necrosis of the 
gastric cancer cell line SGC-7901 however it did appear to have an anti-proliferative effect. Further 
analyses revealed that carnosine treatment reduced the basal oxygen consumption rate and extra 
cellular acidification rate of SGC-7901 cells indicating that carnosine has the potential to inhibit 
glycolysis by these cells (Shen, Yang et al. 2014). Carnosine is broken down by the enzyme 
carnosinase, interestingly it has been found by proteomic analysis that that the carnosinase 1 
precursor (CNDP1) protein is down-regulated in GBM patient plasma compared to healthy control 
plasma (Gautam, Nair et al. 2012). These findings point to an anti-cancer effect of carnosine, if not 
by inducing cell death it affects the proliferation of cancer cells. Either effect would be greatly 
beneficial for the treatment of GBM, due to the relatively rapid growth of GBM tumours and their 
highly invasive nature. This holds promise for the use of carnosine as a therapeutic agent in the 
GBM setting.  
 
1.12. Aims 
The aim of this thesis is to examine the antigen expression profile of human GBM tumours and 
human and murine cell lines with the aim of identifying targetable immunogenic antigens and 
potential antigens that can be targeted immunotherapeutically. Once targetable antigens have 
been identified ImmunoBody® vaccination will be utilised to target the identified tumour associated 
antigens. The effect of IFNγ on the immune profile of GBM cell lines will also be studied as active 
immunotherapy generates IFNγ release from immune cells. Once the efficacy of ImmunoBody® 
vaccination has been demonstrated, PD-1/PD-L1 blockade will be incorporated into the vaccination 
strategy to boost the anti-tumour immune response in a proof of concept pre-clinical in vivo model 
of GBM using antigen expressing tumour cells implanted in the brains of humanised mice. As an 
adjunct to these immunotherapeutic studies the effects of carnosine on GBM cell lines will be 
studied.  
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1. Materials used 
2.1.1. Cell lines 
Name Description Age (Years) Sex Culture medium Supplier 
SEBTA-022 GBM left 
parietal lobe 
67 Male DMEM + 
GlutaMAX 
(Gibco) + 10% 
FCS 
A generous gift 
from the 
Portsmouth neuro-
oncology group 
SEBTA-025 GBM right 
frontal lobe 
24 Male DMEM + 
GlutaMAX 
(Gibco) + 10% 
FCS 
A generous gift 
from the 
Portsmouth neuro-
oncology group 
SEBTA-027 Recurrent 
GBM right 
parieto-
occipital 
region 
59 Female DMEM + 
GlutaMAX 
(Gibco) + 10% 
FCS 
A generous gift 
from the 
Portsmouth neuro-
oncology group 
UP-007 GBM 71 Male DMEM + 
GlutaMAX 
(Gibco) + 10% 
FCS 
A generous gift 
from the 
Portsmouth neuro-
oncology group 
UP-019 GBM 68 Female DMEM + 
GlutaMAX 
(Gibco) + 10% 
FCS 
A generous gift 
from the 
Portsmouth neuro-
oncology group 
UP-029 GBM 66 Male DMEM + 
GlutaMAX 
(Gibco) + 10% 
FCS 
A generous gift 
from the 
Portsmouth neuro-
oncology group 
SF-188 GBM 8 Male DMEM + 
GlutaMAX 
A generous gift 
from the 
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(Gibco) + 10% 
FCS 
Portsmouth neuro-
oncology group 
IN-699 GBM 15 Male DMEM + 
GlutaMAX 
(Gibco) + 10% 
FCS 
A generous gift 
from the 
Portsmouth neuro-
oncology group 
Table 1. Details of the human cell lines used for this study. 
 
Name Description Origin Modifications Culture 
medium 
Supplier 
B16 
HHDII/DR1 
Luc2 
Murine 
melanoma 
Naturally occurring 
tumour taken from 
the C57BL/6 mouse 
Transfected 
with the 
luciferase 
gene and the 
chimeric HLA-
A2/DR1 
receptors 
HHDII/DR1 
RPMI 1640 
+ 1% L-
glutamine + 
10% FCS + 
550 μg/mL 
Zeocin + 
300 μg/mL 
Hygromycin 
+ 500 
μg/mL 
G418 
A generous 
gift from 
Scancell Ltd. 
GL261 
Luc2 
Murine 
glioblastoma 
Induced via 
intracranial 
injection of 
methylcholanthrene 
into a C57BL/6 
mouse 
Transfected 
with the 
luciferase 
gene  
DMEM 
(Lonza) + 
10% FCS + 
100 μg/mL 
G418 
A generous 
gift from the 
Barrow 
Neurological 
Institute 
Table 2. Details of the murine cell lines used for this study. 
2.1.2. Reagents 
Reagent Supplier 
0.22 µm syringe filter Sartorius 
1.0 µm gold microcarriers BioRad 
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1M Tris-HCl Invitrogen 
2-mercaptoethanol Sigma 
4% Paraformaldehyde in PBS Santa Cruz 
40 µm nylon strainer Greiner bio-one 
Agar Bioline 
Agarose Bioline 
Ammonium persulphate (APS) Geneflow 
Ampicillin Sigma 
Anhydrous ethanol Sigma 
Anti PD-1 for in vivo BioXCell 
Avidin D solution Vector labs 
Bicinchoninic acid Sigma 
Biotin solution Vector labs 
Bovine serum albumin (BSA) Merck Millipore 
Brefeldin A BioLegend 
Bromophenol blue Arcos Organics 
Calcium chloride Sigma 
Carnosine Sigma 
Cell culture flasks for GBM cells Greiner bio-one 
Cell culture flasks for murine tissue 
culture 
Sarstedt 
Clarity western ECL substrate BioRad 
Collagenase type 1 from clostridium 
histolyticum 
Sigma 
Conical flasks Pyrex 
Copper (II) sulphate Sigma 
DAPI Vectashield mounting media Vector labs 
Dimethyl sulfoxide (DMSO) Insight biotechnology 
DMEM Lonza 
DMEM+ GLUTAMAX Gibco 
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DNA ladder 1 Kb plus Promega 
DNAse Sigma 
Double distilled water Barnstead, Nanopure Diamond 
DPX mounting media Sigma 
Dulbecco’s phosphate buffered saline Lonza 
EDTA 0.5M Ambion 
Eppendorf tubes Starsedt 
Ethanol Fisher scientific 
Ethyl alcohol absolute VWR 
Ethyldiamine tetraacetic acid (EDTA) Sigma 
FACS tubes Tyco healthcare group 
Falcon tubes Sarstedt 
FCS Fisher Scientific 
Filter paper Schleicher-Schuell 
Flow check beads Beckman Coulter 
Flow set beads Beckman Coulter 
Fungizone (amphotericin B) Promega 
Genetecin (G418) Sigma 
Glacial acetic acid Fisher scientific 
Glass coverslips SLS 
Glass microscope slides SLS 
Glycerol Sigma 
Glycine Sigma 
Goat serum Sigma 
HALT protease and phosphatase 
inhibitor cocktail 
ThermoFisher 
HEPES Lonza 
Hydrochloric acid Fisher scientific 
Hydrogen peroxide Sigma 
Hygromycin Merck Millipore 
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Isopropanol Sigma 
Isoton sheath fluid Beckman Coulter 
LB broth Sigma 
LB broth low salt (Luria) Sigma 
LB broth with agar Sigma 
L-Carnosine Sigma 
L-glutamine Lonza 
L-shaped spreader Sigma 
Marvel skimmed milk powder Marvel 
Mayer’s Haematoxylin Sigma 
Methanol Fisher scientific 
Mitomycin C Sigma 
Monensin Biolegend 
MTT reagent Sigma 
Murine IFNγ elispot kit Mabtech 
OneComp eBeads compensation beads Thermo Fisher 
PD-1 isotype control BioXCell 
P-dimethylaminobenzaldehyde Sigma 
Penicillin/Streptomycin Lonza 
Peptides GenScript 
PerFix-nc kit Beckman Coulter 
Petri dishes Sarstedt 
Phosphate buffered saline (PBS) tablets Oxoid 
Pipette tips Greiner bio-one/Sarstedt 
Polyvinyl pyrrolidone (PVP) Sigma 
Protogel (30% acylamide) GeneFlow 
PVDF blotting membrane GE healthcare 
QIAGEN QUA-filter plasmid midi kit QIAGEN 
Recombinant human IFNγ Peprotech 
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RPMI 1640 Lonza 
Scalpels SLS 
SCIB1 ImmunoBody® plasmid Scancell Ltd. 
Serological pipettes Sarstedt 
Sodium chloride Calbiochem 
Sodium citrate trisodium salt dihydrate Sigma 
Sodium dodecyl sulphate (SDS) Sigma 
Sodium pyruvate Lonza 
Solution 18 ChemoMetec 
Spermidine Sigma 
Staphylococcal enterotoxin B (SEB) Sigma 
Streptavidin alkaline phosphate 
conjugate substrate kit 
BioRad 
Sucrose Sigma 
SYBR® safe DNA gel stain Invitrogen 
Syringes Becton Dickenson 
Tefzel tubing BioRad 
TEMED GeneFlow 
Tetraethylammonium bromide (TEAB) 
25 mM 
Sigma 
Tissue culture plates Sarstedt 
Trichloro-acetic acid (TCA) Sigma 
Triton X-100 Sigma 
Trizma base Sigma 
Trypan blue solution 0.4% Sigma 
TrypLE Express Gibco 
Trypsin/versine Lonza 
TWEEN20 Sigma 
Vectastain Elite ABC HRP kit Vector labs 
WT-1 ImmunoBody® plasmid Scancell Ltd. 
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Xylene Fisher scientific 
Zeocin Invitrogen 
Table 3. Details of the reagents used and the supplier of each reagent 
2.1.3. Buffer recipes  
0.025 mg/mL PVP 
8.75 μL 20 mg/mL PVP 
7 mL anhydrous ethanol 
0.1% triton X100 in PBS 
10 μL triton X100 
10 mL dH2O 
0.5% BSA in PBS 
0.5 g BSA 
100 mL PBS 
0.5 M spermidine 
14.525 g calcium chloride 
100 ml dH2O 
0.05 M spermidine 
50 μL 0.5 M spermidine 
450 μL nuclease free water 
1 M Calcium chloride 
11.098 g calcium chloride 
100 ml dH2O 
1M Sodium chloride 
0.5844 g sodium chloride 
10 mL dH2O 
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1M Tris pH 6.8 
12.114 g trizma base 
90 mL dH2O 
Adjust pH to 6.8 using hydrochloric acid then top up to 100 mL with dH2O 
1.5 M Tris pH 8.8 
18.171 g trizma base 
90 mL dH2O 
Adjust pH to 8.8 using hydrochloric acid then top up to 100 mL with dH2O 
1x PBS 
10 PBS tablets 
1000 mL dH2O 
1x Running buffer 
100 mL 10x Running buffer 
900 mL dH2O 
1x Transfer buffer 
100 mL 10x Transfer buffer 
900 mL dH2O 
3% hydrogen peroxide in methanol 
10 mL 30 % hydrogen peroxide 
90 mL ethanol 
5 % Stacking gel (x1 gel) 
4.1 mL dH2O 
1 mL 30 % acylamide mix 
750 μL 1M Tris pH 6.8 
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60 μL 10 % APS 
60 μL 10 % SDS 
6 μL TEMED 
5x SDS-PAGE loading buffer 
1 mL glycerol 
1g SDS 
3.125 1M Tris-HCl pH 8.0 
2.5 mL beta mercaptoethanol 
1 mL 0.5% bromophenol blue 
1.375 dH2O 
10 % APS 
10 mL dH2O 
1 g APS 
10% Resolving gel (x1 gel) 
4 mL dH2O 
3.3 mL 30 % acylamide mix 
2.5 mL 1.5M Tris pH 8.8 
100 μL 10 % APS 
100 μL 10 % SDS 
4 μL TEMED 
10 % sodium deoxycholate 
0.3 g sodium deoxycholate 
3 mL dH2O 
10 % SDS 
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10 mL dH2O 
1 g SDS 
10 % Triton X100 
600 μL Triton X100 
5.4 mL dH2O 
10x Running buffer 
30.3 g trizma base 
144 g glycine 
10 g SDS 
1000 mL dH2O 
10 x TBS 
24.2 g trizma base 
80 g sodium chloride 
800 mL dH2O 
Adjust pH to 7.6 using hydrochloric acid then top up to 1000 mL with dH2O 
10x Transfer buffer 
30.3 g trizma base 
144 g glycine 
1000 mL dH2O 
20 mg/mL PVP 
10 mg PVP powder 
500 μL anhydrous ethanol 
100 mM EDTA 
0.2922 g EDTA 
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10 mL dH2O 
Complete T-cell media 
50 mL FCS (10 %) 
5 mL penicillin and streptomycin (1 %) 
5 mL L-glutamine (200 mM) 
10 mL HEPES (200 mM) 
0.5 mL fungizone (0.1 %) 
1 mL 1 M beta mercaptoethanol (2 mM) 
428.5 mL RPMI 1640 
Ehrlich’s reagent 
200 mg P-dimethylaminobenzaldehyde 
10 mL glacial acetic acid 
LB broth Luria low salt 
30.5 g LB broth low salt powder 
1000 mL dH2O 
Autoclave at 151 ⁰C for 15 minutes 
LB broth with agar  
40 g LB broth with agar powder 
1000 mL dH2O 
Autoclave at 151 ⁰C for 15 minutes 
5 mg/mL MTT reagent 
250 mg MTT 
50 mL DPBS 
PBST 
57 
 
0.5 mL TWEEN 20 
1000 mL PBS 
RIPA buffer 
2.5 mL 1M Tris-HCl pH 8.0 
7.5 mL 1 M sodium chloride 
0.5 mL 10 % SDS 
2.5 mL sodium deoxycholate 
5 mL 10 % Triton X100 
0.5 mL 100 mM EDTA 
31.5 mL dH2O 
Sodium citrate pH 6.0 
2.94 g sodium citrate trisodium salt dihydrae 
800 mL dH2O adjust pH to 6.0 using hydrochloric acid then top up to 1000 mL with dH2O 
0.5 mL TWEEN 20 
TBST 
100 mL 10 x TBS 
900 mL dH2O 
1 mL TWEEN 20 
TE buffer 
1 mL 1M tris pH 8.0 
200 μL 0.5 M EDTA pH 8.0 
99.8 mL dH2O 
Tris-EDTA pH 9.0 
1.21 g Trizma base 
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0.37 g EDTA 
900 mL dH2O adjust pH to 9.0 using hydrochloric acid or sodium hydroxide then top up to 
1000 mL with dH2O 
0.5 mL TWEEN 20 
Table 4. Recipes for the buffers used. The buffer name is emboldened and the ingredients are listed 
below. 
 
2.1.4. Antibodies for Western blotting 
Antibody Dilution Manufacturer 
Mouse anti-
human HLA-A, B, 
C 
1:1000 Abcam 
Mouse anti-
human HLA-E 
1:1000 Abcam 
Mouse anti-
human HLA-G 
1:1000 Abcam 
Rabbit anti-
human PD-L1 
1:1000 Cell Signalling 
Rabbit anti-
human MGMT 
1:1000 Abcam 
Rabbit anti-
mouse/human 
TRP-2 
1:1000 Abcam 
Rabbit anti-
human/mouse 
WT-1 
1:500 Abcam 
Rabbit anti-
human/mouse 
gp100 
1:500 Abcam 
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Rabbit anti-
human HAGE 
1:250 Sigma 
Rabbit anti 
human/mouse 
Vinculin 
1:10000 Abcam 
Mouse anti 
human IDO 
1:250 Abcam 
HRP conjugated 
goat anti-rabbit 
1:1000 Cell Signalling 
HRP conjugated 
horse anti-mouse 
1:1000 Cell Signalling 
Table 5. Antibodies used for Western blotting 
 
2.1.5. Antibodies for immunohistochemistry 
Antibody Dilution Manufacturer Antigen 
retrieval 
buffer used 
Mouse anti-
human HLA-A, B, 
C 
1:500 Abcam Sodium citrate 
pH 6.0 
Mouse anti-
human HLA-E 
1:500 Abcam Sodium citrate 
pH 6.0 
Mouse anti-
human HLA-G 
1:25 Abcam TRIS-EDTA pH 
9.0 
Rabbit anti-
human PD-L1 
1:50 Cell Signalling Sodium citrate 
pH 6.0 
Rabbit anti-
human MGMT 
1:500 Abcam Sodium citrate 
pH 6.0 
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Rabbit anti-
mouse/human 
TRP-2 
1:500 Abcam TRIS-EDTA pH 
9.0 
Mouse anti-
human WT-1 
1:50 Dako Sodium citrate 
pH 6.0 
Rabbit anti-
human/mouse 
gp100 
1:50 Abcam Sodium citrate 
pH 6.0 
Rabbit anti-
human HAGE 
1:100 Sigma Sodium citrate 
pH 6.0 
Table 6. Antibodies used for immunostaining  
 
2.1.6. Antibodies for immunofluorescence/immunocytochemistry 
Antibody Dilution Manufacturer 
Rabbit anti-
mouse/human 
TRP-2 
1:150 Abcam 
Rabbit anti-
human/mouse 
WT-1 
1:50 Abcam 
Donkey anti-
rabbit Alexa 
Fluor® 488 
1:500 Abcam 
Table 7. Antibodies used for Immunocytochemistry and Immunofluorescence 
 
2.1.7. Antibodies for flow cytometry  
2.1.7.1 Antibodies for cell surface staining of human cells 
Antibody Clone Fluorophore Supplier 
Anti-human 
HLA-A, B, C 
W6/32 APC/Cy7 BioLegend 
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Anti-human 
HLA-E 
3D12 PerCP/Cy5.5 BioLegend 
Anti-human 
HLA-G 
87G PE/Cy7 BioLegend 
Anti-human 
HLA-A2 
BB7.2 APC BioLegend 
Anti-human 
CD80 
2D10 PE/Dazzle™ 594 BioLegend 
CD86 IT2.2 Pacific blue™ BioLegend 
Anti-human 
FasL 
NOK-1 PE BioLegend 
Anti-human 
MICA/B 
6D4 Alexa Fluor® 
488 
BioLegend 
Anti-human PD-
L1 
29E.2A3 APC BioLegend 
Anti-human 
CD40 
53C Alexa Fluor® 
700 
BioLegend 
Anti-human 
CD119 
GIR-208 PE BioLegend 
LIVE/DEAD™ 
fixable violet  
N/A N/A ThermoFisher 
FcR blocking 
reagent 
N/A N/A Miltenyi Biotec 
Table 8. Details of the antibodies used for flow cytometry 
 
2.1.7.2. Antibodies for intracellular murine splenocyte staining 
Antibody Clone Fluorophore Supplier 
Anti-mouse 
CD107a 
MEL-14 FITC BioLegend 
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Anti-mouse TNFα MP6-XT22 PE BioLegend 
Anti-mouse Ki67 SolA15 PE-eFluor 610 eBioscience 
Anti-mouse IL-2 JES6-5H4 PerCP/Cy5.5 BioLegend 
Anti-mouse IFNγ XMG1.2 Pe/Cy7 BioLegend 
Anti-
mouse/human 
Granzyme B 
QA16A02 APC BioLegend 
Anti-mouse CD4  GK1.5 Alexa Fluor®700 BioLegend 
Anti-mouse CD8a 53-6.7 APC/Cy7 BioLegend 
Anti-mouse CD3 17A2 Brilliant violet 
421™ 
BioLegend 
LIVE/DEAD™ 
fixable violet  
N/A N/A ThermoFisher 
Hamster anti-
mouse CD28 (for 
stimulation) 
N/A N/A Becton Dickinson 
Rat anti-mouse 
CD49d (for 
stimulation) 
N/A N/A Becton Dickinson 
Anti-CD16/32 (FcR 
blocking reagent) 
N/A N/A BioLegend 
Table 9. Details of the antibodies used for flow cytometry 
 
2.1.7.3. Antibodies for brain TIL staining 
Antibody Clone Fluorophore Supplier 
Anti-mouse CD69 H1.2F3 PE/Dazzle™ BioLegend 
Anti-mouse FoxP3 MF-14 Pacific blue™ BioLegend 
Anti-mouse CD62L MEL-14 Alexa fluor®488 BioLegend 
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Anti-mouse CD25 3C7 PerCP/Cy5.5 BioLegend 
Anti-mouse CD3 17A2 PE BioLegend 
Anti-mouse PD-1 29F.1A12 APC/Cy7 BioLegend 
Anti-
mouse/human 
CD44 
IM7 Alexa Fluor®700 BioLegend 
Anti-mouse CD4 RM4-5 PE/Cy7 BioLegend 
Anti-mouse CD8a 53-6.7 APC BioLegend 
LIVE/DEAD™ 
fixable violet  
N/A N/A ThermoFisher 
Anti-CD16/32 (FcR 
blocking reagent) 
N/A N/A BioLegend 
Table 10. Details of the antibodies used for flow cytometry 
 
2.2. Methods 
2.2.1. Cell culture 
2.2.1.1 Human cell culture 
All glioblastoma multiforme cell lines were cultured in GBM cell media (detailed in Table 1). Once 
cells had reached 80-90% confluency they were washed once with DPBS. Once washed a thin 
coating of TrypLE express was added to the cells. Cells were then left under TrypLE express at room 
temperature and checked at regular intervals using a light microscope. Once cells were visibly 
detached and floating complete media containing FCS was added to neutralise the TrypLE express. 
The volume of media added depended upon the size of flask used, for a T25 flask 5 mL of media 
was added for a T75 flask 10 mL of media was added and for a T175 flask 20 mL of media was added. 
The media was gently pipetted up and down the cell culture surface to rinse the cells off and then 
the media was transferred to a Falcon tube. The cells were then pelleted by centrifugation at 12,000 
RPM for 5 minutes. Once complete media was removed from the pellet and the pellet was re-
suspended in fresh culture media. Fresh tissue culture flasks had the desired amount of GBM media 
added to them and then the desired amount of cell suspension was added to each flask. Tissue 
culture flasks were then placed in a humidified incubator at 37 ⁰C with 5% CO2 (Sanyo). 
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2.2.1.2. Murine cell culture 
The B16 HHDII/DR1 Luc cell line and the GL261 Luc2 cell lines were cultured in the appropriate 
media detailed above. Once cells had reached 80-90% confluency they were washed once with 
DPBS. Once washed a thin coating of trypsin/versine was added to the cells. Cells were then left 
under trypsin/versine in a 37 ⁰C humidified tissue culture incubator (Sanyo) and checked at regular 
intervals using a light microscope. Once cells were visibly detached and floating complete media 
containing FCS was added to neutralise the trypsin/versine. The volume of media added depended 
upon the size of flask used, for a T25 flask 5 mL of media was added for a T75 flask 10 mL of media 
was added and for a T175 flask 20 mL of media was added. The media was gently pipetted up and 
down the cell culture surface to rinse the cells off and then the media was transferred to a Falcon 
tube. The cells were then pelleted by centrifugation at 12,000 RPM for 5 minutes, once complete 
media was removed from the pellet and the pellet was re-suspended in fresh culture media. Fresh 
tissue culture flasks had the desired amount of GBM media added to them and then the desired 
amount of cell suspension was added to each flask. Tissue culture flasks were then placed in a 
humidified incubator at 37 ⁰C with 5% CO2 (Sanyo). 
 
2.2.1.3. IFNγ treatment of GBM cell lines 
Human GBM cells were cultured in a T75 flask, once cells had reached 80% confluency all of the 
media was removed and replaced with the appropriate culture media containing 100 ng/mL IFNγ. 
Cells were then left for either 24, 48 or 72 hours, at which point they were detached using TrypLE 
express and then either analysed using western blotting or flow cytometry. 
 
2.2.1.4. Carnosine treatment of cell lines 
GBM cells were cultured in a T75 flask, once cells had reached 80% confluency all of the media was 
removed and replaced with carnosine containing media of varying concentrations. The carnosine 
was prepared by dissolving L-carnosine in the appropriate culture media and then this solution 
sterile filtered using a 0.22 µM syringe filter. Carnosine was then added to cells for 24 hours and 
once completed cells were detached and prepared for analysis. 
 
2.2.2. Immunohistochemistry 
2.2.2.1. Immunohistochemistry 
Antibody staining conditions were optimised using the appropriate positive control tissues detailed 
in the table below. The antibody manufacturers’ antigen retrieval conditions and antibody 
concentrations were utilised, as well as slightly higher and lower concentrations of antibodies. In 
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all cases the antibody suppliers’ antigen retrieval method was suitable for the antibodies used, this 
is detailed in the table below. 
Antibody Positive control tissue 
used for optimisation 
Supplier Antigen retrieval 
method 
Mouse anti-human 
HLA-A, B, C 
Tonsil and spleen US Biomax Sodium citrate pH 
6.0 
Mouse anti-human 
HLA-E 
Tonsil US Biomax Sodium citrate pH 
6.0 
Mouse anti-human 
HLA-G 
Spleen US Biomax TRIS-EDTA pH 9.0 
Rabbit anti-human 
PD-L1 
Tonsil and placenta US Biomax Sodium citrate pH 
6.0 
Rabbit anti-human 
MGMT 
Spleen US Biomax Sodium citrate pH 
6.0 
Rabbit anti-
mouse/human TRP-
2 
Melanoma US Biomax TRIS-EDTA pH 9.0 
Rabbit anti-
mouse/human WT-
1 
Embryonic kidney Cell Marque Sodium citrate pH 
6.0 
Rabbit anti-
human/mouse 
gp100 
Melanoma US Biomax Sodium citrate pH 
6.0 
Rabbit anti-human 
HAGE 
Testis US Biomax Sodium citrate pH 
6.0 
Table 11. Positive control tissues used for IHC optimisation 
 
Once conditions were optimised FFPE GBM tissue microarrays (US Biomax) were stained using the 
same antigen retrieval methods and antibody concentrations that were deemed as appropriate 
during optimisation (detailed in Table 11). Prior to commencing immunohistochemical staining 
sections were baked for 30 minutes at 60 ⁰C in a dry oven then they were dewaxed by two 
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consecutive immersions in xylene and then the sections were re-hydrated by immersion in graded 
ethanol (100%, 100%, 90% then 70%). Slides were then briefly immersed in dH2O for 2 minutes 
before endogenous peroxidase activity was blocked using 3% hydrogen peroxide in methanol. 
Slides were then rinsed in dH2O for 3 minutes. After rinsing slides were immediately immersed in 
100 ⁰C antigen retrieval buffer (Tris-EDTA pH 9.0 or sodium citrate pH 6.0) for 20 minutes. The slides 
were then left to cool in the antigen retrieval buffer for 20 minutes on the bench top. Once slides 
had cooled they were washed in TBST (0.1% TWEEN20) for 5 minutes. Sections were then blocked 
with 2.5% normal horse serum (Vectastain Elite ABC HRP kit, Vector labs) for 10 minutes at room 
temperature. Blocking buffer was then removed and avidin D solution (Vector labs) was applied to 
sections for 15 minutes. Slides were then washed in TBST for 2 minutes. Biotin (Vector labs) solution 
was then applied to sections for 15 minutes. After 15 minutes the biotin was removed, and primary 
antibody was applied to the sections for 1 hour at room temperature. Slides were then washed 
twice in TBST for 10 minutes. Pan-specific biotinylated secondary antibody (Vectastain Elite ABC 
HRP kit, Vector labs) was then applied to sections for 10 minutes at room temperature, slides were 
then washed twice in TBST for 10 minutes. Next ABC reagent (Vectastain Elite ABC HRP kit, Vector 
labs) was applied to the sections for 5 minutes, slides were then washed twice in TBST for 10 
minutes. DAB reagent was then added to sections for 3 minutes at room temperature, slides were 
then washed in dH2O for 2 minutes and counterstained with Mayer’s hematoxylin (Sigma). Sections 
were then run through consecutive immersion in 70%, 90%, 100%, 1000% ethanol and then finally 
twice in xylene. Coverslips were then mounted with DPX mountant. Slides were imaged using a 
Leica Ariol (Leica) or Hamatsu NanoZoomer microscope (Hamatsu).  
2.2.3. Western blotting 
2.2.3.1. Preparation of cellular lysates 
A confluent T75 flask of cells were tripsinised and pelleted, then 700 µL of 
radioimmunoprecipitation assay (RIPA) buffer was added (with HALT protease inhibitor), cells were 
then vigorously vortexed then placed on ice every 10 minutes for a 30-minute period. Cells were 
then centrifuged to separate cellular debris from lysate. 
 
2.2.3.2. Bicinchoninic acid (BCA) assay 
 2 mg/mL of BSA was prepared by dissolving BSA in RIPA buffer, this 2 mg/mL BSA stock solution 
was then used to prepare a BSA standard curve as below. 
Final BSA 
concentration 
(μg/mL) 
Volume of BSA (μL) Volume of 
RIPA buffer 
(μL) 
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2000 300 of 2 mg/mL BSA 0 
1500 375 of 2 mg/mL BSA 125 
1000 325 of 2 mg/mL BSA 325 
750 175 of 1500 μg/mL BSA 175 
500 325 of 1000 μg/mL BSA 325 
250 325 of 500 μg/mL BSA 325 
125 325 of 250 μg/mL BSA 325 
25 100 of 125 μg/mL BSA 400 
0 0 400 
Table 12. Preparation of BSA standards for the BSA protein assay 
 
The cellular lysates of unknown protein concentration were diluted 1 in 4 in RIPA buffer and then 
thoroughly vortexed. Once the samples and standards were prepared 25 µL of standards and 
samples were added in triplicate to a flat-bottomed 96 well plate. Once all samples and standards 
were plated working reagent was prepared by diluting copper II sulphate solution 1 in 50 in 
bicinchoninic acid solution. 200 μL of working solution was added to each well containing standards 
and samples. The plate was then covered with foil and left to incubate at 37 ⁰C for 30 minutes. After 
incubation the plate was read with absorbance set to 570 nm in a plate reader (Tecan). When 
analysing data background (0 μg/mL BSA) was subtracted from all measurements and then protein 
concentrations of the unknown samples were then calculated using the standard curve. 
 
2.2.3.3. Western blotting 
A 5% stacking gel with 10% resolving gel was made and 20-30 µg of protein was loaded into the 
gel. The gel was run at 100 V and once complete proteins were transferred to a PVDF membrane 
at 100 V for 90 minutes in cooled transfer buffer. Once transfer was completed membranes were 
blocked in 5% (w/v) milk solution in TBST. Membranes were then washed 5 times for 5 minutes 
in TBST. Once membranes were washed they were incubated in primary antibody diluted in 5% 
(w/v) milk solution in TBST overnight at 4⁰C. After incubation in primary antibody membranes 
were washed 5 times for 5 minutes in TBST. After washing, the membranes were incubated in 
HRP conjugated secondary antibody and anti-ladder secondary diluted in 5% (w/v) milk solution 
in TBST. Membranes were placed in secondary antibody diluted in 5% (w/v) milk in TBST for 1 
hour at room temperature. After incubation in secondary antibody membranes were washed 5 
times for 5 minutes in TBST. After washing membranes were coated with ECL developing solution 
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and imaged using the Syngene G:Box station (Syngene). 
 
2.2.3.4. Western blot quantification using ImageJ 
Once blots had been imaged ImageJ software was used to analyse the intensity of the bands on 
the blots. Each lane was determined and then the intensity peaks were obtained for bands within 
that lane (see Figure 4). 
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Figure 4. ImageJ identification of protein lanes on Western blot membrane image followed by 
intensity peaks for each band. 
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Once the area under the intensity peak was discovered the protein expression was determined 
using the following equation: Intensity of protein of interest / Intensity of loading control. This 
generates a relative intensity compared to the loading control for each lane. 
 
2.2.4. Immunocytochemistry/immunofluorescence 
2.2.4.1. Immunocytochemistry 
Cells were grown on glass coverslips and once sufficiently confluent cells were stained. Cells were 
first fixed in 4% paraformaldehyde in PBS (Santa Cruz) for 1 hour at room temperature. Cells were 
then washed three times with PBS. Cells were then permeabilised with 0.1% Triton X-100 in PBS for 
5 minutes at room temperature. Cells were then washed three times with PBS. Cells were then 
blocked using 2.5% horse serum (Vectastain Elite ABC HRP kit, Vector labs) for 10 minutes at room 
temperature. Serum was then removed, and cells were incubated with avidin D solution (Vector 
labs) for 15 minutes at room temperature. Cells were then washed in PBS for 2 minutes. Biotin 
solution (Vector labs) was then added to cells for 15 minutes at room temperature. Cells were then 
incubated in the appropriate primary antibodies (see table….) diluted in 2.5% horse serum 
overnight at 4⁰C. Cells were washed three times in PBS, cells were then incubated in pan-specific 
biotinylated secondary anti-mouse/rabbit IgG antibody (Vectastain Elite ABC HRP kit, Vector labs) 
for 10 minutes at room temperature. Cells were then washed three times in PBS. Cells were 
incubated in ABC kit streptavidin complex (Vector lab) for 5 minutes at room temperature. Cells 
were washed three times in PBS. Cells were incubated in DAB solution (Vector labs) for 3 minutes. 
Cells were washed in dH2O for 2 minutes. Cells were then counterstained with Mayer’s Hematoxylin 
(Sigma). Cells were then washed under tap water for 5 minutes. The cells on the coverslips were 
then mounted to slides using DPX mounting media (Sigma). Cells were then imaged microscopically 
(Zeiss). 
 
2.2.4.2. Immunofluorescence 
Cells were grown on glass coverslips and once sufficiently confluent cells were stained. Cells were 
first fixed in 4% paraformaldehyde in PBS (Santa Cruz) for 1 hour at room temperature. Cells were 
then washed three times with PBS. Cells were then permeabilised with 0.1% Triton X-100 in PBS for 
5 minutes at room temperature. Cells were then washed three times with PBS. Cells were then 
blocked with 0.5% BSA in PBS for 30 minutes at room temperature. Cells were then incubated in 
primary antibody diluted in 0.5% BSA in PBS overnight at 4⁰C (see Table 5.). Cells were then washed 
three times with PBS. Cells were then incubated in donkey anti-rabbit IgG Alexa Fluor® 488 diluted 
in 0.5% BSA in PBS for 1 hour at room temperature in the dark. Cells were then washed three times 
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with PBS. The cells on the coverslips were then mounted to slides using vectashield hardset DAPI 
mounting medium (Vector labs). Cells were then imaged using a fluorescence microscope (Zeiss). 
 
2.2.5. Flow cytometry 
2.2.5.1. Cell surface flow cytometry 
A confluent flask of cells was trypsinised and then 1 million cells were placed in a polystyrene 
flow cytometry tube, cells were washed with 2 mL of PBS (phosphate buffered saline), cells were 
spun at 300g for 5 minutes and the supernatant was poured off. Cells were re-suspended in 50 
µL of FCS and then FCR block was added and tubes were mixed immediately and incubated for 
15 minutes at 4 ⁰C. The appropriate antibodies diluted in PBS were then added to each tube at 
the manufacturers recommended concentration. Tubes were then incubated for 30 minutes at 4 
⁰C in the dark. After antibody staining cells were washed with 2 mL of PBS, the cells were spun at 
300g for 5 minutes and the supernatant poured off. The cells were then re-suspended in 350 μL 
of isoton and analysed on a Gallios flow cytometer (Beckman Coulter) and data analysis was 
performed using Kaluza software (Beckman Coulter).  
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2.2.5.2. Gating strategy for cell surface staining  
 
 
 
Figure 5. Gating strategy employed when examining the cell surface antigen expression of GBM cell 
lines. 
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Firstly singlets were gated out, once the singlets were gated events with low side scatter and 
forward scatter were excluded as these were deemed to be cellular debris. Next the forward 
scatter time of flight and time were plotted to see if there were any breaks in the flow, if any 
breaks were seen these were gated out (in the above example there is no break in the flow), 
finally FL10 (LIVE/DEAD) was plotted against forward scatter and any events positive on FL10 
were gated out of the analysis as these are dead cells. These live cells were then analysed for 
antigen staining and gates were set to exclude unstained populations. 
 
2.2.5.3. Flow cytometry staining of vaccinated splenocytes  
1 million splenocytes in 50 μL of T-cell media were plated in a flat bottomed 96 well plate. 50 μL 
of T-cell media containing either no peptide, 4 μg/mL of class I peptide or 4 μg/mL of class I 
peptide and 40 μg/mL of class II peptide was then added to the wells containing splenocytes 
(these concentrations are 4 times the final concentration, however further additions to the plate 
result in the final concentrations being 1 μg/mL of class I peptide and 10 μg/mL of class II peptide). 
Next 50 μL of T-cell media containing co-stimulatory anti-CD28 and anti-CD49d (final 
concentration 1μg/mL for both). Cells were then incubated for 1 hour at 37 ⁰C in a tissue culture 
incubator (Sanyo). After incubation 50 μL of Brefeldin A and monensin diluted 1 in 250 in T-cell 
media (final dilution 1 in 1000) was added to each well, wells were then pipette mixed and 3 μL 
of anti-CD107a was added to each well and the plate was incubated for 5 hours at 37 ⁰C in a tissue 
culture incubator (Sanyo). After incubation cells were transferred to a FACS tube and the tube 
was centrifuged at 300 G for 5 minutes, the supernatant was removed and the cell pellet was re-
suspended in 50 μL of FCS, 1 μL of FcR blocking reagent was then added and tubes were mixed 
immediately and incubated for 15 minutes at 4 ⁰C. The appropriate cell surface antibodies 
(CD107a, CD4, CD8, CD3 and LIVE/DEAD) diluted in PBS were then added to each tube at the 
manufacturers recommended concentration. Tubes were then incubated for 30 minutes at 4 ⁰C 
in the dark. 25 μL of fixative agent R1 (Beckman Coulter PerFix-nc kit) was then added to each 
tube and mixed then tubes were incubated for 15 minutes at 4 ⁰C in the dark. 300 μL of 
permebealising reagent R2 (Beckman Coulter PerFix-nc kit) containing the required concentration 
of intracellular antibody (TNFα, Ki67, IL-2, IFNγ and Granzyme B) was added to each tube an mixed 
immediately, the tubes were then incubated for 30 minutes at 4 ⁰C in the dark. 2mL of 1 x reagent 
R3 (Beckman Coulter PerFix-nc kit) was added per tube and the tubes were then centrifuged at 
500 G for 5 minutes. The resulting cell pellets were then re-suspended in 250 μL of reagent R3 
and then run on a Gallios flow cytometer (Beckman Coulter), data was then analysed using Kaluza 
software (Beckman Coulter). 
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2.2.5.4. Gating strategy for intracellular staining of vaccinated splenocytes 
 
Figure 6. Gating strategy employed when examining the cell surface and intracellular antigen 
expression profiles of vaccinated splenocytes. 
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Firstly singlets were gated out, once the singlets were gated events with low side scatter and 
forward scatter were excluded as these were deemed to be cellular debris. Next Live CD3 cells 
were isolated from the splenocyte population using gate L (Figure 6), the CD3 cells were then 
separated into CD4 (Gate D) and CD8 (Gate C) positive cells and then these two populations were 
further analysed. 
 
2.2.5.5. Flow cytometry staining of brain TILs 
A FACS tube containing 1 million cells was centrifuged at 300 G for 5 minutes, the supernatant 
was removed and the cell pellet was re-suspended in 50 μL of FCS, 1 μL of FcR blocking reagent 
was then added and tubes were mixed immediately and incubated for 15 minutes at 4 ⁰C. The 
appropriate cell surface antibodies (CD62L, CD3, CD69, CD25, CD4, CD8a, CD44, PD-1 and 
LIVE/DEAD) diluted in PBS were then added to each tube at the manufacturers recommended 
concentration. Tubes were then incubated for 30 minutes at 4 ⁰C in the dark. 25 μL of fixative 
agent R1 (Beckman Coulter PerFix-nc kit) was then added to each tube and mixed then tubes 
were incubated for 15 minutes at 4 ⁰C in the dark. 300 μL of permebealising reagent R2 (Beckman 
Coulter PerFix-nc kit) containing the required concentration of intracellular antibody (FOXP3) was 
added to each tube an mixed immediately, the tubes were then incubated for 30 minutes at 4 ⁰C 
in the dark. 2mL of 1 x reagent R3 (Beckman Coulter PerFix-nc kit) was added per tube and the 
tubes were then centrifuged at 500 G for 5 minutes. The resulting cell pellets were then re-
suspended in 250 μL of reagent R3 and then run on a Gallios flow cytometer (Beckman Coulter), 
data was then analysed using Kaluza software (Beckman Coulter). 
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2.2.5.6. Gating strategy for brain TILs 
 
Figure 7. Gating strategy employed when examining the cell surface and intracellular antigen 
expression profiles of brain tumour infiltrating lymphocytes. 
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Firstly singlets were gated out, once the singlets were gated events with low side scatter and 
forward scatter were excluded as these were deemed to be cellular debris. Next Live CD3 cells 
were isolated from the population using gate C, the CD3 cells were then separated into CD4 (Gate 
H) and CD8 (Gate E) positive cells and then these two populations were further analysed. 
 
2.2.6. DNA bullet preparation 
2.2.6.1. Bulking up of ImmunoBody® plasmid using XL1-blue E. coli  
Purified ImmunoBody® plasmid was transformed into XL-1 blue E. coli via heat shock. XL-1 cells 
were slowly thawed on ice, once thawed 100 µL of bacteria were transferred to a 1.5 mL Eppendorf 
tube, 1000 ng of plasmid was added to the bacteria and the mixture was left on ice for 30 minutes. 
The tube was then placed in a 42 ⁰C water bath (SLS) for 3 minutes and then placed on ice for 5 
minutes. 400 µL of antibiotic free low salt Laurie broth was then added to the tube and the tube 
was incubated at 37 ⁰C with shaking at 200 RPM for 1 hour. Laurie agar plates containing 35 µg/mL 
of zeocin were then prepared. After 1 hour of incubation 250 µL of the bacteria solution was then 
placed on the zeocin containing agar plate and spread using an L-shaped spreader. The plate was 
incubated for 16 hours in a 37 ⁰C oven. After incubation colonies had formed on the plate, a single 
colony was then taken off the plate and transferred into a 50 mL universal tube containing 30 mL 
of low salt Laurie broth containing 35 µg/mL of zeocin, this tube was then incubated at 37 ⁰C with 
shaking at 200 RPM for 1 hour. This 30 mL was then transferred to a conical flask containing 70 mL 
low salt Laurie broth containing 35 µg/mL of zeocin. This conical flask was then incubated at 37 ⁰C 
with shaking at 200 RPM overnight. After incubation the plasmids were extracted from the bacterial 
using a QIAfilter plasmid midi kit. 
 
2.2.6.2. ImmunoBody® plasmids utilised 
Below in Figure 8 and Figure 9 are the plasmid maps for the ImmunoBody® DNA vaccines used in 
this study. Above each map are the details of the peptide epitopes inserted into the CDRs of the 
encoded antibodies. 
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Figure 8. Plasmid map of the SCIB1 ImmunoBody® plasmid. 
 
 
Figure 9. Plasmid map of the WT1 ImmunoBody® plasmid. 
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2.2.6.3. Plasmid extraction from transformed bacteria 
The plasmid was extracted from the transformed bacteria using the QIAGEN QIAfilter plasmid midi 
kit following the manufacturer’s protocol. After growth the bacteria was transferred to 50 mL flacon 
tubes, these tubes were then spun at 6000 G for 15 minutes at 4 ⁰C to pellet the bacteria. The media 
was poured off the pellet and then the pellet was re-suspended in 4 mL of buffer P1 from the 
QIAfilter kit (QIAGEN). Once the pellet was resuspended 4 mL of buffer P2 (QIAGEN) was added and 
the mixture was incubated for 5 minutes at room temperature. 4 mL of chilled buffer P3 (QIAGEN) 
was then added to the mixture and then this mixture was then transferred to a QIAfilter syringe 
(QIAGEN) and the mixture was left to stand for 10 minutes at room temperature. Whilst this mixture 
was incubating a QIAGEN tip was prepared by allowing 4 mL of buffer QBT (QIAGEN) to run through 
the tip. Once the QIAfilter syringe had stood for 10 minutes a plunger was inserted and the mixture 
was then syringed into the QIAGEN tip where it was allowed to through. Once the solution had 
passed through the tip the tip was washed by allowing 10 mL of buffer QC (QIAGEN) to flow through 
the QIAGEN tip, this was then repeated once the solution had flowed through. The QIAGEN tip was 
then suspended over a 50 mL tube where the DNA was eluted using 5 mL of buffer QF (QIAGEN) 
pre-heated to 65 ⁰C. The flow through then had 3.5 mL of room temperature isopropanol added to 
it, this precipitates the DNA. The DNA containing tube was then spun at 6000 G for 15 minutes at 4 
⁰C, the supernatant was then decanted and then the DNA pellet was re-suspended in 700 µL of 
room temperature 70 % ethanol and transferred to a 1.5 mL Eppendorf tube. The tube was then 
centrifuged at 15000 G for 10 minutes at room temperature. The ethanol was then removed and 
the DNA pellet was allowed to air dry. Once dry the DNA pellet was dissolved in 50 µL of TE buffer. 
Once the DNA was dissolved the DNA concentration was measured using a NanoDrop 
spectrophotometer (Thermo Fisher). 
 
2.2.6.4. Preparation of DNA bullets  
16.6 – 20 mg of gold nanoparticles were weighed out and placed in a 1.5 mL Eppendorf tube. 500 
μL of anhydrous ethanol was added to the gold particles and the tube was centrifuged at 13000 
RPM for 1 minute at room temperature. The ethanol was removed via pipette and then 200 µL of 
0.05M spermidine was added to the gold pellet. The mixture was then sonicated and vortexed and 
then 36 μg of ImmunoBody® plasmid was added to the mixture and this was mixed by brief 
sonication and gentle vortexing. Whilst the mixture was vortexing 1M calcium chloride was added 
in a drop wise manner, the resulting mixture was then left to stand on the bench top for 10 minutes. 
Tefzel tubing (BioRad) was then inserted into a DNA bullet preparation station (BioRad) and 
nitrogen was blown through the tube to remove any dust that there may be within the tube. After 
the tube containing the gold and the plasmid had finished incubating it was centrifuged at 13000 
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RPM for 1 minute at room temperature. The supernatant was then discarded and the pellet was re-
suspended in 1 mL of anhydrous ethanol by gentle sonication and vortexing, the tube was then 
centrifuged at 13000 RPM for 1 minute at room temperature and the supernatant removed, this 
process was then repeated once more. The pellet was then re-suspended in 2 mL of 0.025 mg/mL 
PVP and transferred into a 15 mL falcon tube. A syringe was then attached to the Tefzel tubing and 
it was placed in the gold solution containing falcon tube, the syringe was then used to draw the 
solution up into the plastic tubing whilst the tube was simultaneously being gently sonicated. The 
tube containing the solution was then placed back into the tubing station (with the air turned off) 
with the syringe still attached. The tubing was allowed to stand for 5 minutes and then the attached 
syringe was used to draw the liquid out of the tubing, the syringe was then removed and nitrogen 
gas was slowly flown through the tubing for 15 minutes to dry out. Once dry the tubing was cut 
using a bullet cutter (BioRad) and bullets were test fired. 
 
2.2.7. Immunisation and ELISpot analysis 
2.2.7.1. Immunisation schedule 
When studying the splenocytes from vaccinated mice they were vaccinated as shown in Figure 10 
at the start of the study the mice were given a priming dose of ImmunoBody® followed by a boost 
a week later then a further boost a week after that. Splenocytes were then removed and analysed 
21 days after the initial priming boost. In the prophylactic treatment regime, mice were given the 
same prime, boost, boost regime followed by tumour implantation on day 21. 
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Figure 10. Vaccination schedule used for testing the immune response to ImmunoBody® vaccination 
and for prophylactic experiments. 
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When analysing the use of ImmunoBody® to treat established tumours the vaccination schedule 
from Figure 11 was utilised. Due to the rapid growth of the tumours the vaccination schedule was 
shortened so mice received vaccination with anti-PD-1 antibody of PD-1 isotype control (both given 
in a 250 μg dose intra peritoneally) on days 3, 7 and 10. 
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Figure 11. Vaccination schedule used for the therapeutic treatment of inctracranial B16HHDII/DR1 
Luc2 tumours. 
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Once tumour bearing mice experienced bodyweight loss or displayed symptoms of malaise they 
were humanely culled. 
 
2.2.7.2. Processing of murine splenocytes 
Mice were culled via cervical dislocation and their spleens removed and placed into complete T-cell 
media. The spleen was then placed into a petri dish containing 10 mL of T-cell media, 10 mL of T-
cell media was then drawn up into a 20 mL syringe with a 21 G needle attached. Forceps were used 
to gently hold the spleen and the needle was used to puncture the capsule at each end of the spleen, 
the needle was then inserted into the spleen and the syringe was used to gently flush the 10 mL of 
T-cell media through the spleen, once all of the media was passed through the spleen the needle 
was removed and the capsule was agitated with forceps to remove any remaining splenocytes. The 
resulting solution was then transferred to a 30 mL universal tube and the debris was allowed to 
settle for 5 minutes, at which point the cell suspension was decanted into a fresh universal tube. 
The cells were then centrifuged at 1000 RPM for 10 minutes and the supernatant removed. The cell 
pellet was then re-suspended in 10 mL of T-cell media. Once re-suspended 5 µL of this solution was 
taken and diluted in 45 µL of T-cell media, 2.5 µL of Solution 18 was added to this cell suspension 
and then 10 µL was transferred to a NucleoCounter slide and counted using a NucelCounter NC250 
(Chemometec). 
 
2.2.7.3. ELISpot analysis 
ELISpot plates (Merck Millipore) were coated the day before spleens were processed, this was done 
by adding 50 μL/well of 70% ethanol to the plates for 2 minutes. After incubation plates were 
washed 5 times with 200 μL/well of sterile distilled water. After washing anti-mouse IFNγ capture 
antibody (Mabtech) was diluted 1 in 100 in sterile PBS and then 50 μL/well was added to the plates 
and left overnight at 4 ⁰C. Once incubation with capture antibody was complete it was flicked off 
the plate and then plates were washed 4 times with 200 μL/well of sterile PBS, once complete 100 
μL/well of complete T-cell media was added to plates and then plates were incubated for a 
minimum of 30 minutes at room temperature, after incubation the media was flicked off the plates. 
Once the splenocytes were ready they were diluted to a concentration of 5 million cells per mL and 
then 100 μL (500000 cells)/well was added to the plates as required. Next 100 μL/well of peptides 
(see Table 13. For details) were then added to the plates at the required concentration (1 μg/mL 
final concentration for class I peptide and 10 μg/mL final concentration for class II peptides), if cells 
were used to stimulate splencoytes 100 μL/well of T-cell media containing 50000 cells (500000 
cells/mL) was added to the splenocytes. Plates were then left to incubate for 40 hours at 37 ⁰C in a 
humidified 5 % CO2 tissue culture incubator. After incubation the cells were flicked off the plates 
85 
 
and then plates were washed 5 times with 200 μL/well of PBST. Once washes were complete 50 
μL/well of biotinylated detection antibody (Mabtech) diluted 1 in 1000 PBS was added to the plates 
and left to incubate at room temperature for 2-4 hours. After incubation plates were then washed 
5 times with 200 μL/well of PBST and then 50 μL/well or streptavidin alkaline phosphate (Mabtech) 
diluted 1 in 1000 PBS was added to the plates and left to incubate at room temperature for 1-2 
hours. After incubation plates were washed 6 times with 200 μL/well of PBST. Development 
solution was then prepared using the BioRad streptavidin alkaline phosphate conjugate substrate 
kit, this was done by combining 4.8 mL of distilled water, 200 μL of development buffer (BioRad), 
50 μL of reagent A (BioRad) and 50 μL of reagent B (BioRad) per plate. This development buffer was 
mixed well and then 50 μL/well was added as required. Plates were then incubated until purple 
spots began to develop (seen in the SEB positive control wells), once spots started to develop the 
reaction was stopped by running the plates under tap water. Once plates were fully developed and 
dry they were read using the ELISpot plate reader (ImmunoSpot). 
 
Table 13. Peptides used for in vitro stimulation of splenocytes and their respective SYFPEITHI scores 
(SYFPEITHI). 
 
2.2.7.4. ELISpot peptide titration 
For ELISpot peptide titration the protocol is exactly the same as above however when peptides 
were added the WT-1 class I (ALLPAVPSL) and the TRP-2 (SVYDFFVWL) class I peptides were added 
at 9 different concentrations; 1, 0.1, 0.01, 0.01, 0.001, 0.0001, 0.00001, 0.000001 and 0 μg/mL.  
Peptide Sequence Human HLA-
specificity 
SYFPEITHI score 
WT-1 ALLPAVPSL A2 33 
WT-1 DLNALLPAV A2 27 
WT-1 VRDLNALLPAVPSLG DR1 31 
TRP-2 SVYDFFVWL A2 21 
gp100 AMLGTHTMEV A2 26 
gp100 GTGRAMLGTHTMEVT DR1 24 
gp100 QLYPEWTEA A2 19 
gp100 NRQLYPEWTEAQRLD DR1 14 
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2.2.8. Brain tumour modelling 
2.2.8.1. Intracranial tumour implantation 
All animal work was carried out under a Home Office approved project licence. Intracranial 
implantation of B16HHDII/DR1 Luc2 cells was performed by injecting 5 x 103 cells in 3 μL PBS into 
anaesthetized C57BL/6 HHDII/DR1 mice. Cells were injected using a Hamilton syringe, the needle 
was positioned 2 mm to the left of the bregma, the needle was then inserted to a depth of 3.5 mm 
and then left in place for 60 seconds. After 60 seconds the needle was withdrawn to depth of 3mm 
and then cells were injected at a rate of 1.5 μL per 60 seconds. After implantation the needle was 
left in place for 60 seconds and then withdrawn at a rate of 0.1mm every 2 seconds until clear of 
the brain. Once craniotomy was completed the wound was closed and mice were monitored at 
regular intervals. Mice that developed symptoms indicative of brain tumours or had severe body 
weight loss were humanely euthanized by cervical dislocation.  
 
2.2.8.2. Imaging of intracranial brain tumours 
When mice required imaging they were given a 150mg/kg intraperitoneal dose of XenolightRediJect 
D-luciferin (Perkin Elmer), mice were then left for fifteen minutes and then they were anaesthetised 
ready for imaging. Once mice were unconscious they were placed inside an IVIS (Perkin Elmer) in 
vivo imager where bioluminescence measurements were taken and analysed using the IVIS 
software (Perkin Elmer) 
 
2.2.8.3. Brain tumour processing for flow cytometric analysis 
Once mice were euthanized their brains were extracted and placed into T-cell media, the brain was 
transferred into a petri dish and the tumour containing areas were excised from the rest of the 
brain. The excised tumours were then put into a new petri dish containing 10 mL of T-cell media 
and minced using a scalpel. The resulting cell suspension was transferred into a 50 mL Falcon tube 
and DNAse and collagenase I were added to give a final concentration of 50 μg/mL DNAse and 0.1 
U/mL of collagenase I. The falcon tube was then placed into a 37 ⁰C orbital incubator at 200 RPM 
for 30 minutes, after 30 minutes the tube was removed and the suspension was passed through a 
40 μM cell strainer, any remaining lumps were mashed through using a syringe plunger. The cell 
strainer was then washed with 10mL of T-cell media. The resulting cell suspension was then spun 
at 300 G for 5 minutes, the supernatant removed and the pellet was re-suspended in 5 mL of T-cell 
media. Cells were then counted using the NucleoCounter NC250 (Chemometec). 1 million cells was 
then transferred to a polystyrene FACS tube for staining. 
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2.2.9. Kynurenine assay 
2.2.9.1. Colorimetric kynurenine assay 
Cells were treated with 100 ng/mL IFNγ for 24, 48 or 72 hours, for each time point there were also 
untreated control cells that were left under normal media for 24, 48 and 72 hours. After treatment 
media was collected from the cells. Kynurenine standards were made using L-Kynurenine ranging 
from 0-200 µM kynurenine in GBM culture media. Once prepared 300 µL of media and 300 µL of 
kynurenine standard was mixed with 150 µL 30 % trichloroacetic acid to precipitate protein out of 
the mixture. Tubes were then vortexed and then centrifuged at 8000 g for 5 minutes at 4 ᵒC. After 
centrifugation 75 µL of the standards and media from cells were added to a 96 well flat-bottomed 
plate in triplicate. The media was mixed with 75 µL of Ehrlich’s reagent (20 mg/mL p-
dimethylaminobenzaldehyde in glacial acetic acid). The plate was incubated for 15 minutes at room 
temperature and then it was read at 492 nm in a plate reader (Tecan). Background readings from 
media alone were subtracted from all wells and then the concentration of the unknown samples 
was calculated using the standard curve. This process was repeated across 3 different passages. 
 
2.2.10. Carnosine related experiments 
2.2.10.1. MTT assay of carnosine treated cells 
Cells were seeded onto a 96 well tissue culture plate alongside wells containing cells there were 
three control wells containing culture medium alone. Cells were left overnight in a 37 ⁰C humidified 
5% CO2 tissue culture incubator (Sanyo) to attach. Once cells were attached all of the culture media 
was removed and replaced with 200 µL/well carnosine containing media ranging from a 
concentration of 0-130 mM going up in 10 mM increments. After 24 hours of carnosine treatment 
20 µL/well of 5 mg/mL MTT reagent assay was added to each well and then the plate was left at 37 
⁰C for 2-4 hours. Once incubation was complete all media was removed from the cells and 100 
µL/well of DMSO was added to dissolve formazan crystals, the plate was then left on a plate shaker 
for 10 minutes. Absorbance was then measured at 570 nm using a Tecan plate reader (Tecan). The 
values for the blank wells containing no cells was subtracted from all readings. 
 
2.2.10.2. IncuCyte scratch assay of carnosine treated cells 
Cells were seeded on a 96 well plate and once they reached 100 % confluency a scratch was made 
through the monolayer of cells using the IncuCyte wound maker (Essen bioscience). Once scratches 
has been made all media was removed and the cells were given a gentle wash with sterile D-PBS, 
after washing carnosine containing media was then placed on the cells and the cells were placed in 
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an IncuCyte live cell analysis incubator. The analyser then took images every two hours using the 
10 x objective for a period of 110 hours.  
 
2.2.10.3. Subcutaneous implantation of GL261 LUC2 cells in NOD-SCID mice and subsequent 
carnosine treatment 
2500000 GL261 Luc2 cells in 100 µL PBS were implanted subcutaneously in the flank of NOD-SCID 
mice. Once palpable tumours 4-6 mm2 had developed a single dose of 1 M carnosine in PBS (20 µL) 
was injected directly into the tumours. Tumours were then monitored twice weekly using callipers, 
and mice were imaged once a week using an IVIS in vivo imager (PerkinElmer).  
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CHAPTER 3: ANTIGENS EXPRESSION PROFILE OF GLIOBLASTOMA 
MULTIFORME TISSUES AND CELL LINES 
 
3.1. Introduction 
The current ‘gold standard’ treatment for GBM is surgical resection followed by radiotherapy and 
temozolomide (TMZ) chemotherapy. This therapeutic regime has been the standard for over 10 
years and very little progress has been made in terms of therapeutic developments for GBM. The 
median survival for patients after undergoing standard therapy is still just under 15 months (Stupp, 
Mason et al. 2005). In some cases, GBM patients may express an enzyme called O-6-methylguanine-
DNA methyltransferase (MGMT), this enzyme conveys a resistance to TMZ chemotherapy, and 
MGMT promoter methylation has been shown to be a prognostic factor for patients receiving 
standard therapy (Dunn, J., Baborie et al. 2009). The dismally poor survival of GBM patients 
highlights the need for novel therapeutic approaches for treating this disease. Immunotherapy 
represents an attractive treatment, specifically active immunotherapy induced by vaccination. This 
method of immunotherapy is highly attractive due to its tumour specificity and the ability of 
immune cells to target tumours located within the brain (Prins, Shu et al. 2008). Previous studies 
have utilised vaccination as a method for treating GBM; early clinical trials have been promising 
however no treatments thus far have progressed past phase III clinical trial (Swartz, Shen et al. 
2018). Whilst GBM is poorly immunogenic it has been shown to express several tumour antigens 
that enable immune recognition of these tumours. As previously mentioned in chapter 1, the cells 
of the skin and the brain are derived from the same neuroectodermal tissues. As a result GBM 
shares many of the same antigens as melanoma skin tumours. Previous research has found that 
GBMs express the melanoma associated antigens gp100, TRP-2, MAGE-A1, MAGE-A3 and MAGE-
A11 (Saikali, Avril et al. 2007, Guo, L., Sang et al. 2013). GBM tumours have also been shown to 
express several other immunogenic antigens such as EGFRvIII and IL-13Rα2 (Saikali, Avril et al. 2007). 
Assessment of patient derived glioblastoma cell lines has also revealed expression of a plethora of 
other immunogenic cancer testis –antigens (Akiyama, Komiyama et al. 2014). These studies reveal 
varying levels of expression of these antigens and differing methods have been used to study the 
expression of these cancer related antigens.  
As well as expressing immunogenic antigens these tumours also express numerous antigens that 
interact with immune cells and dampen the anti-tumour immune response. The immune evasive 
profile of glioblastoma multiforme is well documented (Jackson, Ruzevick et al. 2011, Reardon, 
Freeman et al. 2014). GBM tumours have been shown to express the immunosuppressive 
checkpoint ligand PD-L1, and the expression of PD-L1 has been linked to loss of phosphatase and 
tensin homolog (PTEN) (Parsa, Waldron et al. 2007). The expression of PD-L1 is not ubiquitous 
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across all glioblastoma multiforme cases, however PD-L1 is an interferon gamma inducible gene, 
meaning that tumour reactive immune cells secreting IFNγ near the tumour can lead to induction 
of PD-L1 expression. HLA-E is a ligand for the NKG2A immune inhibitory receptor expressed by NK 
and T-cells, previous research has found that GBM (grade IV) tumours express the HLA-E antigen to 
a significantly higher level than lower grade brain tumours (Mittelbronn, Simon et al. 2007). HLA-G 
is another non-classical MHC molecule that interacts with CD8+ and CD4+ T-cells to prevent 
immune activation and enable GBM cells to avoid immune detection (Wiendl, Mitsdoerffer et al. 
2002). HLA-G also has a soluble form that has been detected in the cancer setting with cancer 
patients being found to have higher levels of soluble HLA-G in their plasma. HLA-G interacts with 
NK and T-cells via LILRB1, LILRB2 and KIR2DL4 receptors (Sheu, Shih 2010). Tumours are also 
believed to down regulate MHC-I and MHC-II molecules on their surface to evade immune 
recognition, this phenomenon has been shown in the glioblastoma setting, with invasive GBM cells 
downregulating these antigens (Zagzag, Salnikow et al. 2005). 
Temozolomide is an oral alkylating agent used as a chemotherapeutic in the GBM setting. TMZ is a 
pro-drug that is hydrolysed at physiological pH, generating the active metabolite MTIC, this is then 
hydrolysed to AIC and a methyldiazonium ion. The methyldiazonium ion then methylates DNA at 
several residues. The N3 position of adenine, the N3 position of guanine, the N7 position of guanine 
and the O6 position of guanine are methylated by TMZ’s methyldiazonium ion (see Figure 13) (Kaina, 
Christmann et al. 2007, Lee 2016). 
 
 
 
 
 
 
91 
 
 
Figure 12. Diagrams of adenine and guanine bases with the atoms methylated by temozolomide 
highlighted. 
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Whilst TMZ therapy generates numerous methyl adducts on adenine and guanine, the adduct on 
the O6 position of guanine is essential for its anti-tumour activity. The N3 adducts on guanine and 
adenine are short lived and readily hydrolysed, the N7 methylguanine adduct is longer lasting, but 
still relatively transient and the O6 methylguanine adduct is much longer lasting. The methylation 
of guanine by the methyldiazonium ion (see Figure 13) leads to a series of downstream events that 
triggers apoptosis (Kaina, Christmann et al. 2007, Lee 2016). 
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Figure 13. Methylation of guanine by the methyldiazonium ion. The methyl group is represented by 
the pink CH3 highlighted on the figure. 
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The O6 methylguanine adduct results in mispairing during DNA replication, it results in GC to AT 
point mutations after two rounds of DNA replication. O6 methylguanine requires mismatch repair 
to induce apoptosis. During DNA synthesis O6 methylguanine mis-pairs with thymine, activating 
mismatch repair causing MutSα (a heterodimer formed of MSH2 and 6) to bind to the adduct, 
MutLα (a heterodimer formed of PMS2 and MLH1) is then recruited along with exonuclease 1 
leading to excision of the thymine base, however this is futile as thymine is re-paired with the O6 
methylguanine present in the DNA. After multiple DNA replications, this futile reinsertion of 
thymine creates long strands of single stranded DNA resulting in double strand breaks of the DNA 
and subsequent cell death (Roos, Kaina 2013). 
The responsiveness of GBM to temozolomide chemotherapy is dependent upon expression of a key 
protein: O6-methylguanine-DNA methyltransferase, this protein conveys a resistance to alkylating 
temozolomide chemotherapy by removing lethal adducts from the DNA, preventing apoptosis of 
tumour cells. MGMT repairs O6 methylguanine adducts by transferring the methyl group from the 
guanine to a cysteine residue within the MGMT active site, inactivating the MGMT enzyme, 
resulting in the degradation of MGMT. The level of MGMT within cells is the rate limiting factor 
regarding DNA repair (Zhang, J., Stevens, and Bradshaw 2012). MGMT functions to protect normal 
cells from DNA damage, however in the cancer setting some tumours may express this protein 
making them difficult to treat with chemotherapy.  
The expression of MGMT has been shown to be a key prognostic indicator in GBM temozolomide 
therapy responsiveness. Methylation of the MGMT promoter has been linked to improved overall 
survival in GBM patients treated with alkylating agents. This promoter methylation was shown to 
be advantageous even in cases where alkylating agents were not utilised for therapy (Zhang, K., 
Wang et al. 2013). The presence of MGMT within these GBM tumours makes them resistant to 
standard therapy making immunotherapy an attractive alternative. 
 
3.2. Aims and hypothesis 
The aim of this chapter was to examine the expression of various proteins in GBM tissues and cell 
lines. The emphasis will be on discovering immunogenic targets for targeting with vaccination. The 
immune profile of these tumours will be assessed with the aim of incorporating combinatorial 
checkpoint blockade therapy with the vaccine-based therapy. These analyses will enable the 
development of an immunotherapeutic strategy to target these tumours, taking immune evasion 
strategies into account. Once target antigens have been identified in human GBMs their expression 
will also be examined in murine cell lines that could potentially be used for in vivo modelling of the 
disease. 
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3.3. Results 
3.3.1. IHC analysis of GBM tissues reveals that the immunogenic TRP-2 and WT-1 
antigens are viable targets for immunotherapeutic targeting of GBM  
 
In order to target GBMs immunotherapeutically suitable GBM specific immunogenic antigens need 
to be discovered. These antigens need to be present in a large portion of tissues studied and they 
need to be known to be immunogenic. Immunohistochemistry was used to study tissue expression 
of several immunogenic tumour antigens in GBM tissues. Immunohistochemical staining of 
commercially available tissue microarrays revealed that GBM tumours express the immunogenic 
antigens TRP-2 and WT-1. The expression levels of these antigens vary, and their expression is not 
ubiquitous across all tumours. Despite expression not being ubiquitous many tumours express at 
least one of these antigens. Amongst the antigens tested WT-1 was the most expressed with 82% 
of the cores staining positively followed by TRP2 (66%) and HAGE (21%). The antigen gp100 was 
only expressed by one case. Images of staining can be seen in Appendix 1. 
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Figure 14. TRP-2, WT-1, gp100, HAGE and MGMT expression as observed in tissue microarray 
staining. A) A graphical representation of target antigen expression as observed in tissue microarray 
staining. B) Numerical representation of positive staining results. Percentages show the number of 
cases that stained positively, irrespective of the strength of the staining. 
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Stained sections were then given a staining score by a pathologist with a score between 0 and 3 
given to the tissue. 0 represents no staining, 1 represents mild staining, 2 represents moderate 
staining and 3 represents strong staining, these results are represented below in Table 14 with 
examples of the pathologist’s scoring being given in Figures 15 and 16. Whilst looking at the 
intensity of the staining WT-1 represents the antigen that is most strongly expressed in the 33 GBM 
cases studied, with TRP-2 being the second most intensely expressed. Even more importantly it was 
found that 20 (61%) of the GBM cases stained express both the TRP-2 and WT-1 antigens. 
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Figure 15. Examples of pathologist’s WT-1 IHC scoring A) 3 (deemed as strong staining) B) 2 (deemed 
as moderate staining) C) 1 (deemed as weak staining) D) 0 (no staining). Scale bar = 100 µm. 
 
 
Figure 16. Examples of pathologist’s TRP-2 IHC scoring A) 3 (deemed as strong staining) B) 2 
(deemed as moderate staining) C) 1 (deemed as weak staining) D) 0 (no staining). Scale bar = 100 
µm. 
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Table 14. Pathologist’s IHC scoring of GBM TMA tissue staining intensity. Examples of staining can 
be seen in figures 15 and 16. 
 
3.3.2. TRP-2 and WT-1 expression are also commonly expressed in GBM cell lines as well 
as in tissues 
 
As well as studying GBM tumour tissues it was also decided to analyse the antigen expression profile 
of patient derived GBM cell lines. This helps to identify cell lines that can be used for in vitro analyses 
of the immune response generated by vaccination. These analyses also helped to reveal how much 
the cell lines utilised are representative of the tissue phenotype. Western blotting was used to study 
the antigen expression profile of these cell lines as it was a quick and easy method to analyse 
multiple cell lines side by side. Western blotting analyses revealed that all the cell lines studied 
expressed high level of TRP-2, but only two out of eight expressed WT-1 and most had very low 
level of HAGE protein; these results differ from the GBM tissue phenotype (see previous section). 
The SEBTA027 and SF188 cell lines were found to both express WT-1 and TRP-2 with very low levels 
of the gp100 protein. MGMT is a prognostic indicator in GBM associated with a poorer response to 
temozolomide chemotherapy and as a result poorer survival. Five of the eight cell lines probed 
expressed the MGMT protein. The benefit of utilising immunotherapy is that this natural 
chemotherapy resistance provided by MGMT expression can be overcome (Figure 17). 
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Figure 17. TRP-2, HAGE, WT-1, MGMT and gp100 expression in GBM cell lines as determined by 
Western blotting, 20 μg of protein was loaded per lane as described in chapter 2 A) TRP-2 expression  
as detected by a TRP-2 specific antibody B) HAGE expression as detected by a HAGE specific antibody, 
PCI-13 is a head and neck cancer cell line that is known to be positive for HAGE expression and as a 
result was used as a positive control (this lysate was obtained ready prepared for use) C) WT-1 
expression  as detected by a WT-1 specific antibody D) MGMT expression  as detected by a MGMT 
specific antibody E) gp100 expression  as detected by a gp100 specific antibody. All membranes were 
also probed with an anti-vinculin antibody that acted as a loading control due to its abundant 
expression. 
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3.3.3. Analysis of GBM tumour tissues reveal that these tissues have an 
immunosuppressive phenotype, but these tissues appear to maintain their antigen 
presentation capabilities 
 
Whilst discovering antigens for targeting immunotherapeutically was of high importance it was also 
necessary to study the immune landscape of GBM tumours. These tumours are renowned for being 
immunosuppressive and therefore this needs to be considered when targeting these cancers with 
immunotherapy. It was decided to stain TMAs all from the same tissue block with antibodies against 
several immune suppressive ligands and the pan-MHC class I antibody HLA-A, B, C. The results are 
shown below in Figure 18 and Table 15. 
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Figure 18. PD-L1, HLA-G, HLA-E and HLA-A, B, C expression as observed in tissue microarray staining. 
A) A graphical representation of the percentage of cases the stained positive for each antigen B) 
Numerical representation of the staining results. Percentages show the number of cases that stained 
positively, irrespective of the strength of the staining. 
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All the brain tumour tissues apart from one studied expressed HLA-A, B, C indicating that almost all 
the tumours studied express MHC class I molecules and can present immunogenic antigens, making 
this type of cancer targetable with immunotherapeutic approaches. In accordance with the 
literature these tumours also express the immunosuppressive ligands PD-L1, HLA-E and HLA-G. Only 
a small proportion of tumours express these antigens (15% PD-L1, 6% HLA-G and 27% HLA-E) so 
immunotherapy is a viable therapeutic avenue. Images of staining can be seen in Appendix 1. It is 
however important to note that the genes encoding these proteins are interferon gamma 
responsive, as a result it is of importance to take this into account. The expression of these proteins 
after interferon gamma exposure will be explored in a later chapter.  
Stained sections were then given a staining score by a pathologist with a score between 0 and 3 
given to the tissue. 0 represents no staining, 1 represents mild staining, 2 represents moderate 
staining and 3 represents strong staining, these results are represented below in Table 15 with 
examples of pathologist’s scoring being shown in Figures 19 and 20. Whilst looking at the intensity 
of the staining it can be seen that the HLA-A, B, C staining was intense in most of the cases stained, 
the immunosuppressive ligands PD-L1, HLA-E and HLA-G are much less intensely stained, this may 
be due to the expression of these molecules primarily on a small subset of ‘stem-like’ cancer cells, 
a phenomenon previously shown to occur (Wolpert, Roth et al. 2012, Silver, Sinyuk et al. 2016). 
 
Table 15. Pathologist’s IHC scoring of GBM TMA tissue staining intensity. Examples of staining can 
be seen below. 
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Figure 19. Example of pathologist’s HLA-E IHC scoring. A) 3 (deemed as strong staining) B) 2 
(deemed as moderate staining) C) 1 (deemed as weak staining) D) 0 (no staining). Scale bar = 100 
µm. 
 
Figure 20. Example of pathologist’s HLA-A,B,C IHC scoring. A) 3 (deemed as strong staining) B) 2 
(deemed as moderate staining) C) 1 (deemed as weak staining) D) 0 (no staining). Scale bar = 100 
µm. 
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3.3.4. GBM cell lines also have an immunosuppressive phenotype much like the tissues 
they are derived from  
 
Western blotting was used to study the antigen expression profile of GBM patient derived cell lines 
this was performed to see if these cell lines were representative of the tumour tissues. Western 
blotting analyses of cell lines reveals expression of PD-L1, HLA-E and HLA-G. These proteins enable 
these tumours to escape immune surveillance and as a result their targeting needs to be considered 
when utilising immunotherapy to treat GBM. Much like tumour tissues tumour cell lines appear to 
express high levels of HLA-A, B, C, indicating that they express MHC class I and are capable of 
presenting class I peptides to CD8+ T-cells. The location of these proteins within the cellular 
architecture is key for their immune dampening effects. Expression of PD-L1, HLA-E and HLA-G on 
the cell surface hampers the activity of immune cells that make direct contact with the tumour cells. 
In order to fully elucidate the cellular location of these proteins flow cytometric surface staining 
was performed. 
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Figure 21. HLA-G, PD-L1, HLA-E and HLA-A, B, C expression in GBM cell lines as determined by 
Western blotting, 20 μg of protein was loaded per lane as described in chapter 2 A) HLA-G expression  
as detected by a HLA-G specific antibody B) PD-L1 expression  as detected by a PD-L1 specific 
antibody C) HLA-E expression  as detected by a HLA-E specific antibody D) MHC class I expression  as 
detected by a HLA-A, B, C pan-specific antibody. All membranes were also probed with an anti-
vinculin antibody that acted as a loading control due to its abundant expression.  
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3.4.5. Flow cytometric analyses GBM cell lines reveals expression of both immune 
inhibitory and immune activating proteins on the surface of these cells  
 
Western blotting revealed that all the cell lines studied expressed MHC class I (HLA-A, B, C) however 
the specific HLA haplotype was unknown. HLA-A2 is the most common haplotype in the Caucasian 
population and many vaccines target HLA-A2 specific peptides in the Western world due to its 
prevalence, making vaccination applicable to a large proportion of patients. Flow cytometry was 
used to study the cell surface expression of the HLA-A2 protein on GBM cell lines. Flow cytometric 
surface staining reveals that four out of five of the cell lines studied express the HLA-A2 antigen on 
their surface (see Figure 22). This is of importance because the ImmunoBody® vaccination utilised 
in this study encodes peptides specific for the HLA-A2 haplotype.  
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Figure 22. Flow cytometric surface staining histograms of HLA-A2 the green peaks represent 
unstained cells whereas the red peaks represent cells stained with HLA-A2 APC. A) SEBTA-025 B) 
SEBTA-027 C) SF188 D) UP-007 E) UP-019. 
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Cell surface staining was also performed for the immune stimulating ligands CD40, CD80, CD86, 
MICA/B and HLA-A, B, C. The immunosuppressive ligands HLA-E, HLA-G and FasL were also stained 
for. These analyses help further characterise the immune phenotype of GBM cell lines and since 
surface staining was used it revealed the location of many of these immune system interacting 
proteins. A representative set of histograms for the SEBTA-025 cell line are shown below in Figure 
23. The histograms for each cell line studied are in appendix 2. The data for all the cell lines is 
tabulated in Table 16. 
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Figure 23. SEBTA-025 flow cytometry surface staining, the green peaks represent unstained cells 
whereas the red peaks represent stained cells. Each antigen is labelled on the X axis of each 
histogram. The table in the right-hand corner details the percentage of cells positive for each antigen. 
Further detailed histograms for each cell line can be seen in appendix 1. 
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Table 16. Flow cytometric surface staining results for the SEBTA-025, SEBTA-027, SF-188, UP-007 and UP-019 cell lines. The percentage of live cells stained as well as 
the median fluorescence intensity is detailed for each antigen. The gating strategy utilised is outlined in chapter 2.
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These analyses reveal that GBM cell lines express several immune activating and immune inhibitory 
molecules on their surface, in order to target these cell lines immunotherapeutically the balance 
must be shifted towards the immune activating pathways as opposed to the immune inhibitory 
pathways, this can be done via checkpoint blockade, a concept that will be further explored later 
within this thesis. PD-L1 expression appears to be a common feature of GBM cell lines with all of 
the cell lines studied exhibiting expression of PD-L1. All the cell lines also appear to express immune 
stimulating CD40 on their surface as well as MHC class I, these are highly desirable features for 
immunotherapeutic targeting of GBM. 
Table 17 below provides a brief summary of the antigens of interest expressed by the cell lines 
studied. Due to the prevalence of the WT-1 and TRP-2 antigens in GBM tumour tissues and cell lines 
these antigens will be targeted immunotherapeutically. In order to vaccinate against these antigens, 
the ImmunoBody® DNA vaccine will be utilised. The ImmunoBody® encodes peptides specific for 
the HLA class I antigen HLA-A2, therefore the expression of HLA-A2 was probed. The SF-188 and 
SEBTA-027 cell lines are of great interest for further study due to both cell lines expressing WT-1 
and TRP-2. The key difference between these two cell lines is their HLA-A2 expression, with SF-188 
expressing this antigen and SEBTA-027 displaying no HLA-A2 expression. This differing HLA-A2 
expression will allow for HLA-A2 specificity of the ImmunoBody® generated immune response. 
 
Table 17. A brief summary of antigens of interest expressed in the GBM cell lines studied. These 
results are the collated western blot and flow cytometry data obtained for each cell line, revealing 
the overall antigen expression for each cell line.  
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3.3.6. The TRP-2 and WT-1 antigens are expressed by the murine GL261 Luc2 and B16 
HHDII/DR1 Luc2 cell lines 
 
In order to try and model GBM pre-clinically it would be beneficial to utilise murine cell lines that 
express the antigens of interest that are present in human GBMs. Due to the previous tissue and 
cell line analysis the TRP-2 and WT-1 antigens were chosen as GBM specific targets for 
ImmunoBody® vaccine therapy. It was decided to examine the expression of TRP-2 and WT-1 in the 
GL261 Luc2 murine GBM cell line and the B16 HHDII/DR1 Luc2 humanised murine melanoma cell 
line using immunofluorescence and immunocytochemistry. The results of these analyses are 
detailed in Figures 24 and 25. 
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Figure 24. Representative images of immunofluorescence staining of the GL261Luc2 cell line. A) 
Positive TRP-2 staining as detected by an anti-mouse/human TRP-2 antibody, 100% of cells stained 
were positive for TRP-2 B) Positive WT-1 staining as detected by an anti-mouse/human WT-1 
antibody, 100% of cells stained were positive for WT-1 C) No primary antibody control. Nuclei are 
counterstained blue with DAPI and positive antigen staining is represented by green fluorescence. 
Scale bar = 50 µm. 
115 
 
 
Figure 25. Representative images of Immunocytochemical staining of the B16HHDII/DRI/Luc2 cell 
line. A) Positive TRP-2 staining as detected by an anti-mouse/human TRP-2 antibody, staining is 
apparent on the surface of cells B) Positive WT-1 staining as detected by an anti-mouse/human WT-
1 antibody, staining can be seen localised in small cytoplasmic areas this is due to WT-1 being a 
transcription factor. Black arrows highlight some areas of positive staining C) No primary antibody 
control. Nuclei are stained blue/light purple and positive antigen staining is represented by brown 
colouration. Scale bar = 150 µm. 
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The B16HHDD/DR1 Luc cell line expresses the TRP-2 and WT-1 antigens as reported in the literature. 
The GL261 Luc2 cell line also expressed the TRP-2 and WT-1 antigens. As a result, these cell lines 
will be used in in vitro models to assess potential TRP-2 and WT-1 directed immunotherapy.  
 
3.4. Discussion 
Glioblastoma multiforme has a dismal prognosis and as a result novel therapies are required with 
the hope of improving patient survival whether at first instance of GBM or after recurrence. 
Immunotherapy provides an exciting novel avenue for treating many types of cancer, including 
GBM due to its tumour specificity, and reduced bystander effects as compared to chemotherapy 
and radiotherapy. In order to target GBM tumours with immunotherapy immunogenic targets 
needed to be identified. The original goal of this project was to target the HAGE (DDX43) antigen in 
the GBM setting. Whilst HAGE expression was detected at low levels in many of the cell lines studied 
it was not detected in GBM tissue staining. The HAGE expression observed in the cell lines may be 
due to changes induced by the culture of the cells, a phenomenon known to occur in vitro (Pallini, 
Casalbore et al. 2000).  
The analyses revealed that TRP-2 was expressed in GBM tissues and cells lines. TRP-2 (Tyrosinase-
related protein 2) is a protein frequently expressed in the melanin producing cells within the skin, 
as a result it is a protein commonly found in melanoma tumours. Cells within the brain and the skin 
are derived from the same progenitors during embryogenesis; the neuroectoderm. Because of this 
shared lineage tumours of the skin and brain often express similar antigens. In the melanoma 
setting TRP-2 has been a found to be a viable immunogenic target. In the B16 murine melanoma 
model an 8 amino acid long sequence within TRP-2 was found to be essential for the rejection of 
B16 tumours in C57BL/6 mice (Bloom, Perry-Lalley et al. 1997). In human beings’ expansion of 
melanoma infiltrating lymphocytes has revealed that these lymphocytes react to the TRP-2 protein. 
Adoptive transfer of these tumour infiltrating lymphocytes with the cytokine IL-2 resulted in clinical 
responses within patients. Immunogenic peptide sequences within the TRP-2 antigen have been 
discovered and are being utilised in immunotherapeutic approaches. For this study a peptide 
specific for the HLA-A2 MHC-I haplotype will be studied, HLA-A2 being the most prevalently 
expressed family of MHC class I molecule within the Caucasian population, with 46% of American 
melanoma patients expressing HLA-A2. The sequence corresponding to amino acids 180-188 of 
TRP-2 is specific for HLA-A2 and has previously been shown to induce TRP-2 reactive lymphocytes 
(Parkhurst, Fitzgerald et al. 1998). More importantly this peptide sequence is ubiquitous to all 
isoforms of the TRP-2 protein and HLA-A2 positive GBM cell lines have been shown to present this 
peptide, resulting in the recognition of the MR7 cell line (a TRP-2 180-188 specific T-cell) (Liu, G., 
Khong et al. 2003). In the GBM setting TRP-2 was shown to be expressed by most of these tumours 
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and 100 % of patient derived cell lines studied making this antigen a viable target for 
immunotherapy. Moreover, cytotoxic T-cell targeting of TRP-2 expressing GBM cells rendered them 
more sensitive to chemotherapy suggesting a possible synergy between vaccination and 
chemotherapy (Liu, G., Akasaki et al. 2005). Importantly, however, after TRP-2 specific targeting 
patients whose tumour recurred expressed significantly lower levels of TRP-2 due to the eradication 
of TRP-2 high expressing cells, emphasising the need to target multiple antigens. Interestingly 
however, was the fact that the cells derived from the recurrent tumours were more sensitive to 
TMZ chemotherapy than cells derived from the primary tumour. In order to confirm these findings, 
researchers transfected GBM cells with TRP-2 and treated them with TMZ. These in vitro studies 
showed that the TRP-2-transfected cells were indeed more resistant to TMZ chemotherapy than 
their un-transfected counterparts. The increased TRP2 levels after transfection did not, however, 
alter the levels of chemotherapy resistance proteins such as MGMT and breast cancer resistance 
protein-1 (BCRP-1) (Liu, G., Akasaki et al. 2005) indicating that the newly acquired chemo sensitivity 
was not due to a reduced level in these proteins. In search of an additional GBM target gp100, 
another melanoma associated antigen commonly expressed in melanin producing cells was 
assessed and low levels was detected within GBM cell lines and tissues. Analysis of cytotoxic T-cells 
within melanoma patients’ peripheral blood cells and tumour infiltrating lymphocytes revealed the 
presence of gp100 reactive cells (Eisenberg, Machlenkin et al. 2010). Previous studies have found 
much like TRP-2, gp100 is also expressed in GBM due to the shared neuroectodermal lineage (Saikali, 
Avril et al. 2007, Liu, G., Ying et al. 2004). What is even more important is that cytotoxic T-cells 
recognise the gp100 protein when it is expressed by GBM cells (Liu, G., Ying et al. 2004). However, 
gp100 was only detected in two GBM cell lines at a low level and therefore for the purpose of this 
study it was deemed necessary to identify an additional target with a more widespread and 
pronounced expression within the cell lines studied.   
WT-1 is a zinc finger transcription factor involved in development of the mammalian kidney during 
embryogenesis. This WT-1 expression is lost upon birth (Fanni, Fanos et al. 2011). Previous research 
has revealed high levels of WT-1 expression in GBM tumours and cell lines (Nakahara, Okamoto et 
al. 2004, Menssen, Bertelmann et al. 2000). Due to the observed expression of WT-1 within 
glioblastoma multiforme tumours its use as an immunotherapeutic target has previously been 
studied in clinical trials. WT-1 peptide pulsed dendritic cells have been administered to patients 
with recurrent GBM, these patients notoriously have a very poor prognosis and as a result novel 
therapeutics are desperately required. This early trial revealed that WT-1 pulsed dendritic cells 
generated WT-1 reactive T cells in patients, 5/7 of the patients treated with WT-1 pulsed dendritic 
cell vaccination exhibited stable disease (Sakai, Shimodaira et al. 2015). WT-1 peptide vaccination 
has also been explored as a therapeutic avenue in the GBM setting. Not only does WT-1 represent 
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an immunogenic target it also appears to have a functional role in the tumorigenicity of GBM cells. 
Indeed, WT-1 knock-down using WT-1 shRNA has been shown to reduce the proliferation of the 
U251MG cell lines in vitro, as well as in vivo when injected into mice (Clark, Ware et al. 2010). Similar 
in vitro and in vivo findings have been found with the U87MG GBM cell line, where WT-1 knockdown 
showed a reduced cell proliferation and tumour formation (Kijima, Hosen et al. 2014). These 
characteristics make WT-1 an even more attractive therapeutic target due to its role in GBM tumour 
growth. 
Murine B16 and GL261 cell lines both express the TRP-2 and WT-1 antigens, sharing the same trend 
seen in human brain tumours (GL261) expressing many of the same antigens as melanoma tumours 
(B16) due to their shared developmental lineage. This is of great use for future in vivo modelling of 
GBM. 
Unfortunately, whilst immunogenic targets were discovered the immune inhibitory nature of GBM 
was also revealed. PD-L1 expression was prevalent in patient derived GBM cell lines. This antigen 
has previously been shown to be expressed in GBM tumours and the tissue and cell line analysed 
in this chapter confirmed these findings. The expression of PD-L1 by GBM tumour cell lines has been 
shown to be dependent upon AKT activation. Mutation or loss of the tumour suppressor PTEN has 
been shown to result in an increased expression of PD-L1 by GBM cell lines (Parsa, Waldron et al. 
2007). Knockdown of PD-L1 in the U87MG cell line prevented formation of GBM tumours in a 
xenograft model using immunocompromised Balb/c nude mice whereas normal U87MG cells 
successfully formed tumours. Overexpression of PD-L1 was also shown to increase GBM cell 
migration in vitro (Qiu, Hu et al. 2018). The flow cytometry analyses revealed that this PD-L1 is 
expressed on the surface of the cell lines studied, meaning that it can exert its immune inhibitory 
effects when these cells encounter activated PD-1 expressing T-cells. However, this cell-surface 
expression also allows for the PD-L1 to be targeted via therapeutic blocking antibodies, allowing 
the immune inhibitory effect to be nullified.  
HLA-E was evident in Western blotting however this was not detected on the surface of the GBM 
cell lines studied. HLA-G just like HLA-E has a secreted soluble form (sHLA-G) which is stored in 
intracellular vesicles. This would explain the presence of this protein within the cellular lysates 
obtained from cells that are negative for cell surface staining of HLA-G. HLA-E and HLA-G are 
immune inhibitory proteins that bind to inhibitory receptors on the surface of NK cells. It is 
therefore possible that the HLA-E expressed by GBM cells is the soluble form as opposed to the cell 
surface form as was found for melanoma, colorectal, lung, kidney, ovary, breast, prostate and 
thyroid cancer cell lines in vitro (Allard, Oger et al. 2011). Melanoma patients have been shown to 
have higher levels of sHLA-E in their sera compared to healthy controls (Allard, Oger et al. 2011). In 
future it would be of great interest to measure levels of sHLA-E within the sera or CSF of GBM 
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patients in order to confirm this hypothesis. Glioblastoma multiforme stem-like cells have been 
shown to express HLA-E on their surface to escape immune surveillance by NK cells, this was 
confirmed by knockdown of HLA-E. GBM stem-like cells with HLA-E gene silencing were more 
susceptible to NK cell mediated lysis (Wolpert, Roth et al. 2012). HLA-G expression is limited 
throughout normal tissues and it acts to protect cells from NK cell mediated lysis, however tumour 
cells have been shown to co-opt this HLA-G expression as an immune evasion strategy. GBM cell 
lines have also been previously shown to express HLA-G and expression of HLA-G has been shown 
to reduce tumour cell lysis by PBMCs, even more interestingly is the small number of HLA-G-
expressing cells to inhibit the immune cell lysis of an entire population of cells i.e. even when only 
10% of cells express HLA-G, lysis of HLA-G negative cells was inhibited (Wiendl, Mitsdoerffer et al. 
2002). 
The expression of Fas L was also probed, because previous research has shown that GBM tumours 
can express the Fas ligand (FasL). This ligand binds to the Fas receptor on T-cells which then results 
in caspase activation and apoptosis of T-cells enabling GBM tumour cells to escape immune 
surveillance (Didenko, Ngo et al. 2002). Fortunately, the cell lines studied here did not appear to 
express the Fas ligand meaning that they are incapable of inducing apoptosis of Fas expressing T 
cells. 
HLA-A, B, C represents the classical MHC class I molecules, those molecules responsible for 
presentation of class I peptides to cytotoxic CD8 T-cells. Many tumours downregulate MHC class I 
molecules in order to avoid immune surveillance by cytotoxic T-cells, this phenomenon has been 
witnessed in the GBM setting. Invasive GBM cells have been shown in both the in vitro and in vivo 
settings to down regulate MHC class I expression allowing them to spread the tumour whilst 
evading immune regulation, GBM cell invasion is well documented and is the major cause of tumour 
recurrence (Zagzag, Salnikow et al. 2005). The mice used in this study express the chimeric HLA-A2 
molecule and therefore potential target cells for the assessment of vaccine induced T-cell response 
will need to be HLA-A2 positive. In addition to this HLA-A2 is the most common HLA haplotype in 
the Western world. As a result, the HLA-A2 expression was studied in all of the cell lines available, 
this revealed that the majority of these cells lines expressed HLA-A2, with only SEBTA-027 and UP-
029 being negative for HLA-A2 expression. 
CD40 expression was also discovered on the surface of all the cell lines studied, this is a 
phenomenon observed in many cancers (Tong, Stone 2003a). CD40 binds to its ligand CD40L; 
activated CD4+ T-helper cells have been shown to express the CD40L ligand on their surface. The 
interaction between CD40 on antigen presenting cells and CD40L on these CD4+ T-cells has been 
shown to improve antigen presentation by APCs thus improving CD8 cytotoxic T-cell priming 
(Schoenberger, Toes et al. 1998).  Interestingly the activation of B-cells by CD40 enables them to 
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present cancer associated peptides via MHC class II to T-cells enabling the generation of antigen 
specific T-cells (Lapointe, Bellemare-Pelletier et al. 2003). It would be of great interest to see if 
exposing the CD40 positive GBM cells to B-cells would alter their antigen presentation and result in 
improved T-cell recognition of GBM cell lines. Ligation of CD40 on tumour cells has been shown to 
have anti-cancer effects and the use of CD40L therapy has been studied in a plethora of cancer 
types and numerous clinical trials using CD40L are ongoing (Tong, Stone 2003b). Interestingly CD40L 
therapy has not been studied in the GBM setting and there are currently no active clinical trials. It 
may be of interest to examine the potential of this type of therapy in the GBM setting. 
MICA and MICB (MHC class I chain-related protein A and B) are ligands of NKG2D, a receptor 
expressed on NK and CD8+ T-cells. The NKG2D ligands are not widely expressed in normal tissues, 
however their expression has been evidenced in cancer marking a potential cancer target. GBMs 
have previously been shown to express MICA (Spear, Wu et al. 2013). The binding of NKG2D to its 
ligands has been shown to be involved in tumour immunosurveillance, the expression on MHC class 
I prevents NK-cell mediated cytolytic activity, in the GBM setting MICA and MICB are expressed 
however these tumours also appear to have MHC class I expression which acts to dampen NK cell 
mediated lysis (Friese, Platten et al. 2003). 
Preliminary analyses of GBM tissues reveal that these tumours express immunogenic antigens that 
are targetable, however these tumours seem to also express several immunosuppressive antigens 
in their native environment a result that will need to be taken into consideration when assessing 
the vaccine in vivo. These results provide promising targets; however the second set of findings 
make it difficult to target these tumours with activated immune cells. As a result, checkpoint 
blockade will have to be incorporated into future immunotherapeutic approaches.  
3.5. Conclusion 
TRP-2 and WT-1 proteins are viable targets for GBM immunotherapy due to their presence within 
the majority of the GBM tumours studied in this thesis and their absence from normal brain tissues. 
Unfortunately, flow cytometric and Western blotting analyses revealed that despite expressing 
targetable antigens these tumours are highly immunosuppressive. Because of the expression of 
several immunosuppressive proteins future immunotherapeutic targeting of these tumours will 
need to take immunosuppression into account, this may be done by blocking some of these 
immunosuppressive checkpoints whilst targeting the antigens expressed via active immunotherapy 
(a concept that will be explored later in this thesis). The expression of MGMT renders patients’ 
resistant to temozolomide chemotherapy. Western blotting analyses of the GBM cell lines revealed 
that five out of the eight cell lines studied express the MGMT protein. This indicates a high 
proportion of temozolomide resistance, as a result it is of great interest to discover novel methods 
for targeting these tumours, and this is where immunotherapy comes into play. 
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CHAPTER 4: PRE-CLINICAL EVALUATION OF THE IMMUNOBODY® DNA 
VACCINES 
 
4.1. Introduction 
4.1.1. Vaccination 
 
Vaccination has been a key discovery in the history of medicine, traditionally vaccination was used 
to protect against infection however it has also been explored in a therapeutic context. The earliest 
documented case of therapeutic vaccination for cancer is the work published by William B. Coley in 
the late 19th century. Coley used injection of bacteria into patient tumours to induce a localised 
immune response (Coley 1891). Whilst Coley utilised bacteria to induce an immune response to 
tumours there are numerous other anti-tumour vaccination methods. Cancer immunotherapy was 
Science magazine’s breakthrough of the year in 2013 (Couzin-Frankel 2013) and numerous 
immunotherapeutic approaches are being approved and currently being trialled in the cancer 
setting. Currently there are no approved immunotherapeutic treatments for glioblastoma 
multiforme available however there are numerous immunotherapeutic treatments currently being 
trialled (, clinicaltrials.gov - PubMed - NCBI). 
The purpose of a vaccination is to eliminate pathogens/cancer cells utilising the body’s own immune 
system. This involves “educating” cells within the immune system to recognise, kill and remove 
these pathogens/deleterious cells. In the context of cancer cells, antigens recognised by the 
immune system are not necessarily foreign in nature, the immune system also appears to recognise 
cells overexpressing certain antigens, which is often the case in cancer. Tumour antigens can 
broadly be grouped into tumour-associated antigens (TAAs) and tumour specific antigens (TSAs). 
Tumour specific antigens are antigens that are exclusive to tumour cells, quite often these may be 
mutated, or truncated forms of native antigens normally expressed within the body, one such 
example is the EGFRvIII antigen, which is a truncated version of the epidermal growth factor 
receptor with deletion of exons 2-7 of the corresponding gene. Another type of ‘tumour specific’ 
antigens are the cancer testis antigens. These are antigens which are expressed by tumour cells and 
the testes; the reason why these antigens are considered tumour specific is that the testes are an 
immune privileged site, essentially making antigens they express invisible to the immune system 
and therefore to the immune system these antigens appear to be exclusive to cancer cells due to 
their ‘foreign’ nature. Tumour associated antigens are antigens expressed normally within the body, 
however they are usually more abundant in tumour cells, this elicits an immune reaction due to the 
abnormal expression levels. The presence of these antigens provides us with a means to target 
these tumours and turn the immune system onto them (Reardon, Freeman et al. 2014).  
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Tumours can be targeted by identifying the antigens they express and targeting these antigens. The 
most straightforward way to home the immune system onto tumour cells is to vaccinate patients 
with their own tumour cells. The preparation methods of the tumour cells can be varied, and the 
reasoning behind using autologous tumour cells is that they should contain all the patient’s tumour 
antigens. With regards to preparation prior to vaccination the tumour cells may be irradiated, lysed 
or even genetically modified. This prevents the tumorigenicity of these cells whilst allowing their 
antigens to stimulate the immune system (de Gruijl, van den Eertwegh et al. 2008). Irradiated 
tumour cells given in conjunction with an immune adjuvant have been shown in animal models to 
protect from subsequent tumour challenge, the administration of this vaccination in colorectal 
cancer resulted in improved disease-free survival, however further analysis of this vaccination 
method highlighted the importance of standardising the vaccination preparation procedure. This 
was highlighted by the variability of the quality of the vaccinations produced at different 
experimental sites (de Gruijl, van den Eertwegh et al. 2008).  
Dendritic cells like macrophages are professional antigen presenting cells, whose function is to clear 
the body of dead cells/debris/proteins, “digest” these into smaller peptide fragments that are then 
presented via MHC molecules to other immune cells, thereby kick starting the immune response 
(Guermonprez, Valladeau et al. 2002). Utilising dendritic cells as a method of vaccination is another 
avenue for therapy. Dendritic cells can be obtained from the patient’s body; this is done by 
extracting PBMCs from the patient via leukapheresis. PBMCs are then treated with cytokines 
resulting in their differentiation into dendritic cells and then these cells are expanded in vitro. These 
patient derived dendritic cells can then either be pulsed with autologous tumour cell lysate or a 
peptide/multiple peptides. These dendritic cells can then be matured and re-introduced into the 
patient with the goal of priming the immune cells within the body to recognise tumour antigens 
and generate an anti-tumour immune response. DCVax®L is one such example of this type of 
therapy utilised in the glioblastoma multiforme setting (Polyzoidis, Ashkan 2014). This vaccine is 
generated by using patient monocyte-derived DCs and pulsing them with autologous tumour lysate. 
This method of vaccine therapy has undergone numerous clinical trials and early Phase I/II trials 
were promising with 33% of patients surviving for over 4 years, and 27% surviving more than 6 
years. As a result of these promising early results DCVax®L progressed into Phase III trial (Hdeib, 
Sloan 2015). Preliminary results from the phase III study of DCVax®L for GBM have revealed that 
the median overall survival of the intent-to-treat population was 23.1 months from surgery vs the 
15 months achieved via standard therapy. Upon recurrence all patients could receive DCVax®L and 
as a result 90% of patients enrolled received DCVax®L vaccinations. Only 7% of patients within the 
study experienced serious adverse side effects. It would be of great interest to see how DCVax®L 
affects survival once the data has been unblinded, but these early results are promising (Liau, 
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Ashkan et al. 2018). ICT-107 is another example of a dendritic cell vaccine being tested in GBM 
(Wen, Reardon et al. 2019). ICT-107 uses patients’ monocyte-derived DCs pulsed with six synthetic 
GBM associated peptides (MAGE-1, HER-2, AIM-2, TRP-2, gp100 and IL13-Rα2) before being re-
administered into patients. In a Phase II study comparing ICT-107 with unpulsed dendritic cells it 
was found that overall survival of ICT-107 treated patients two months longer than control patients 
given unpulsed dendritic cells (Wen, Reardon et al. 2019). Unfortunately, due to funding constraints 
Phase III study of ICT-107 has been halted. These methods of generating vaccinations are extremely 
expensive and the methods for generating these vaccines highly invasive with patients needing to 
undergo leukapheresis sessions. These vaccines also require time to develop so there may be a 
latency period between surgery and receipt of dendritic cell vaccination (Mastelic-Gavillet, Balint 
et al. 2019). 
The immune system can also be simply educated via injection of immunogenic cancer-specific 
peptide sequences that home immune cells onto tumours. This method of vaccination is less 
invasive and far more rapid than dendritic cell vaccination making it an attractive method for 
generating an immune response. Often these peptides will need to be given in conjunction with 
immune boosting adjuvants. One such example of a peptide vaccination for the treatment of GBM 
is Rindopepimut (Swartz, Li et al. 2014). Rindopeptimut is a 14 amino acid long peptide sequence 
specific for the previously mentioned GBM antigen EGFRviii conjugated to keyhole limpet 
hemocyanin; an immunogenic carrier protein. Keyhole limpet hemocyanin is a highly immunogenic 
protein that can activate dendritic cells via its interaction with the mannose receptor resulting in 
increased cytokine release and upregulation of costimulatory molecules (Presicce, Taddeo et al. 
2008). Due to pre-clinical successes Rindopepimut was moved into the clinic for early trials, in a 
Phase II trial combining Rindopepimut vaccination with the immune adjuvant GM-CSF, low toxicity 
was observed. EGFRviii positive patients were treated with Rindopepimut; the overall survival for 
treated patients was 26 months compared to 15.2 months for matched controls. In patients whose 
tumours recurred 82% had complete loss of EGFRviii expression and of those still expressing 
EGFRviii less than 1% of cells within the tumour expressed the protein. Rindopepimut was advanced 
to Phase III in newly diagnosed patients whose tumours expressed EGFRviii. Patients were given 
Rindopepimut with GM-CSF along with standard therapy (TMZ+RT), in this phase II trial the overall 
survival of patients was 24.6 months compared to the 15.2 months of matched controls (Swartz, Li 
et al. 2014). In a further Phase III trial utilising Rindopepimut in combination with TMZ for the 
treatment of EGFRviii positive de novo GBM post-surgical resection and completion of standard 
radiation. The control group received just keyhole limpet hemocyanin along with TMZ. Comparison 
of the control and treatment groups revealed that there was no increase in overall survival, as a 
result Rindopepimut’s usage has not been approved for use in GBM (Weller, Butowski et al. 2017).  
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4.1.2. Antigen presentation and the immunoproteasome 
 
All internal proteins and misfolded proteins are eventually ubiquitinated and sent for “recycling”. 
This natural degradation process is performed by a complex of enzymes called proteasomes at the 
end of which process peptides are produced and presented via MHC class I molecules (expressed 
by all nucleated cells in the body) to CD8+ T-cells. The 26S proteasome is responsible for degrading 
polyubiquitylated proteins. The 26S complex is made up of the 20S proteasome and two 19S 
regulator complexes. The 20S protease unit is composed of alpha and beta subunits that form a 
barrel shaped complex is the catalytic core comprised of seven beta subunits, three of which are 
responsible for its hydrolytic activity (Basler, Kirk et al. 2013). The 19S regulator units are composed 
of 6 ATPase subunits and 9-10 non-ATPase subunits; these attach to the outer alpha rings of the 
20S core. Defective proteins known as defective ribosomal products are synthesised by cells, due 
to their defects they are ubiquitylated and degraded by the proteasome, resulting in the production 
of antigenic peptides. Protein synthesis is key for the generation of MHC class I peptides however 
many proteins need to be hydrolysed to yield MHC class I epitopes. Interferon gamma has been 
shown to enhance antigen presentation via MHC upregulation. Interferon gamma also leads to 
replacement of the β1, β2 and β5 hydrolytic subunits of the 20S core with LMP2, LMP7 and MECL-
1 leading to formation of the ‘immunoproteasome’: a proteasome that is more efficient at 
generating immunogenic peptides than the standard proteasome. IFNγ also leads to regulation of 
the proteasome activator complex PA28 (comprised of the α and β PA28 subunits). This complex 
binds to the α rings on the 20S complex enhancing its proteolytic activity. This leads to increased 
protein break down and as a result a generation of more potentially immunogenic peptide 
sequences due to the increased rate of proteolysis and production of immunoproteasome specific 
peptides (Kloetzel, Ossendorp 2004). Once immunogenic peptides are generated, they are shuttled 
to the endoplasmic reticulum by TAP (Transporter associated with antigen presentation). These 
peptides are then trimmed by aminopeptidases enabling their binding to MHC class I. These MHC 
class I peptide (now 8-11 amino-acids long) complexes are then shuttled to the cell surface where 
they are presented to CD8+ T-cells (Wearsch, Cresswell 2008). 
MHC class II is only expressed by antigen presenting cells, thymic epithelial cells, some endothelial 
cells and B cells (Roche, Furuta 2015). The majority of peptides bound to MHC class II are derived 
from the processing of proteins that have been internalised from within the microenvironment. 
These MHC class II molecules present peptides of 11-20 amino-acid long to CD4+ T-helper cells. The 
presentation of peptides to CD4+ T-cells results in their differentiation into the differing T-helper 
cell subsets, the type of cell presenting these class II peptides, along with differing costimulatory 
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signals result in the generation of differing cell subsets. Once MHC class II molecules are produced 
within cells, they bind to a protein known as the invariant chain, this invariant chain is involved in 
the shuttling of the MHC class II molecules to the endosomal-lysosomal antigen processing 
compartments. MHC class II bound to the invariant chain is shuttled to the endosomal-lysosomal 
processing compartment where it is exposed to antigenic peptides. The invariant chain prevents 
the binding of peptides to the MHC class II molecule, so the invariant chain is proteolytically 
degraded freeing up the MHC molecule for peptide binding (Cresswell 1996). After peptide binding 
to the MHC class II molecule the MHC peptide complex is transported to the plasma membrane for 
recognition by CD4+ T-cells. Antigens are obtained from various sources; antigen presenting cells 
can take up extracellular proteins via a process known as micropinocytosis (Lim, Gleeson 2011). 
Dendritic cells are the most potent antigen presenting cells within the immune system being at the 
centre of innate and adaptive immune responses. Immature dendritic cells have a high level of basal 
macropinocytosis, and this is believed to be the major route of antigen acquisition used by these. 
B cells on the other hand have little to no macropinocytic activity and they uptake antigenic material 
via receptor mediated endocytosis (Roche, Furuta 2015). As dendritic cells mature their rate of 
macropinocytic activity decreases. APCs and B cells have several cell surface receptors that enable 
binding and uptake of antigenic material. These are receptors such as the B cell receptors, 
complement receptors and the Fcγ receptors (FcγR) specific for IgG. FcγRs are present on both 
immature and mature dendritic cells enabling these cells to uptake immune complexes and process 
them for antigen presentation. Once antigenic material is bound to these receptors they are 
internalised and shuttled to the antigen-processing compartments by clathrin-mediated 
endocytosis (Roche, Furuta 2015). This receptor mediated method of antigen processing is far more 
efficient at priming CD4+ T-cells than micropinocytosis, roughly one thousand times more efficient 
(Rock, Benacerraf et al. 1984). Antigens can also be taken up via phagocytosis, uptake of apoptotic 
cells via this method enables antigen presenting cells to present self-peptides resulting in the 
generation of peripheral tolerance. Mature dendritic cells are still capable of performing 
phagocytosis. Antigenic cargo is internalised by phagosomes, these are relatively non-proteolytic 
so these phagosomes fuse with lysosomes generating phagolysosomes. The phagolysosome breaks 
down the antigenic cargo contained, and it contains the complete MHC class II peptide-loading 
machinery allowing for peptide loading and presentation. The phagolysosome is tightly regulated 
in order to prevent the breakdown of potentially antigenic peptide sequences. MHC class II peptides 
can also be obtained by autophagy. Autophagosomes engulf cytosolic macromolecules and 
organelles which fuse with lysosomes to form autophagolysosomes resulting in breakdown of 
peptides and presentation via MHC class II. In immature dendritic cells large amounts of MHC class 
II are present, upon activation of dendritic cells there is a change in MCH class II expression and 
cellular localisation. In immature dendritic cells MHC class II is present on the plasma membrane 
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and within intracellular endosomes and lysosomes, MHC class II is primarily on the plasma 
membrane of mature dendritic cells (Roche, Furuta 2015).  
The Fc gamma receptor FcγR is an important regulator of immune responses due to its ability to 
bind to IgG antibodies. The immune response is a fine balance between immune activation and 
inhibition, modulated by cytokine action, cell signalling and cell-cell contact. When pro-
inflammatory signals dominate pathogens are eliminated. When there is a lack of positive 
stimulation anti-inflammatory mechanisms down regulate immune activation. The FcγRs are key 
regulators of a balanced immune system setting thresholds for immune cell activation by 
simultaneous stimulation of activating and inhibitory pathways. FcγRs have roles in antigen 
presentation and immune-complex mediated maturation of dendritic cells, as a result FcγRs can 
regulate dendritic cell activity and control whether an immunogenic or tolerogenic response is 
initiated after peptide recognition. FcγRs bind to IgG antibodies via their Fc fragment. FcγRs on 
dendritic cells are essential for endocytosis and/or phagocytosis of antibody-antigen immune 
complexes and the resultant processing and presentation of antigenic peptides on MHC molecules, 
regulating the activity of dendritic cells. Immune complexes are strong activators of dendritic cells 
and they have been shown to prime a stronger immune response than antigen alone. Immune 
complex internalisation via the FcγRs has been shown to result in priming of both CD8+ and CD4+ T-
cell responses (Nimmerjahn, Ravetch 2008). 
Cross priming is key for the generation of a robust immune response. This is the process by which 
dendritic cells present tumour antigens to T-cells providing the necessary co-stimulatory signals 
required for immune cell activation that are lacking when the tumours present antigens on their 
surface. As previously mentioned, dendritic cells are the most potent antigen presenting cells of 
the immune system. Dendritic cells process and present antigens via both MHC class I and class II 
molecules enabling them to activate both CD8+ and CD4+ T-cells using the methods mentioned 
above. Dendritic cells can endocytose cellular debris enabling uptake and presentation of tumour 
antigens. These dendritic cells can then travel to lymph nodes where they present the antigens they 
have taken up to T-cells. Intratumoural dendritic cells can also present antigens to T-cells located 
within tumours along with co-stimulatory signals that result in T-cell activation (Sanchez-Paulete, 
Teijeira et al. 2017). For dendritic cells to induce T-cell maturation they need to present peptides 
on MHC molecules to naive T-cells; these peptides bind to the T-cell receptor (TCR) on the surface 
of the T-cell forming an immunological synapse. The strength of this synapse contributes to the 
level of T-cell activation. Costimulatory molecules also function to enhance the T-cell response, with 
engagement of CD28 on T-cells to B7 molecules expressed on dendritic cells resulting in a 100-fold 
increase in TCR signalling; this occurs via the increased recruitment of downstream kinases. 
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Cytokines released by activated T-cells into the microenvironment contribute to T-cell proliferation 
expanding these antigen specific T-cells (Lanzavecchia, Sallusto 2001). 
 
4.1.3. Immune escape and the three Es 
 
It is now well known that there are active interactions between tumours and the immune system, 
even in the GBM setting despite its perceived ‘immune privileged’ state. In the case of advanced 
late stage cancers such as grade IV glioblastoma multiforme these tumours have developed 
methods for escaping basal immune surveillance resulting in their increased growth and 
aggressiveness (Mittelbronn, Platten et al. 2011). In the cancer setting there are several stages 
leading to the immune escape of tumours, these are known as the three Es: elimination, equilibrium 
and escape. During the elimination phase tumour cells are actively targeted by the immune system 
and as a result there is eradication of tumour cells. This hypothesis is supported by data showing 
that the presence of tumour infiltrating lymphocytes within tumours are a positive prognostic 
factor. Despite the presence of a healthy immune system people still develop cancer, this suggests 
that there is an active response by cancer cells that enables some cells to evade the immune 
response and this eventually leads to the development of a tumour. After elimination of tumour 
cells by the immune system any cells that have survived immune surveillance are held in equilibrium 
by the immune system where the tumour cells can survive but they do not expand to produce an 
aggressive tumour mass. Many of these tumour cells may be eradicated, but new immune escape 
variants develop due to the highly adaptive nature of tumour cells. After continuous immune 
pressure, populations of immune-resistant tumour cells that have developed mechanisms to 
escape the immune system eventually start to grow, leading to the development of cancer (Dunn, 
G. P., Old et al. 2004). In the active immunotherapy setting tumours can also adapt to overcome 
the immune pressures put upon them, this has been seen in the GBM setting with patients 
immunised with Rindopepimut (a vaccine targeting the EGFRviii peptide expressed by GBM 
tumours). Patients vaccinated with Rindopepimut developed EGFRviii immune responses and 
slightly improved survival, however tumours eventually recurred, and the tumours that recurred 
no longer expressed the EGFRviii antigen. This is an indication that an immune escape variant has 
developed, with all EGFRviii expressing tumour cells being eradicated improving patient survival, 
equilibrium phase followed. Unfortunately by the emergence of a cell which managed to survive 
without the need of EGFRviii protein this immune escape variant was then free to expand resulting 
in the tumour recurrence (Sampson, Heimberger et al. 2010). In order to prevent such an immune 
escape multiple antigens need to be targeted. Not only can antigen-escape variants develop, cancer 
cells displaying an immune suppressive phenotype can expand and prevent immune responses 
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within the tumour mass. As a result, combinatorial therapies may be utilised to overcome 
development of a potentially more aggressive cancer. 
 
4.1.4. Epitope dominance 
 
The risk of targeting multiple antigens is the phenomenon of epitope dominance (Kedl, Kappler et 
al. 2003). Immunodominance can result in a selective immune response towards one antigen over 
the other one. The immunodominance of one epitope may prevent the development of responses 
to other antigenic antigens expressed by tumour cells. The ability of an antigen to become 
immunodominant appears to be due to its capability of generating a rapid response when 
compared to other antigens, therefore dominance is given to the antigen that seems to induce the 
first response. Research has shown that when a combination of five immunodominant epitopes are 
presented as a mixed antigen only two of the epitopes generate a dominant immune response, 
revealing that a hierarchy emerges when numerous dominant epitopes are encountered (Sandberg, 
Grufman et al. 1998). New hierarchies can also develop when an immunodominant antigen is lost 
by immune selection. As tumours progress, they acquire more mutations which can lead to the 
expression of an increased repertoire of immunogenic antigens. It has been found that a response 
to an antigen already present on a tumour will prevent responses to newly developed immunogenic 
antigens even if the new antigens that have developed generate a stronger response. This indicates 
that there is an innate priority to the first response (Schreiber, Wu et al. 2002). Tumours have been 
shown to evade immune regulation via loss of a single HLA molecule. This allows tumours to escape 
cytolysis by immunodominant CD8+ T-cells due to the immunodominant epitope not being 
presented. Uptake of antigenic material from these HLA-deficient immune-escape variants by 
dendritic cells still allows for presentation of antigenic material by the dendritic cells to the CD8+ T-
cells maintaining this immunodominant phenotype, preventing T-cells from responding to new 
antigens the cancer has developed. One way to overcome immunodominance is to administer 
subdominant epitopes prior to immunodominant epitopes this will allow for the induction of new 
immunodominant CD8+ T-cell subtypes specific for previously weakly antigenic epitopes (Chen, W., 
McCluskey 2006). 
 
4.1.5. ImmunoBody® vaccination 
 
The ImmunoBody® vaccination (Scancell Ltd.) is a DNA plasmid vaccination that codes an IgG1 
antibody that contains peptide targets of interest engrafted into the complementarity determining 
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regions (CDRs) (Metheringham, Pudney et al. 2009, Durrant, Parsons et al. 2001). The plasmid is 
administered and then the DNA is transcribed into mRNA and the resultant mRNA is then translated 
into the IgG1 protein. The IgG1 acts as a carrier for the immunogenic peptides of interest. IgG1 is 
ideal due to its long half-life and the ability of antigen presenting cells to interact with the IgG via 
the Fc region of the antibody. ImmunoBody® can work by two distinct methods: direct presentation 
and cross presentation. Direct presentation is when antigen presenting cells are transfected with 
the ImmunoBody® plasmid. These cells then process the DNA resulting in production of the 
encoded IgG. The immunoproteasome then breaks down the resultant IgG resulting in loading of 
the immunogenic peptides onto MHC class I and class II molecules where they are then presented 
to T-cells. Cross presentation is when ‘bystander’ cells are transfected. These cells then process the 
DNA leading to production of the encoded IgG. This IgG is then secreted by these cells where it is 
then taken up by antigen presenting cells via the Fc region of the IgG. Removal of the Fc region from 
the IgG results in a one thousand-fold reduction of T-cell activation, revealing that this cross 
presentation is vital for boosting the immune response (Metheringham, Pudney et al. 2009, Durrant, 
Parsons et al. 2001). The ImmunoBody® vaccine can be administered using intramuscular 
electroporation in humans, and pre-clinical experiments have administered the plasmid biolistically 
using a gene gun that utilises helium gas to shoot plasmid coated gold nanoparticles into the skin 
of test animals. Due to its preclinical efficacy a TRP-2/gp100 directed ImmunoBody® vaccination 
known as SCIB1 is being trialled in melanoma patients. In Phase I/II trial SCIB1 vaccination induced 
T-cell responses in 88% of patients treated, seven out of fifteen tumour bearing patients were 
shown to have stable disease and 100% patients with resected tumours remained alive at the 
conclusion of the study (median observation time of 37 months) (Patel, P. M., Ottensmeier et al. 
2018). 
 
4.1.6. The humanised HHDII/DR1 C57BL/6 mouse model 
 
The HHDII/DR1 mouse is a transgenic mouse that allows for the study of human HLA-A2.1 and HLA-
DR1 restricted peptide immune responses. This mouse strain was generated from a parental 
C57BL/6 mouse, the parental mice had H-2Db and β2M knocked out (Pascolo, Bervas et al. 1997). 
The transgenic HHDII consists of a murine MHC class I alpha 3 chain and transmembrane domain 
connected to a human alpha 1 and alpha 2 chain. The human alpha 1 chain is covalently linked to a 
human beta 2 M subunit (see Figure 26) (Pascolo, Bervas et al. 1997). This transgenic HHDII mouse 
was then bred with a transgenic HLA-DR1 mouse to generate the HHDII/DR1 mouse. The HLA-DR1 
transgenic mouse was generated via knockout of murine MHC class II (IAβ0/0) in C57BL/6 mice and 
knock in of a chimeric mouse/human HLA-DR1.  
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Figure 26. A diagram of the transgenic HHDII MHC class I molecule. The transmembrane and α3 
domain are of murine origin whereas the α1 and α2 domains are of human origin with the human 
β2M being covalently linked to the α1 domain. 
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This mouse model allows for the screening of candidate vaccines for use in humans without any 
interference from murine MHC meaning that translation from mouse to man should be more 
efficient. 
 
4.2. Aims and hypothesis 
After identifying suitable target antigens for therapy (as discussed in chapter 3), the next step was 
to target these with a therapeutic vaccine. For the reasons explained above ImmunoBody® was 
selected as the vaccination method for this study. To study the effects of the ImmunoBody® the 
humanised HHDII/DR1 mouse were used, in order for the study to indirectly assess what the human 
response would be like for HLA-A2 and HLA-DR1 positive individuals, providing a more translatable 
model for the study of immune responses. The response of immunised mice to the ImmunoBody® 
vaccination was measured using ELISpot and flow cytometry. 
 
4.3. Results 
4.3.1. ImmunoBody® vaccination generates a strong anti-TRP-2 and WT-1 immune 
response in the C57BL/6 HHDII/DR1 mouse 
 
Mice were vaccinated as summarised in Figure 27, where day 0 mice were immunised with gold-
coated ImmunoBody® plasmids (see methods in chapter 2.2.) using a helium air gun on the flank of 
the mice, followed by two booster doses administered seven days apart (on day 7 and 14 post 
prime). This vaccination schedule was chosen because it had previously been shown to be the most 
efficient at inducing a persistent peptide specific immune response (Metheringham, Pudney et al. 
2009). On day twenty-one immunised (or naive) HHDII/DR1 mice were humanely culled and their 
spleen harvested. The splenocytes extracted from these mice were then used in an IFN ELISpot 
assay where TRP2 and/or WT1 peptides were used (see methods in chapter 2.2.). Wells containing 
cells only were used as controls while wells with cells receiving the super antigen staphylococcal 
enterotoxin B (SEB) were used as positive controls, all conditions were performed in triplicate and 
each experiment contained three mice per group. SEB is a bacterial antigen known to generate IFNγ 
release from immune cells without prior exposure. 
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Figure 27. The vaccination schedule utilised to study the immunogenicity of the ImmunoBody® 
vaccine. The top left area of the figure details the days that mice were dosed, with vaccines 
administered at weekly intervals. Mice were split into three groups; one receiving SCIB1 (TRP-2) 
ImmunoBody®, one receiving WT-1 ImmunoBody® and one receiving both SCIB1 (TRP-2) and WT-1 
ImmunoBody®. 
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Table 18. A list of the peptides used to stimulate splenocytes ex vivo. In silico analysis was 
performed using SYFPEITHI, a data base that provides predicted MHC binding scores. The higher 
the score the stronger the binding of the peptide with the HLA molecule, and therefore the more 
likely this peptide is to be presented via MHC molecules. 
 
Mice immunised with either SCIB1 or WT1-ImmunoBody® generated vaccine and peptide specific- 
responses with the exception of gp100 where no significant gp100 specific immune response could 
be detected after the co-culture of splenocytes derived from SCIB1 vaccinated with gp100 peptides 
(see Figure 28). However, since tumour tissues analysed previously appeared not to express the 
gp100 protein this will not impact on the efficacy of the proposed vaccine combination.   
The WT-1 ImmunoBody® generated a strong response to the full 15mer class II sequence encoded 
within the ImmunoBody® construct. Two of the HLA-A2 specific sequences within the 15mer 
peptide were also used to stimulate the splenocytes from WT-1 ImmunoBody® vaccinated mice. 
The two sequences used were: ALLPAVPSL and DLNALLPAV, of the two sequences ALLPAVPSL 
generated a strong IFNγ response from the splenocytes of WT-1 ImmunoBody® vaccinated mice 
(see Figure 29). The DLNALLPAV peptide sequence did generate an IFNγ response from vaccinated 
splenocytes however this was at a much lower level than the ALLPAVPASL sequence and the 
response was deemed non-significant (see Figure 29). When looking to the in silico SYFPEITHI HLA-
A2 binding scores the ALLPAVPSL sequence has a higher binding score than the DLNALLPAV 
sequence which can explain the dominance of the ALLPAVPSL sequence observed.  
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Figure 28.  IFNγ ELISpot results from splenocytes from SCIB1 ImmunoBody® vaccinated mice. N= 9-
3, *= P ≤ 0.05 as defined by a two-way ANOVA followed by Tukey’s post hoc test. The three letter 
annotations after the peptide correspond to the first three amino acids of the peptide used to 
stimulate the splenocytes, the full sequences of these peptides are detailed in the methods (chapter 
2). 
 
 
Figure 29.  IFNγ ELISpot results from splenocytes from WT-1 ImmunoBody® vaccinated mice. N= 9-
3, *= P ≤ 0.05, ***= P ≤ 0.001 as defined by a two-way ANOVA followed by Tukey’s post hoc test. 
The three letter annotations after the peptide correspond to the first three amino acids of the 
peptide used to stimulate the splenocytes, the full sequences of these peptides are detailed in the 
methods (chapter 2). 
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The aim of this study is to use both vaccines together, the next sets of experiments compared the 
IFNγ responses after mice were immunised with either SCIB1, WT1-ImmunoBody® or both. 
This is particularly important because it allows for a broader range of patients to be treated and it 
acts to eradicate as much of the heterogeneous tumour population as possible whilst overcoming 
the possibility of antigen escape variants developing. When the two vaccines are administered 
together there is a significant response to both the WT-1 and TRP-2 peptides as was the case when 
the two vaccines were given individually. What is even more important is that there is no significant 
difference in the response between the dual and both single vaccines.  
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Figure 30. IFNγ ELISpot results from splenocytes from SCIB1 and WT-1 ImmunoBody® vaccinated 
mice compared with mice vaccinated with both SCIB1 and WT-1 ImmunoBody® simultaneously. N= 
9, ns= not significant as deemed by a two-way ANOVA followed by Tukey’s post hoc test. The three 
letter annotations after the peptide correspond to the first three amino acids of the peptide used 
to stimulate the splenocytes, the full sequences of these peptides are detailed in the methods 
(chapter 2). 
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Due to the frequency of the IFNγ response being equivalent in both the singly and dually vaccinated 
mice, it is also important to see if the avidity of these responses is equivalent. In order to do this a 
peptide titration of the WT-1 and TRP-2 HLA-A2 specific peptides was performed to measure the 
avidity of the immune response of splenocytes from singly and dually vaccinated mice.  
Peptide titration revealed that when both ImmunoBody® vaccines were given together the avidity 
of the response to the TRP2 HLA-A2 specific peptide was equivalent with no significant difference 
being found between the two peptide dose response curves. Nonlinear regression analysis found 
no significant difference between the EC50 of the TRP-2 peptide for both the dually and singly 
vaccinated splenocytes. The WT-1 peptide titration also reveals the same results with no significant 
difference being found between the EC50 for both the singly and dually vaccinated splenocytes.  
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Figure 31.  IFNγ ELISpot results from splenocytes from SCIB1 ImmunoBody® vaccinated mice 
compared with mice vaccinated with both SCIB1 and WT-1 ImmunoBody® simultaneously. A) 
Splenocytes were treated with the SVYDFVWL TRP-2 peptide sequence diluted in 10-fold increments 
from 1 µg/mL- 0.0000001 µg/mL. B) Data was normalised and transformed, and non-linear fit 
comparisons were made, these analyses revealed that there was no significant difference between 
the EC50 of SCIB1 and dual vaccinated mice. 
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Figure 32. IFNγ ELISpot results from splenocytes from WT-1 ImmunoBody® vaccinated mice 
compared with mice vaccinated with both SCIB1 and WT-1 ImmunoBody® simultaneously. A) 
Splenocytes were treated with the ALLPAVPSL WT-1 peptide sequence diluted in 10-fold increments 
from 1 µg/mL- 0.0000001 µg/mL. B) Data was normalised and transformed, and non-linear fit 
comparisons were made, these analyses revealed that there was no significant difference between 
the EC50 of WT-1 and dual vaccinated mice.  
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4.3.2. Flow cytometric analysis of the ImmunoBody® activated immune cells revels that 
ImmunoBody® vaccination generates a strong CD8+ T-cell response 
 
Flow cytometry was utilised to study the lymphocytes from vaccinated animals. The splenocytes 
from these animals were stimulated in vitro and then surface staining was used to differentiate 
between CD3, CD4+ and CD3, CD8+ T-cell populations. Once these two populations were identified 
their expression of immune activating ligands and cytokines was stained for allowing for the 
immune response of vaccinated and unvaccinated splenocytes to immunologic peptides to be 
measured. 
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Figure 33. A representative set of flow cytometry plots of splenocytes isolated from vaccinated mice 
after peptide stimulation. These plots are from a mouse that received dual vaccination. The gating 
strategy can be seen in the methods sections (Chapter 2). All these plots are from CD3 positive live 
cells. A) Histogram of the CD8+ CD107+ cells. B) Histogram of the CD4+ CD107+ cells. C) Histogram of 
the CD8+ TNFα+ cells. D) Histogram of the CD4+ TNFα+ cells. E) Histogram of the CD8+ Ki67+ cells. F) 
Histogram of the CD4+ Ki67+ cells. G) Histogram of the CD8+ IL-2+ cells. H) Histogram of the CD4+ IL-
2+ cells. I) Histogram of the CD8+ IFNγ+ cells. J) Histogram of the CD4+ IFNγ+ cells.  K) Histogram of 
the CD8+ Granzyme B+ cells.  L) Histogram of the CD4+ Granzyme B+ cells. Plots M-O show scatter 
plots of the CD8+ cells stained with TNFα (on the x axis) and IFNγ (on the y axis). Double positive cells 
are in the top right quadrant. M) Splenocytes receiving no peptide stimulation. N) Splenocytes 
receiving class I peptide stimulation. O) Splenocytes receiving class I and class II peptide stimulation. 
Plots P-R show scatter plots of the CD4+ cells stained with TNFα (on the x axis) and IFNγ (on the y 
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axis). Double positive cells are in the top right quadrant. P) Splenocytes receiving no peptide 
stimulation. Q) Splenocytes receiving class I peptide stimulation. R) Splenocytes receiving class I and 
class II peptide stimulation. For plots A-L the blue peak represents splenocytes stimulated with both 
class I and II peptides, the green peak represents splenocytes stimulated with class I peptides only 
and the red peak represents splenocytes that received no peptide stimulation. The gate used to 
determine the percentage of positive cells is shown on each histogram and the percentage of 
positive cells gated is shown next to the histogram. 
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Figure 34. Flow cytometric analysis of CD3+ CD8+ splenocytes from SCIB1 ImmunoBody® vaccinated 
mice that were either unstimulated (no peptide) or stimulated with TRP-2 class I (SVYDFFVWL) 
peptide. A) % CD107+ CD8 T cells. B) % TNFα+ CD8 T cells. C) % Ki67+ CD8 T cells. D) % IFNγ+ CD8 T 
cells. E) % Granzyme B+ CD8 T cells. F) % TNFα+ and IFNγ+CD8 T cells. N = 4, *= p≤ 0.05 as deemed 
by a paired T-test.  
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When studying the CD8+ T-cells from SCIB1 ImmunoBody® vaccinated mice there was a significant 
increase in the percentage of cells that stained positive for CD107a when these cells were 
stimulated with class I peptide. There is also a slight increase in the percentage of granzyme B 
positive cells. This increase of CD107a and granzyme B indicates an increase of the cytolytic activity 
of these CD8+ T-cells. These cells also increase their expression of the immune stimulating cytokines 
TNFα and IFNγ, promoting an inflammatory anti-tumour microenvironment. Finally, the increase in 
marker of proliferation Ki67 expressing cells also indicates that there is an antigen-specific increase 
in proliferation of CD8+ T-cells when vaccinated splenocytes are stimulated with peptide. Taken 
together these changes indicate that the SCIB1 ImmunoBody® vaccination generates a SCIB1 
specific immune response from HHDII/DR1 mice and there appears to be an immunological memory 
directed towards the TRP-2 antigen encoded within the ImmunoBody® plasmid. 
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Figure 35. Flow cytometric analysis of CD3+ CD8+ splenocytes from WT-1 ImmunoBody® vaccinated 
mice that were either unstimulated (no peptide), stimulated with WT-1 class I (ALLPAVPSL) peptide 
or stimulated with both class I (ALLPAVPSL) and class II (VRDLNALLPAVPSLG) peptides. A) % CD107+ 
CD8 T cells. B) % TNFα+ CD8 T cells. C) % Ki67+ CD8 T cells. D) % IFNγ+ CD8 T cells. E) % Granzyme B+ 
CD8 T cells. F) % TNFα+ and IFNγ+CD8 T cells.  N = 7, all results were deemed non-significant by a 
one-way ANOVA followed by Tukey’s post-hoc test.  
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When stimulated with class I peptides there is a slight increase in the percentage of CD107a, TNFa, 
Ki67 and IFNγ positive cytotoxic T-cells from WT-1 ImmunoBody® vaccinated mice when stimulated 
in vitro. These cells increase their expression of the immune stimulating cytokines TNFα and IFNγ, 
promoting an inflammatory anti-tumour microenvironment. Finally, the increase in Ki67 expressing 
cells also indicates that there is an antigen-specific increase in proliferation of CD8+ T-cells. This 
trend is also the same for splenocytes exposed to both class I and II peptides. Unfortunately, these 
results are non-significant, but they do indicate there is some antigen specific immune cell 
responses. 
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Figure 36. Flow cytometric analysis of CD3+ CD8+ splenocytes from dual SCIB1 and WT-1 
ImmunoBody® vaccinated mice that were either unstimulated (no peptide), stimulated with TRP-2 
and WT-1 class I peptides or stimulated with both class I (TRP-2 and WT-1) and WT-1 class II peptides. 
A) % CD107+ CD8 T cells. B) % TNFα+ CD8 T cells. C) % Ki67+ CD8 T cells. D) % IFNγ+ CD8 T cells. E) % 
Granzyme B+ CD8 T cells. F) % TNFα+ and IFNγ+CD8 T cells. N = 7, * = P ≤ 0.05 as deemed by a one-
way ANOVA followed by Tukey’s post-hoc test.  
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Dual vaccination with both the WT-1 and SCIB ImmunoBodies® appears to generate a stronger 
cytokine response to antigenic peptide stimulation than when the vaccines were administered 
alone. Peptide stimulation of dually vaccinated splenocytes leads to a significant increase in the 
percentage of TNFα and IFNγ positive CD8+ T-cells (as well as double positive TNFα and IFNγ cells). 
These responses are indicative of immune recognition of the target antigens and generation of 
immunological memory. The stimulation of these CD8+ T-cells also leads to increased proliferation 
of these cells (indicated by Ki67) further highlighting the presence of immune memory and an active 
anti-antigen immune response. There is also evidence of an increase in the percentage of granzyme 
B positive cells after in vitro stimulation. This would translate to increased lytic activity of these cells 
in vivo, indicating that these cells are capable of killing antigen expressing target cells. 
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Figure 37. Flow cytometric analysis of CD3+ CD8+ splenocytes from naive mice that were either 
unstimulated (no peptide), stimulated with TRP-2 and WT-1 class I peptides or stimulated with both 
class I and WT-1 class II peptides. A) % CD107+ CD8 T cells. B) % TNFα+ CD8 T cells. C) % Ki67+ CD8 T 
cells. D) % IFNγ+ CD8 T cells. E) % Granzyme B+ CD8 T cells. F) % TNFα+ and IFNγ+CD8 T cells.  N = 7, 
all results are non-significant as deemed by a one-way ANOVA followed by Tukey’s post-hoc test.  
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In order to see if the CD8+ T-cell responses observed were due to immunological memory generated 
by vaccination, naive splenocytes were extracted and stimulated in vitro and stained in the same 
manner as the splenocytes from vaccinated mice. Flow cytometric analysis revealed that there were 
no significant changes in the expression of any immune activating cytokines. These data confirm 
that the changes observed in vaccinated mice are due to immunological memory. 
The CD4+ T-cell population was also studied in these mice and their response to class I and class II 
peptide stimulation was measured. The in vitro stimulation of these CD3+, CD4+ cells revealed that 
there were no changes observed in antigen expression profile of the CD4+ T-cell population (data 
not shown). 
 
4.3.3. Splenocytes from ImmunoBody® vaccinated mice recognise GBM cell lines 
expressing TRP-2 and WT-1 in an HLA-A2 restricted manner 
 
Data from chapter 3 revealed that the human GBM cell lines SF-188 and SEBTA-027 express the 
TRP-2 and WT-1 antigens. What is of even more importance is that the SF-188 cell line is HLA-A2 
positive and the SEBTA-027 cell line is HLA-A2 negative. As a result, splenocytes from vaccinated 
mice were incubated with either SF-188 or SEBTA-027 in a 10:1 effector: target ratio and the IFNγ 
response was measured using ELISpot (see Figure 38). 
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Figure 38. IFNγ ELISpot results from splenocytes from SCIB1 and WT-1 ImmunoBody® vaccinated 
mice compared with mice vaccinated with both SCIB1 and WT-1 ImmunoBody® simultaneously 
when exposed to the human GBM cell lines SF-188 and SEBTA-027. When splenocytes were co-
cultured with the SEBTA-027 cell line they produced a number of spots above the maximum 
detectable limit, as a result these results were counted as 600 (the maximum number the machine 
can count).  N= 9, ****= P ≤ 0.0001, ns= not significant as deemed by a two-way ANOVA followed 
by Tukey’s post hoc test. 
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When splenocytes from SCIB1, WT-1 and dual ImmunoBody® mice are co-incubated with SF-188 
cells there is a strong IFNγ response. All three vaccination conditions induce a maximal response 
when assessed via IFNγ ELISpot. What is even more important is that this response is significantly 
greater than the response to the SEBTA-027 cell line. No significant difference in response to SEBTA-
027 cells is observed in any of these conditions (when compared to unstimulated no peptide 
splenocytes). This strong response to the SF-188 cell line when compared to the SEBTA-027 cell line 
helps highlight that the ImmunoBody® vaccination generates an HLA-A2 specific response. Due to 
the SF-188 cell line being HLA-A2 positive it should present the same peptide sequences as those 
encoded by the ImmunoBody® vaccines utilised, therefore it should generate a strong anti-SF-188 
response due to the immunised CD8+ T-cells recognising the same peptides as those presented on 
the surface of SF-188. Since the SEBTA-027 cell line is not HLA-A2 positive it does not present the 
same peptide sequences as those encoded within the ImmunoBody® vaccines utilised. This is 
apparent with the SEBTA-027 cell line failing to generate a significantly stronger IFNγ response from 
vaccinated splenocytes than when these splenocytes are incubated with no peptide.  
 
4.4. Discussion 
The ImmunoBody® plasmid vaccination is an effective method for generating antigen specific 
responses without the need for immune adjuvants. These analyses reveal that the SCIB1 
ImmunoBody® generates a strong TRP-2 directed response, unfortunately the SCIB1 ImmunoBody® 
failed to generate a strong response to the gp100 peptides encoded within the construct. There is 
a lack of response to the gp100 peptide sequences reveals that the TRP-2 epitope encoded 
generates an immunodominant response that appears to override the gp100 directed immune 
responses. The WT-1 ImmunoBody® also appeared to generate a strong WT-1 directed immune 
response. The future aim is to utilise both the SCIB1 and WT-1 ImmunoBody® vaccines in tandem 
to try and treat GBM; as a result, it was of great interest to see if there was immunodominance 
between these two antigens when the two vaccines are given at the same time. Fortunately, there 
appeared to be no immunodominance to either WT-1 or TRP-2 when both vaccines were given 
together, splenocytes stimulated with WT-1 and TRP-2 class I peptides generated an equivalent 
immune response as the singly vaccinated mice. Both the frequency and the avidity of the immune 
response was equivalent between both singly and dually vaccinated mice. What is also of great 
importance is that the splenocytes from HHDII/DRI ImmunoBody® vaccinated mice showed a clear 
anti-GBM cell line response, specific for the HLA-A2 positive GBM cell line SF-188. These results 
provide great promise for the use of the SCIB1 and WT-1 ImmunoBody® vaccinations for HLA-A2 
positive patients and this highlights the importance of the HHDII/DR1 mouse model for the research 
of human vaccines. Both singly and dually vaccinated mice generated a strong SF-188 response that 
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was equivalent between both the single and dual vaccinated groups. These preliminary results 
reveal that this dual vaccination combination is enough to generate GBM antigen-specific immune 
cell responses as a result this dual method of vaccination will be taken forward and tested in animal 
models of GBM.  
Flow cytometric analysis reveals that ImmunoBody® vaccination results in an increase in the 
number of cytotoxic CD8+ T-cells compared to unvaccinated mice. There is also an increase in CD8+ 
T-cell proliferation when these cells are exposed to their peptide targets, indicating an antigen-
specific CD8+ T-cell expansion and providing proof of an antigen-specific CD8+ T-cell response and 
the presence of CD8+ memory T-cells. There also appears to be a clear CD8+ antigen-specific 
response with an increase in the percentage of CD8 T-cells positive for the cytokines IFNγ and TNFα 
in ImmunoBody® vaccinated mice when stimulated with the target peptides. TNFα is a pro-
inflammatory cytokine with potential anti-cancer effects. TNFα can mediate cancer cell death via a 
variety of mechanisms; this can either be by direct binding to cell-surface receptors, blocking of 
regulatory T-cell activity, attracting neutrophils and monocytes to tumour sites and switching of 
tumour associated macrophages to the immune stimulating M1 phenotype (Josephs, Ichim et al. 
2018). IFNγ and TNFα have previously been shown to be essential for CD8 anti-tumour activity. 
When CD8+ tumour infiltrating lymphocytes are adoptively transferred into tumour bearing mice 
they induce tumour regression. This even occurs when non-lytic clones are transferred into tumour 
bearing mice. This regression was shown to be due to the secretion of IFNγ and TNFα in response 
to the presence of tumour. Blockade of IFNγ or TNFα with antibodies inhibits the anti-tumour 
effects of these CD8+ TILs in vivo (Barth, Mule et al. 1991). These results highlight the importance 
of these IFNγ and TNFα positive CD8+ T-cells in mounting an effective anti-tumour response. It is 
important to note that IFNγ also has a similar immune activating and dampening effect. IFNγ can 
itself have anti-cancer effects and as a result IFNγ itself has been used as an anti-cancer agent. IFNγ 
has an anti-proliferative effect on GBM cells and induces apoptosis via activation of STAT-1 and 
caspases. IFNγ can also lead to the up-regulation of MHC molecules on the surface of tumour cells 
increasing their immune recognition, however immune-inhibitory markers such as PD-L1 are also 
upregulated (Kane, Yang 2010). This expression of both IL-2 and IFNγ indicates an active immune 
response to the antigenic targets encoded within the ImmunoBody® vaccine. These flow cytometric 
results indicate that there is a memory response with an increase in cytokine secreting T-cells in 
response to antigen exposure after ImmunoBody® vaccination. 
What is of great importance is the ability of the ImmunoBody® vaccination to generate both a CD8+ 
cytotoxic and a CD4+ helper T-cell response. This activation of both T-cell subsets is pivotal for a 
durable anti-tumour response. Immune responses have previously been generated in mice using 
GM-CSF transfected irradiated B16 melanoma cells injected into the flank, mice were then 
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challenged with normal B16 cells and their responses monitored (Hung, Hayashi et al. 1998). CD4 
knockout mice did not appear to mount an anti-tumour response and died after a similar amount 
of time as mice that did not receive vaccination with B16-GM-CSF. Interestingly CD8 knockout mice 
managed to mount an anti-tumour response with around 40% of mice surviving long term, in 
comparison 70% of wild-type mice displayed long term survival following tumour challenge (Hung, 
Hayashi et al. 1998). These results overturn the previously held dogma that CD8+ T-cells are 
responsible for tumour rejection. Th1 and Th2 CD4+ T-helper cells appear to be required for tumour 
rejection as evidenced by the presence of IFNγ (Th1) and IL-4 (Th2) at the tumour challenge site in 
CD4 competent mice. These cytokines were absent in the CD4 null mice. Knockout of either IFNγ or 
IL-4 impaired the tumour protection granted to mice provided by the B16-GM-CSF vaccination 
(Hung, Hayashi et al. 1998). Th1 and Th2 cells can both initiate CTL immune responses, via cell-
surface molecules or secretion of cytokines. Th cells themselves can also induce tumour cell death 
via the binding of Fas ligand on their surface to the Fas receptor on tumour cells. Interferon gamma 
release by Th1 cells has been shown to activate tumour macrophages resulting in increased super- 
and nitric-oxide production necessary for tumour cell killing (Knutson, Disis 2005). Th2 cells can also 
activate eosinophils that help to eradicate tumour cells. These findings suggest that CD4+ cells do 
not just function within the adaptive immune system, they also exert their effects on the innate 
immune system to boost anti-tumour immunity. Th1 cells secrete IFNγ gamma and this activates 
the immunoproteasome improving antigen presentation by antigen presenting cells. This improved 
antigen presentation can result in the promotion of subdominant antigens improving tumour 
recognition and preventing the development on antigen escape variants (Knutson, Disis 2005). 
Previous immunotherapeutic approaches for GBM have provided lacklustre results with many 
vaccine therapies failing at phase III clinical trials. As a result combinatorial immunotherapy is being 
heralded as the future of GBM immunotherapy. In order to fully gain the benefits from the anti-
tumour immune response generated by immunotherapy several other types of therapy can be 
combined with active immunotherapy to boost the response. Traditionally chemotherapy has been 
considered immunosuppressive with leukopenia being a common side effect of temozolomide 
chemotherapy. It is believed however that chemotherapy induces immunogenic cell death with 
increased dendritic cell recruitment and expression of co-stimulatory molecules. Chemotherapy 
also leads to an increase in pro-inflammatory cytokine and a reduction in the number of regulatory 
T-cells within the tumour microenvironment. Radiotherapy can also synergise with immunotherapy 
by leading to up-regulation of immune co-stimulatory molecules and MHC class I molecules. 
However, it is important to note that there are also some negative side effects of these chemo and 
radiotherapeutic approaches such as increased PD-L1 expression and TGFβ release by tumour cells 
(Derer, Spiljar et al. 2016, Zhang, M., Kleber et al. 2011) . As a result of these potential down sides 
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it may be necessary to investigate alternative chemotherapeutic regimes such as low dose 
metronomic chemotherapy when combining these therapies with immunotherapy. Anti-angiogenic 
therapy is one of the few approved therapies approved in GBM with the anti-VEGF antibody 
bevacizumab receiving FDA approval for the treatment of GBM (Cohen, Shen et al. 2009). VEGF has 
previously been shown to have an immunosuppressive effect with the enhancement of regulatory 
T-cell activity and induction of the apoptosis of cytotoxic T-cells. Since VEGF has immune inhibitory 
activity it would make sense to combine bevacizumab with immunotherapy, what is more 
bevacizumab is already approved in the GBM setting to annexing it with novel therapies makes 
sense when translating into the clinic. In the GBM setting Rindopepimut (EGFRviii-KLH peptide) 
vaccination has been combined with bevacizumab, this combination was shown to generate a 
longer overall survival when compared to bevacizumab alone (Reardon, Gilbert et al. 2015). 
Another approach is to combine numerous immunotherapeutic modalities together such as active 
vaccination combined with immune checkpoint blockade.  
 
4.5. Conclusion 
Dual SCIB1 and WT-1 ImmunoBody® vaccination generates an equivalent anti-TRP-2 and anti-WT-
1 response to when the vaccines are administered singly. The targeting of numerous tumour 
antigens enables a large variety of cells within the heterogeneous tumour population to be targeted 
preventing potential tumour immune escape. Unfortunately, due to the highly immunosuppressive 
nature of GBM immunotherapy alone is not enough to treat and potentially cure the disease; as a 
result, combinatorial immunotherapy needs to be explored. Combining the dual ImmunoBody® 
vaccination with checkpoint blockade would make the most sense, this idea will be explored later 
within this thesis. These analyses reveal that the ImmunoBody® vaccination results in IFNγ release 
from activated splenocytes, IFNγ has many immune altering functions and as a result it is of great 
interest to examine what immune augmenting effects this IFNγ has on the profile of glioblastoma 
multiforme. 
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CHAPTER 5: IMMUNE ESCAPE MECHANISMS EMPLOYED BY GLIOBLASTOMA 
MULTIFORME IN RESPONSE TO IMMUNOTHERAPY 
 
5.1. Introduction 
Upon activation by immune therapy such as antigen specific vaccine, immune cells, specifically T-
cells and NK-cells release pleiotropic cytokines such as interferon gamma (IFNγ). IFNγ exerts many 
effects that alter the immune system, some of these can be immune stimulatory and some can be 
immune inhibitory. IFNγ exerts its effects by binding to the IFNγ receptor (comprised of CD119/ 
IFNγR1 and IFNγR2) activating downstream pathways such as the JAK-STAT, PI3K-AKT-mTOR and 
MEK-ERK pathway. These pathways affect numerous processes within cells contributing to the 
pleiotropic nature of IFNγ (Boehm, Klamp et al. 1997). IFNγ does not just exert its effects on immune 
cells it can also act upon native tissues within the body. This is due to the abundant expression of 
the IFNγ receptor within the human body. Tumour cells can also express the IFNγ receptor meaning 
that they will also be affected by an IFNγ rich environment. Interferon gamma is a central regulator 
of the immune response, originally thought of as an anti-viral agent; further research revealed that 
IFNγ exerted a host of many other effects all centred in on regulation of the immune system. As 
previously mentioned IFNγ activates the JAK-STAT pathway, a pathway commonly activated by 
cytokines. IFNγ binding to its receptor leads to its dimerization, which in turn, induces its 
phosphorylation and subsequently the activation of the JAKs, which then phosphorylate STAT1α 
leading to the formation of STAT1α-homodimers. These homodimers then shuttle to the nucleus 
where they bind to specific DNA-sequences known as gamma activated sites, initiating transcription 
of specific genes known as gamma responsive genes (Boehm, Klamp et al. 1997). Many 
immumoregulatory genes such as those encoding cell signalling chemokines and inhibitory proteins 
such as macrophage inhibitory protein as well as immune stimulating molecules such as the MHC 
molecules (McLaren, Ramji 2009). 
IFNγ has been used in the clinical setting to try and treat many cancers. It has been shown to exert 
anti-GBM effects in vitro reducing adhesion and invasion of malignant glioma cells. The induction 
of IFNγ in the tumour microenvironment via adenoviruses expressing IFNγ was shown to improve 
T-cell infiltration in a murine model of GBM. This IFNγ also induced increased MHCI and MHCII 
expression on tumour cells (Ehtesham, Samoto et al. 2002). All these changes point towards a 
potential therapeutic role for IFNγ however many trials using IFNγ to treat solid tumours have 
provided lacklustre results (Okura, Smith et al. 2014). Recombinant IFNγ was administered into the 
surgical cavity of newly diagnosed high grade glioma patients. No noticeable toxicities were 
observed however the median survival of the IFNγ treated patients was in fact 11 weeks less than 
patients treated via conventional methods (41 weeks vs. 52 weeks) (Farkkila, Jaaskelainen et al. 
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1994). IFNγ has been shown to be upregulated in GBM tumours, leading to increased MHCI and II 
expression and therefore improved antigen presentation, however IFNγ also leads to an increase in 
PD-L1 potentially counteracting the increased antigen presentation (Zhu, V. F., Yang et al. 2012). 
This up-regulation of immune inhibiting factors could explain the shortcomings of IFNγ therapy in 
the GBM setting. 
Indoleamine 2, 3-dioxygenase (IDO) is an immunoregulatory enzyme that catabolises tryptophan 
into numerous bioactive catabolites. It is important to note that IDO expression is also inducible by 
IFNγ exposure. IDO has been shown to be expressed in several tumours and this is thought to 
contribute to tumour immune tolerance. It is also important to note that antigen presenting cells 
themselves can also express IDO and this may also be a mechanism by which tumours induce 
immune tolerance. Macrophages and dendritic cells expressing IDO have been shown to reduce the 
proliferation of T-cells and tumour cells transfected with the IDO gene have also been shown to 
have the same effect (Munn, Mellor 2004). IDO expression in patient tumours was shown to result 
in decreased survival when compared to patients whose tumours had lower IDO levels (Wainwright, 
Balyasnikova et al. 2012). IDO expression levels seem to correlate with tumour grade, with grade 4 
GBM tumours expressing much higher levels of IDO compared to lower grade gliomas (Wainwright, 
Balyasnikova et al. 2012). Murine models helped to reveal that tumour derived IDO as opposed to 
peripheral IDO results in a reduced survival and increased regulatory T-cell recruitment to the 
tumour sites in murine models of GBM. Not only did tumour derived IDO increase regulatory T cell 
recruitment but it also led to fewer CD8+ T-cells within the tumour infiltrating lymphocyte 
population (Wainwright, Balyasnikova et al. 2012).  
One important immune modulating catabolite produced by IDO which, induces tryptophan 
degradation, is kynurenine (see Figure 39). This kynurenine induces naive T-cells to differentiate 
into regulatory T-cells and increase their activities (Mandi, Vecsei 2012). In addition, the depletion 
of tryptophan by IDO prevents the clonal expansion of antigen specific T-cells.  
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Figure 39. A schematic representation of tryptophan catabolism and the enzymes involved. IDO= 
indoleamine 2,3-dioxygenase, TDO= tryptophan 2,3-dioxygenase, KMO= kynurenine 3-
monooxygenase, KYNU= kynureninase, QPRT= Quinolinate phosphoribosyltransferase. 
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This is why many researchers have come up with ways to inhibit IDO, one of the most commonly 
used IDO inhibitors is 1-methyl-tryptophan (1MT). The use of 1MT has been examined in vitro 
(Miyazaki, Moritake et al. 2009) and in pre-clinical murine GBM models (Li, M., Bolduc et al. 2014, 
Hanihara, Kawataki et al. 2016). These analyses reveal that blockade of IDO with 1-MT with 
standard therapy conveys a survival benefit in mice harbouring GBM tumours (Li, M., Bolduc et al. 
2014, Hanihara, Kawataki et al. 2016). Promising pre-clinical results have resulted in clinical trialling 
of IDO inhibitors in GBM patients with five clinical trials involving IDO blockade being listed on 
clinicaltrials.gov at the time of writing. 
Not only does IFNγ induce the expression of IDO it also increased the expression of MHC class I 
molecules. As well as increasing classical MHC class I expression IFNγ can also lead to expression of 
non-classical MHCI molecules such as HLA-E and HLA-G. These non-classical MHC class I proteins 
have immunosuppressive activities that enable tumour immune escape by inducing resistance to 
NK and CTL mediated killing. Indeed, IFNγ has previously been shown to result in the up-regulation 
of HLA-E on acute myeloid leukaemia blasts which prevented their lysis by NK cells (Nguyen, Beziat 
et al. 2009). IFNγ has also been shown to increase the expression of HLA-E by GBM stem-cells and 
this helped protecting them from NK cell lysis (Wolpert, Roth et al. 2012). HLA-G has previously 
been shown to be expressed by some GBM cell lines and exposure to IFNγ enhanced further its 
expression which then protected GBM cells from cytolytic T-cell activity (Maier, Geraghty et al. 1999, 
Wiendl, Mitsdoerffer et al. 2002).  
IFNγ induces expression of numerous other genes such as macrophage inhibitory protein (McLaren, 
Ramji 2009), PD-L1 and PD-L2 (Garcia-Diaz, Shin et al. 2019).  
 that can affect tumour cells and stromal cells in the microenvironment promoting a potentially 
immunosuppressive microenvironment. In the immunotherapy setting interferon gamma can be a 
‘double-edged’ sword with some pro-immune and some anti-immune effects observed. 
5.2. Aims and hypothesis 
The two vaccines used in this study generated T-cells that were shown to produce strong IFNγ 
responses upon ex-vivo incubation with the vaccine-derived peptides (See chapter 4). It was 
therefore important to assess the effect of IFNγ on the GBM cells aimed to be used as targets 
against vaccine-induced T-cells. 
 
5.3. Results 
5.3.1. Analysis of CD119 expression on GBM cell lines 
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The aim of this chapter was to assess the effect of IFNγ on the selected GBM target cells (SEBTA-
027 and SF-188, due to their expression of both TRP-2 and WT-1) and therefore it was necessary to 
confirm that they expressed the receptor for IFNγ (CD119). The flow cytometry analysis of the cells 
stained with the anti-CD119-PE conjugated antibody clearly shows that both the cell lines studied 
express the CD119 subunit of the IFNγ receptor.  This implies that these cells can actively respond 
to IFNγ. 
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Figure 40. Representative flow cytometry histograms of CD119 staining of A) SEBTA-027 B) SF-188 
cells, the red peak represents stained cells and the green peak represents unstained cells. 
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5.3.2. The effects of IFNγ on the immune profile of the SF-188 and SEBTA-027 
glioblastoma multiforme cell lines as determined by flow cytometry 
 
Cells were treated with IFNγ and thereafter stained for HLA-E, HLA-G, pan-MCHI, FasL, PD-L1 and 
the co-stimulatory molecules CD80, CD86, MICA/B and CD40. Flow cytometric analysis revealed an 
increase in the number of SF-188 cells that stained positive for HLA-E, HLA-G and CD40. CD40 and 
HLA-G which increased significantly in time-dependent manner, with increased IFNγ exposure 
resulting in an increase in the percentage of cells positive for these antigens (Figure 41 and 42). It 
is important to note that no change was seen in the percentage of cells that stained positive for 
HLA-A, B, C and PD-L1 because these cells are already 100% positive prior to IFNγ exposure.  
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Figure 41. Representative flow cytometry histograms of IFNγ and control untreated live SF-188 cells. 
The red peak represents 24hr control cells, the green peak represents 48hr control cells, the blue 
peak represents 72hr control cells, the purple peak represents cells treated with IFNγ for 24 hours, 
the orange peak represents cells treated with IFNγ for 48 hours and the light blue peak represents 
cells treated with IFNγ for 72 hours. The gate is shown on each plot and the % of cells gated and the 
median fluorescence intensity (X-med) are shown alongside each plot. A) MICA/B B) FasL C) CD80 D) 
HLA-E E) HLA-G F) PD-L1 G) CD40 H) HLA-A,B,C I) CD86 staining. 
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Figure 42. Percentage of cells positive for cell surface expression of A) HLA-E B) HLA-G C) CD40 after 
24,48 and 72 hours exposure to IFNγ. ****= P ≥0.0001, ***= P ≤0.001, **= P ≤0.01, *= P ≤0.05 
relative to control as deemed by a one-way ANOVA followed by Tukey’s ad-hoc test. N= 9-3. The 
control group is composed of control cells that had normal carnosine free GBM media on them for 
24, 48 and 72 hours, these controls were grouped as the time difference was not deemed to have a 
significant effect on antigen expression.  
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However when looking at the median fluorescence intensity for IFNγ treated SF-188 cells a clear 
increase in the surface expression of PD-L1, HLA-E, HLA-G, HLA-A, B, C and CD40 was dectected. 
Similar to HLA-E/-G/and CD40 this increase was time dependant with increased exposure time to 
IFNγ resulting in a further increase in cell-surface expression of these antigens (Figure 43). IFNγ 
treatment did not alter the cell-surface levels of the FasL, MICA/MICB, CD86 and CD80 (data not 
shown). In order to verify that the changes observed after IFNγ exposure are due to IFNγ and not 
just an effect that naturally occurs over time the cell surface expression was observed for cells that 
were grown in IFNγ free-media for 24, 48 and 72 hours, the results are shown below.  
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Figure 43. Median fluorescence intensity results for IFNγ treated SF-188 cells A) PD-L1 B) HLA-E C) 
HLA-G D) HLA-A, B, C E) CD40. ****= P ≥0.0001, *= P ≤0.05 relative to control as deemed by a 
one-way ANOVA followed by Tukey’s ad-hoc test. N= 9-3. The control group is composed of control 
cells that had normal media on them for 24, 48 and 72 hours. The increase in MFI indicates an 
increase in the number of molecules present on the cell surface. 
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Analysis of cells cultured in normal media reveals that the changes in HLA-E, HLA-G, CD40, PD-L1 
and HLA-A, B, C expression observed in IFNγ treated cells is in fact due to IFNγ and not due to 
temporal changes that may occur in cultured cells (see Figures 44 and 45).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 
 
 
Figure 44. Percentage of cells positive for cell surface expression of A) HLA-E B) HLA-G C) CD40 after 
24, 48 and 72 hours growth in normal ‘control’ media that lacked IFNγ. There is no significant 
difference between any of the conditions as deemed by a one-way ANOVA followed by Tukey’s ad-
hoc test. N= 3. 
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Figure 45. Median fluorescence intensity results for SF-188 cells grown in normal media for 24, 48 
and 72 hours A) PD-L1 B) HLA-E C) HLA-G D) HLA-A, B, C E) CD40. There is no significant difference 
between any of the conditions as deemed by a one-way ANOVA followed by Tukey’s ad-hoc test. N= 
3. 
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Due to the changes observed in the SF-188 cell lines it was decided to also analyse the SEBTA-027 
cell line after IFNγ exposure. Seeing as the most marked changes were observed after 72 hours of 
IFNγ exposure it was decided to treat the SEBTA-027 cells for 72 hours, the changes observed are 
detailed in Figure 46 and Figure 47 below. 
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Figure 46. Percentage of SEBTA-027 cells positive for cell surface expression of A) HLA-A B) PD-L1 C) 
CD86 after 72 hours exposure to IFNγ, *= P ≤0.05 relative to control as deemed by a paired T-test. 
N= 3. 
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The percentage of PD-L1 and CD86 positive SEBTA-027 cells increases after 72 hours of IFNγ 
exposure. As mentioned previously PD-L1 is immunosuppressive, however CD86 is a co-stimulatory 
molecule that is required for T-cell activation. 
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Figure 47. Median fluorescence intensity results for SEBTA-027 cells positive for cell surface 
expression of A) HLA-A, B, C B) PD-L1after 72 hours exposure to IFNγ, **= P ≤0.01 relative to control 
as deemed by a paired T-test. N= 3. 
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In the SEBTA-027 cell line much like the SF-188 cell line the cell surface expression of MHC class I 
(HLA-A, B, C) and PD-L1 increases after IFNγ exposure. The expression of HLA-E, HLA-G and CD40 
did not change in the SEBTA-027 cell line (data not shown). 
 
These findings show that exposure of GBM cell lines to IFNγ leads to an increase in both immune 
stimulating (CD40, MHC class I and CD86) and immune-evasion markers (HLA-G, HLA-E and PD-L1) 
on the surface of these cells. The two main markers that are upregulated are MHC class I and PD-
L1 in both cell lines, this is to be expected as both of these are IFNγ responsive genes. 
 
5.3.3. Expression of IDO in IFNγ treated GBM cell lines and measurement of IDO activity 
 
The SF-188 and SEBTA-027 cell lines were treated with interferon gamma for 24, 48 and 72 hours 
and the change in expression levels of IDO was measured using Western blotting. As stated 
previously these cell lines are being further probed due to their antigen expression profile (detailed 
in chapter 3) and relevance to the immunotherapeutic approach. Both cell lines revealed that 
treatment with IFNγ induces the expression of IDO which continues to  increase with increased 
exposure time (See Figure 48). 
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Figure 48. The effects of IFNγ exposure on the expression of IDO in SF-188 and SEBTA-027 cell lines 
as measured by Western blotting. A) Representative blot for IFNγ treated SF-188 cells. B) 
Qunatification of IFNγ treated SF-188 blots using ImageJ software to determine the IDO expression 
relative to the vinculin loading control. C) Representative blot for IFNγ treated SEBTA-027 cells. D) 
Qunatification of IFNγ treated SEBTA-027 blots using ImageJ software to determine the IDO 
expression relative to the vinculin loading control. N=3  ****= P ≥0.0001, ***= P ≤0.001, **= P ≤0.01, 
*= P ≤0.05 as deemed by a two-way ANOVA followed by Tukey’s ad-hoc test.  
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The increase in IDO protein expression does not always mean that the catabolism of tryptophan 
into kynurenine is also increased, therefore levels of kynurenine within the culture media of the 
IFNγ treated SF-188 and SEBTA-027 cell lines was also measured, the results are shown in Figure 49. 
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Figure 49. Kynurenine concentration in A) SF-188 cell culture media and B) SEBTA-027 cell culture 
media after 24, 48 and 72 hours in normal control media (black circles) and IFNγ containing media 
(black squares). N= 3 ****= P ≤0.0001, ***= P ≤0.001, **= P ≤0.01 as deemed by two way ANOVA 
followed by Sidak’s multiple comparisons test. 
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The increase in IDO expression observed in the GBM cell lines studied after IFNγ exposure, led to a 
significant increase in kynurenine production by these cells as indicated by the increased 
kynurenine levels observed in the cell culture media. Another important enzyme that needs to be 
considered is tryptophan 2,3-dioxygenase (TDO), this much less frequently occurring enzyme also 
contributes to the degradation of tryptophan and resultant production of kynurenine. The 
expression of TDO after exposure of GBM cells to IFNγ was also assessed, however TDO enzyme 
could not be detected in both treated and untreated cells (data not shown). All of these results 
taken together strongly link IFNγ exposure to enhanced immune escape, although it should be 
noted that there also seem to be some pro-immune functions enhanced by IFNγ exposure, such as 
the increased expression of MHC class I (HLA-A, B, C) on the surface of cells. 
 
5.4. Discussion 
In vitro investigation of IFNγ treatment on GBM cell lines allows for a rudimentary understanding 
of how GBM tumours might respond to immunotherapy which will need to be taken into 
consideration for future immunotherapy. These analyses indicate that GBM cells actively adapt to 
IFNγ exposure enhancing their immune escape. However, vaccines are likely to be given after the 
majority of the tumour cells have been removed by surgery and therefore the small number of 
remaining cells might then be killed by a large number of vaccine-induced high avidity T-cells. It is 
also important however to note that as well as these deleterious effects IFNγ can in fact also result 
in an increase of MHC class I and class II molecules and therefore increased antigen presentation 
(Zhou 2009, Steimle, Siegrist et al. 1994), a finding which the HLA-A, B, C staining corroborates. 
Indeed, IFNγ leads to adaptation of the proteasome with replacement of the β1, β2 and β5 
hydrolytic subunits of the 20S core (within the 26S proteasome) with LMP2, LMP7 and MECL-1 
resulting in formation of the immunoproteasome (Kloetzel, Ossendorp 2004). This shift results in 
increased proteolytic peptide processing and presentation via the increased MHC expressed, 
ultimately resulting in increased generation of immune epitopes and resultant anti-tumour T-cell 
activity (Kloetzel, Ossendorp 2004). 
The upregulation of many of these immunosuppressive antigens provides a rational for combining 
checkpoint blockade with active immunotherapy, this would help dampen the immune nullifying 
effects of IFNγ and help enhance its immune stimulating properties, helping to boost the immune 
response to vaccination. 
These analyses show a clear increase in IDO expression in the two cell lines studied. What is of even 
more interest is that in both the SF-188 and SEBTA-027 cell lines this IDO is active leading to the 
catabolism of tryptophan to kynurenine. IDO expression by antigen presenting cells after IFNγ 
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exposure is a counter measure to maintain immune balance after activation of these cells by IFNγ. 
Unfortunately it also appears that cancer cells react to IFNγ in the same manner. IDO is a key 
enzyme in the kynurenine pathway along with TDO (see Figure 39). Several of the metabolites 
produced by the tryptophan pathway lead to a reduction of proliferation and apoptosis of TH1 T-
helper cells. These metabolites also have anti-proliferative effects on other cell types such as B and 
NK cells. The kynurenine pathway appears to have a globally immunosuppressive effect and not 
just an effect limited to individual immune cell populations. IFNγ was shown to increase the levels 
of kynurenine within the culture media of GBM cells. Kynurenine specifically has been shown to 
affect antigen-specific T-cells reducing their proliferation (Mandi, Vecsei 2012). It is also thought 
that IDO activation can result in increased TH2 cell immune responses. Kynurenine also leads to 
conversion of CD4 T-cells into regulatory T-cells; a well-defined immune inhibitory T-cell subset 
(Mandi, Vecsei 2012). Due to the immune inhibitory effects of IDO its inhibition has been studied 
in the clinical setting for multiple malignancies. IDO has been previously shown to be a viable target 
for the therapy of GBM, with its expression being linked with poorer patient survival (Miyazaki, 
Moritake et al. 2009, Wainwright, Balyasnikova et al. 2012). IDO inhibition has been explored pre-
clinically in GBM mouse models (Wainwright, Chang et al. 2014, Hanihara, Kawataki et al. 2016). As 
of writing this thesis (2019) there are five clinical trials listed as recruiting or completed utilising IDO 
blockade for brain tumours on clinicaltrials.gov. 
Not only does IFNγ induce the expression of immune inhibitory IDO in GBM tumour cells, it also 
induces/increases expression of several immune inhibitory cell-surface proteins. Whilst it appears 
that IFNγ leads to the upregulation of MHC class I (HLA-A, B, C) unfortunately it also appears that 
IFNγ leads to up-regulation of the non-classical MHC class I molecules HLA-E and HLA-G. As detailed 
previously HLA-E and HLA-G have immune dampening effects enabling GBM cells to escape NK-cell 
mediated lysis. The upregulation of these molecules on the surface of GBM cells provides a rational 
for combining potential blockade of HLA-E and/or HLA-G with active immunotherapy as a means 
for overcoming the IFNγ induced immunosuppression. Whilst there are no clinical trials blocking 
HLA-E or –G in glioblastoma multiforme several methods for targeting these checkpoints are being 
developed. RNA interference of the HLA-G gene has been shown to increase NK mediated lysis of 
tumour cells (Zidi, Ben Amor 2012). Antibodies that block the interaction of HLA-E with the NK cell 
inhibitory receptor NKG2A have been developed to enhance NK mediated tumour cells lysis; 
monalizumab is an NKG2A blocking antibody and has been tested in clinical trials for cancer 
(Guillerey, Huntington et al. 2016). No results have been published about the use of monalizumab 
in the GBM setting but previous research has found that monalizumab shows promise for head and 
neck cancer and ovarian cancer (Carotta 2016). The immune suppressive checkpoint PD-L1 was also 
upregulated after IFNγ exposure. This increased PD-L1 expression on the surface of GBM cells is 
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potentially problematic, however this opens up the opportunity to use PD1/PD-L1 blockade in 
combination with immunotherapy even in cases where the patient’s tumour does not express PD-
L1. 
IFNγ was also found to increase the expression of CD40 on the surface of the SF-188 GBM cell line. 
CD40 is a member of the tumour necrosis factor receptor family. CD40 has previously been shown 
to be expressed on a variety of cancers including GBM. The interaction of CD40 with its ligand 
(CD40L) has been shown to be vital for induction of T-cell help for CTL mediated lysis, this is due to 
ligation of CD40 on dendritic cells with CD40L on stimulated T-helper cells (Schoenberger, Toes et 
al. 1998). CD40 stimulation has also been shown to lead to increased antigen presentation by 
tumour cells. Ligation of CD40L on NK cells with CD40 on tumour cells also leads to NK cell activation 
and tumour cell killing (Eliopoulos, Young 2004). CD40 ligation to CD40L provides strong co-
stimulatory signals to T-cells. In vitro experiments have shown that ligation of CD40L with CD40 on 
cancer cells leads to upregulation of Fas and FasL by these cells. There is also increased secretion 
of the cytokines IL-6, IL-8, GM-CSF and TNFα by tumour cells upon CD40 ligation. These changes 
promote cancer cell-death and immune cell attraction. What is also of interest is that CD40 ligation 
reduces the growth of cancer cells. Transfection of CD40 into cancer cells that do not express CD40 
results in greater T-cell activation, revealing the important role of CD40 in tumour specific immune 
responses (Alexandroff, Jackson et al. 2000). CD40 is an attractive target for anti-cancer therapy 
and its upregulation by IFNγ increases the susceptibility of GBM cells to potential immune attack. 
This could provide a rationale for the use of CD40 agonists in conjunction with active 
immunotherapy. 
Whilst IFNγ is essential for immune signalling and immune cell function it also acts to prevent over-
activity of the immune system, and thus it also acts to dampen the immune system and prevent 
over-activation of immune cells and therefore prevent deleterious immune activity in the normal 
setting. GBM cells also appear to react to interferon gamma in a similar manner, with tumour cells 
upregulating many immune inhibitory molecules. These results suggest that combinatorial 
immunotherapy would be the most effective way to approach GBM therapy in the clinic. 
Interestingly in a pre-clinical GBM model combined blockade of IDO, PD-L1 and CTLA-4 has been 
shown to result in 100 % long-term survival in mice bearing GL261 tumours (Wainwright, Chang et 
al. 2014). This combinatorial therapy was shown to significantly reduce regulatory T-cell infiltrate 
into these experimental brain tumours whilst increasing the presence of activated CD8+ T-
cells(Wainwright, Chang et al. 2014). Combinatorial therapy utilising IDO inhibition, PD-1 blockade 
and radiotherapy has also shown great promise in the therapy of intracranial GL261 and CT-2A GBM 
like tumours (Ladomersky, Zhai et al. 2018). These results highlight the necessity for combined 
immunotherapy when targeting cancer, especially GBM. 
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5.5. Conclusion 
These preliminary analyses reveal that GBM tumour cells actively respond to the presence of the 
immune-related cytokine IFNγ. Exposure to IFNγ resulted in the increase of both immune inhibitory 
and immune-stimulatory molecules, with a more predominant increase in the inhibitory factors. 
Under normal circumstances these changes take place to protect the body from auto-immune 
attack however in the case of GBM these changes enable these tumours to escape immune 
surveillance. As a result, the active adaptation of the tumour in response to immune therapy needs 
to be accounted for when utilising ImmunoBody® immunotherapy. These results indicate that 
combining checkpoint blockade and potentially IDO blockade with vaccine therapy would help 
overcome the immune escape mechanisms employed by GBM cells.  
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CHAPTER 6: PRE-CLINICAL ANTI-TUMOUR ASSESSMENT OF THE COMBINED 
IMMUNOBODY® VACCINES  
 
6.1. Introduction 
Cancer immunotherapy was heralded as Science magazine’s breakthrough of the year 2013 
(Couzin-Frankel 2013). The utilisation of the immune system to target cancer has garnered great 
interest and the utilisation of immune therapies for cancer treatment have progressed in leaps and 
bounds. Sipuleucel-T was the first FDA approved immunotherapy for the treatment of prostate 
cancer. Sipuleucel-T is generated by co-culturing in vitro the patient’s PBMCs with a recombinant 
fusion protein of PAP and granulocyte-macrophage colony-stimulating factor. After activation the 
stimulated PBMCs are then reintroduced back into the patient (Higano, Small et al. 2010). As 
understanding of the interactions between the immune system and cancer has increased so have 
differing methods of augmenting the immune system. With this understanding came the 
development of immune checkpoint inhibition. Immune checkpoints function to dampen the 
immune response and prevent immune over activation. Some tissues also express immune 
inhibitory checkpoints on their surface to prevent them from generating an immune response, and 
one example is the placenta that expresses the PD-L1 checkpoint inhibitor. One of the first major 
steps towards the development of immune checkpoint inhibitors was the discovery of cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4). Upon T-cell receptor engagement CTLA-4 translocates 
to the surface of T-cells where it out competes CD28 for binding to its ligands CD80/86 preventing 
important costimulatory signals The binding of CTLA-4 to CD80/86 has also been shown to lead to 
the transfer of CD80 and CD86 to CTLA-4 expressing cells, these CTLA-4 expressing cells then 
degrade these CD80 and CD86 molecules. This results in decreased immune cell activity and stunts 
the immune cell activation capabilities of dendritic cells (Qureshi, Zheng et al. 2011). Pre-clinical 
studies in mice showed that treating tumour bearing mice with a CTLA-4 blocking antibody led to 
durable regression (Leach, Krummel et al. 1996). As a result, two fully human anti-CTLA-4 antibodies: 
Ipilimumab and Tremelimumab were developed and entered clinical trials. Early results revealed 
that CTLA-4 blockade could on rare occasions result in tumour regression however these 
occurrences were accompanied by toxicities due to tissue-specific inflammation. Anti-CTLA-4 
therapy was shown to increase survival of patients suffering with metastatic melanoma and as a 
result Ipilimumab was approved by the FDA in 2011 (Ribas, Wolchok 2018). It is important to note 
that the response to ipilimumab was not 100% and only around 20-30% of patients displayed 
improved survival (Ledford 2011). Another important immune checkpoint that has been discovered 
and targeted is programmed death-1 (PD-1). PD-1 is expressed on activated T-cells and it binds to 
its ligands PD-L1 (frequently expressed on tumour cells) or PD-L2; this binding results in apoptosis 
of activated T-cells. PD-1 blockade has been shown to have less toxic side effects than CTLA-4 
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blockade (Callahan, Wolchok 2013), this is thought to be due to its activity being more specific for 
anti-tumour T-cells due to their chronic stimulation. Currently there are two FDA approved anti-PD-
1 and three approved PD-L1 blocking antibodies for use in the cancer setting. Unfortunately, no 
immune-checkpoint blocking antibodies have been approved for glioblastoma multiforme, 
however their use is being explored in late stage clinical trials (Ribas, Wolchok 2018). As of 2017 
there were 62 clinical trials investigating the use of immune checkpoint blockade in the GBM setting 
either alone or in combination with other treatment modalities, with even more combinations 
being explored subsequently. The use of these immune checkpoints is also being explored in the 
adjuvant and neoadjuvant setting. With neoadjuvant treatment the checkpoint blockade is 
administered prior to surgical excision of the tumour, the aim of this is to try and minimise the 
tumour prior to surgery. This also allows for the expansion and activation of tumour specific T-cells 
before resection. In phase III clinical trials Ipilimumab (anti-CTLA4) and Nivolumab (anti-PD-1) 
therapies have been combined for the treatment of melanoma, this was shown to prolong patient 
progression free survival compared to either antibody alone, unfortunately this treatment is also 
accompanied with adverse events with 55% of patients studied experiencing high-grade adverse 
events (Maxwell, Jackson et al. 2017). Nivolumab and Ipilimumab have also been combined in the 
recurrent GBM setting, with a high proportion of patients experiencing adverse events much like in 
the melanoma setting (Maxwell, Jackson et al. 2017). Unfortunately, in the recurrent GBM setting 
Nivolumab therapy was found to be ineffective at improving patient survival in a phase III trial (Filley, 
Henriquez et al. 2017). 
The main issues that can arise from using these immune checkpoint antibodies is the potential for 
adverse inflammatory events to occur and potential autoimmune reactions. These side effects are 
commonly managed via the use of corticosteroids. The CNS actively interacts with the immune 
system so checkpoint inhibitors are attractive avenues for therapies. PD-L1 expression has been 
shown to be prevalent in GBM tumours with as many as 88% of cases from newly diagnosed GBM 
expressing PD-L1 and 72% of recurrent GBM expressing PD-L1 (Preusser, Lim et al. 2015). The 
analyses performed in chapter 3 have also confirmed that PD-L1 expression appears to be a 
hallmark of GBM tumours. Glioma cells have also been shown to secrete IL-10 which induces PD-L1 
expression on tumour infiltrating macrophages and circulating monocytes. PD-1 positive T-cells are 
found in 33% of GBM samples, as a result blockade of the PD-1/PD-L1 axis represents an attractive 
avenue for the therapeutic treatment of GBM. Pre-clinical blockade of this axis in animal models of 
GBM has shown great promise and as a result the use of these checkpoint blockade antibodies has 
progressed into clinical trials for GBM. What is of great interest is the combination of immune 
checkpoint blockade with other therapies, the utilisation of PD-1/PD-L1 blockade as a monotherapy 
has shown moderate success but the idea of combining these therapies with other therapies to 
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further boost patient anti-tumour response is an exciting prospect for the field of cancer 
immunotherapy (Preusser, Lim et al. 2015). 
Combining immune checkpoint blockade with vaccination therapy presents an attractive avenue 
for immunotherapy, with the active vaccination educating T-cells and homing them in on tumours, 
and checkpoint blockade removing the ‘breaks’ applied by the tumour on the activated immune 
cells. It has already been demonstrated that ImmunoBody® vaccination generates a strong immune 
response directed towards the tumour antigens TRP-2 and WT-1. Synergising ImmunoBody® 
vaccination with PD-1/PD-L1 blockade represents an attractive avenue for GBM therapy. Previous 
pre-clinical research has shown that combining SCIB-1 (TRP-2/gp100) ImmunoBody® vaccination 
with anti-PD-1 antibody blockade has immune boosting effects. Xue W. et al. (2016) combined SCIB-
1 ImmunoBody® vaccination with PD-1 blockade for the treatment of humanised B16 murine 
melanoma in a humanised mouse model. Vaccination with SCIB-1 resulted in increased T-cell 
infiltration into the tumour and combination of SCIB-1 with anti-PD-1 improved CD-8 T-cell 
infiltration. This increased T-cell infiltration also led to improved survival, with 80% of mice showing 
long term survival compared to 40% of SCIB-1 and 50% of anti-PD-1 treated mice (Xue, W., 
Brentville, Symonds, Cook, Yagita, Metheringham, and Durrant 2016). In a phase II clinical trial 
utilising an autologous heat shock protein vaccination to treat GBM patients PD-L1 expression on 
myeloid cells was a predictor of survival when patients received this vaccine. Examining the 
expression of PD-L1 on circulating myeloid cells revealed that patients with high PD-L1 expression 
had a median overall survival of 18 months after treatment compared to 44.7 months for patients 
with low PD-L1 expression on their circulating myeloid cells (Bloch, Lim et al. 2017). These results 
highlight the influence of these immune checkpoints on immunotherapeutic modalities.  
The combination of an anti-cancer vaccine with immune checkpoint inhibition has previously been 
shown to improve survival in tumour bearing animals. In a study utilising a dendritic cell vaccination 
it was found that vaccination increased T-cell infiltration into established intracranial GL261 murine 
GBM tumours, however in animals with elevated tumour burden this increased T-cell infiltrate was 
not associated with a significant increase in survival. This indicates that vaccination generates an 
immune response leading to increased immune cell infiltrate, however factors within the tumour 
microenvironment are preventing these cells from mounting an effective anti-tumour immune 
response (Antonios, Soto et al. 2016). Analysis of tumour infiltrating lymphocytes revealed that 
there was an increased expression of PD-1 on these cells, as a result it was hypothesised that the 
failure of the vaccine to improve survival was due to immune suppression mediated by the PD-
1/PD-L1 pathway. Dendritic cell vaccination was administered in conjunction with anti-PD-1 
antibody to treat established intracranial GL261 glioblastoma, this regime significantly improved 
the survival of mice, with 40% long-term survival observed (Antonios, Soto et al. 2016). 
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6.1.1. The intracranial B16 HHDII/DR1 proof of concept model 
 
As discussed in chapter 4 the HHDII/DR1 mouse provides a mouse model that helps to closely 
emulate the human immune system in a pre-clinical mouse model. Previous research from chapter 
4 has shown that the combined ImmunoBody® vaccines generates a strong anti-WT-1 and TRP-2 
response. When SCIB1 and WT-1 ImmunoBody® vaccines are given together they generate 
splenocytes that are reactive to both WT-1 and TRP-2 to the same extent as singly vaccinated 
splenocytes. The B16 HHDII/DR1 cell line is a murine melanoma cell line that has been genetically 
modified to lack murine class I and II molecules, these class I and class II molecules have been 
replaced by a chimeric version of the human HLA-A2.1 class I molecule and the human HLA-DR1 
class two molecule. What is also vital is that this cell line also expressed the TRP-2 and WT-1 
antigens that were found to be expressed in human GBM tumours, and the antigenic targets of 
choice for ImmunoBody® vaccine therapy. What is also of great importance is that there is high 
homology between the murine and human TRP-2 and WT-1 peptide sequences. The TRP-2 180-188 
(SVYDFFVWL) peptide sequence encoded in the SCIB1 ImmunoBody® is identical between both the 
human and mouse TRP-2 protein. Whilst the human and murine WT-1 peptide sequences are highly 
homologous between mouse and man, the sequence encoded by the WT-1 ImmunoBody® vaccine 
(5-19) is one amino acid different from the human sequence, the human sequence is 
VRDLNALLPAVPSLG whereas the murine sequence is VRDLNALLPAVSSLG. What is even more 
important is that the most stimulating class I peptide is one amino acid different between mouse 
and human. Gp100 does not have high sequence homology between mouse and humans, however 
this is of little concern as the ImmunoBody® vaccination did not generate a strong anti gp100 
response and only one of the GBM tumours studied in chapter 3 expressed gp100. 
 
6.2. Aims and hypothesis 
The aim of this chapter is to see how efficient dual SCIB1 and WT-1 ImmunoBody® vaccination is at 
preventing and treating intracranial B16 HHDII/DR1 tumours in the C57BL6 HHDII/DR1 humanised 
mouse model. The addition of checkpoint blockade to the vaccination schedule will also be studied 
to see if the immune response can be boosted. 
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6.3. Results 
6.3.1. Prophylactic vaccination with dual SCIB1 and WT-1 ImmunoBody® vaccination 
prolongs survival in mice bearing intracranial B16 HHDII/DR1 Luc2 tumours 
 
In chapter 4 the use of the WT-1 and SCIB1 ImmunoBody® vaccines was shown to result in a peptide 
specific response to the TRP-2 and WT-1 peptides encoded within the ImmunoBody® construct. 
This dual vaccination also generated splenocytes that responded to GBM cells in an HLA-A2 
restricted manner. The ability of this dual ImmunoBody® vaccination regime to prevent/delay the 
growth of intracranially implanted B16 HHDII/DR1 cells was then tested to see if these in vitro 
results translated into in vivo results. Mice were vaccinated as detailed in the methods section 
(chapter 2 section 2.2.) and seven days after the last vaccination 5 x 103 B16HHDII/DR1 Luc2 cells 
in 3 μL PBS were implanted into the brains of these mice. This dosage of cells was previously shown 
to result in intracranial tumour development in 100 % of animals during optimisation experiments. 
The B16 HHDII/DR1 Luc2 cells had been transfected with the luciferase enzyme, this enzyme breaks 
down luciferin resulting in bioluminescence. This allowed for monitoring of in vivo tumour growth 
via intraperitoneal injection of luciferin followed by imaging on an IVIS machine (Perkin Elmer). Not 
only were the tumours monitored but the mice themselves were monitored to ensure their well-
being. If mice experienced bodyweight loss (of more than 15% from baseline) or displayed any 
clinical signs they were humanely euthanised and their tissues were collected for analysis.  
The B16HHDII/DR1 intracranial tumour model was chosen to act as a proof of concept model to 
prove that immune cells generated by the ImmunoBody® vaccine can affect tumours located within 
the brain. B16 is a murine melanoma cell line, but it displays aggressive growth much like GBM 
tumours. What was of even more importance was that in vitro analysis performed in chapter 3 
revealed that these B16 HHDII/DR1 cells express both the TRP-2 and WT-1 antigens making them 
suitable targets. What is of even more importance is that these cells express the chimeric HLA-A2 
molecule HHDII and the chimeric HLA-DR1 MHC class II molecule. 
The prophylactic treatment of C57BL/6 HHDII/DR1 mice with dual ImmunoBody® vaccination 
significantly increased their symptom free survival after being challenged with intracranial B16 
HHDII/DR1 tumours in comparison to sham (empty bullet) vaccinated mice. This result highlights 
the anti-tumour activity of the combined SCIB1 and WT-1 ImmunoBody® vaccines is sufficient to 
generate immune cells that can reach the brain and delay tumour formation. 
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Figure 50. Kaplan-Meier survival analysis of mice prophylactically vaccinated with SCIB1 and WT-1 
ImmunoBody® vaccination compared to unvaccinated mice. The green line represents the sham 
vaccinated control group, and the red line represents dually vaccinated mice. Control group n=7, 
treatment group n=8, ** = P ≤ 0.01 as determined by the log rank test. 
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6.3.2. Addition of checkpoint blockade into the ImmunoBody® vaccination strategy 
effects on tumour bearing animal survival 
 
Prophylactic analysis revealed that dual ImmunoBody® vaccination delayed the growth of 
intracranial B16HHDII/DR1 tumours. As a result, it was decided to see if the dual ImmunoBody® 
vaccination could affect the survival of mice bearing established intracranial B16 HHDII/DR1 Luc2 
tumours. It was also decided to study if adding anti-PD-1 antibody checkpoint blockade to the 
vaccination regime could further increase survival of mice bearing established tumours. PD-1 was 
selected for targeting due to the interferon gamma induced expression of PD-L1 on tumour cells 
(see Chapter 5), this enables PD-1 blockade to counteract the active response of tumour cells to 
activated immune cells within the local environment. Clinical trialling of PD-1 blockade with 
pembrolizumab and CTLA-4 blockade with ipilimumab revealed in melanoma patients that 
ipilimumab is associated with increased high-grade treatment-related adverse effects when 
compared to pembrolizumab. Pembrolizumab was also shown to increase overall survival of 
patients with malignant melanoma when compared to ipilimumab  (Robert, Schachter et al. 2015). 
Blockade of CTLA-4 has also been linked to an increased rate of liver damage when compared to 
anti-PD-1 therapies (Nishida, Kudo 2019). Whilst PD-1 blockade has some potential negative side 
effects its side effects appear to be less damaging than those associated with CTLA-4 blockade as a 
result the combination of ImmunoBody® vaccination with anti-PD-1 therapy was investigated.  
Due to the aggressive growth of intracranial B16 HHDII/DR1 the vaccination schedule had to be 
altered to try and provide optimum protection before these tumours become fatal. During 
optimisation it was found that these tumours were usually fatal after around 21 days, meaning that 
the normal vaccination schedule may not be completed for many animals. Mice were immunised 
on days 3-, 7- and 10-days post tumour implant. This shortened vaccination regime has been 
previously used with ImmunoBody® vaccination in pre-clinical tumour models and it has shown to 
still provide anti-tumour benefits (Xue, W., Brentville, Symonds, Cook, Yagita, Metheringham, and 
Durrant 2016, Xue, W., Metheringham et al. 2016). As before tumours were monitored using 
luciferin and the mice were monitored for signs of malaise. 
Dual ImmunoBody® vaccination combined with anti-PD-1 appeared to provide a moderate survival 
advantage for mice bearing intracranial B16 HHDII/DR1 tumours when compared to the dual 
ImmunoBody® vaccination with PD-1 isotype control, however when comparing both groups with 
the control there is no significant difference in survival (see Figure 50). There may be several 
reasons for this, one such reason is the undesired spread of the tumours within the brain (see Figure 
51). 
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Figure 51. Kaplan-Meier survival analysis of intracranial B16 bearing HHDII/DR1 mice treated with 
dual SCIB1 and WT-1 ImmunoBody® vaccination either in combination with anti-PD-1 or PD-1 
isotype control and untreated mice. N= 10. * = P ≤ 0.05 as determined by the log rank test. The green 
line represents dually vaccinated mice that received anti-PD-1 antibody therapy, the blue line 
represents dually vaccinated mice that received isotype control antibody and the orange line 
represents the sham vaccinated control group. 
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In Figure 52 one can see that the injected tumours have spread to the cerebellum, whilst these 
tumours are relatively small, they are located within a vital area of the brain (in this case the 
cerebellum). The main reason for culling the animal was weight loss, the cerebellum has previously 
been linked to feeding control (Zhu, J. N., Wang 2008) and this may explain the weight loss observed. 
The cerebellum is also important for motor control and therefore tumours located within this 
region can cause serious clinical symptoms. Whilst brain tumours are highly invasive pre-clinical 
models of the disease are usually well contained and spread outside the area of implantation is 
uncommon. The spread of tumours from the site of injection is often as a result of tumour cells 
being injected into the cerebrospinal fluid located within the ventricles, this then leads to tumour 
spread down the cerebellum and spinal cord (Baumann, Dorsey et al. 2012). 
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Figure 52. Some examples of the cerebellar spread of intracranially implanted tumours observed in 
the therapeutic study; cerebellar tumours are highlighted by the red arrows, the white arrow 
represents the site of cell injection. Mice 14-16 are from the dual ImmunoBody® + anti-PD-1 group 
and mouse 27 is from the untreated control group. 
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6.3.3. Flow cytometric analysis of brain tumour infiltrating lymphocytes from mice given 
therapeutic ImmunoBody® and anti-PD-1 treatment 
 
Once mice displayed clinical symptoms or showed over fifteen percent body weight loss they were 
humanely euthanised and their brains were collected. The brains were then processed (as detailed 
in chapter 2 section 2.2.) allowing for the flow cytometric analysis of the brain tumour infiltrating 
lymphocytes. The gating strategy utilised is also detailed in chapter 2. CD3, CD4 and CD8 cell surface 
staining allowed for the identification of different T-cell subsets located within the tumour and 
these subsets were further analysed (an example of this flowy cytometric analysis can be seen in 
appendix 3). Mice were split into three groups, group 1 had received dual TRP-2 and WT-1 
vaccination with PD-1 isotype control antibody, group 2 received dual TRP-2 and WT-1 vaccination 
with anti-PD-1 blockade and finally group 3 represents untreated control mice. Dual ImmunoBody® 
vaccination increases the number of CD3, CD8 positive cells within the tumour infiltrating 
lymphocyte population (see Figure 53). The addition of anti-PD-1 immune checkpoint blockade to 
the vaccine regime does not appear to significantly alter the number of tumour infiltrating CD8+ 
cells so this indicates that the dual ImmunoBody® vaccination causes the increased CD8+ T-cell 
infiltrate observed. 
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Figure 53. Number of CD3, CD8+ positive TILs obtained from intracranial B16HHDII/DR1 tumours. 
Group 1= Dual vaccination + PD-1 isotype control, Group 2= Dual vaccination + anti-PD1, Group 3= 
Untreated controls. N= 10. 
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Further analyses were only performed on runs in which over 500 CD3, CD8+ events were measured. 
Dual ImmunoBody® vaccination in combination with anti-PD-1 immune checkpoint blockade 
increases the percentage of CD8+ and CD4+ positive CD3 cells within the TIL population (see Figure 
54). Dual ImmunoBody® vaccination with PD-1 isotype control also led to a slight increase in the 
percentage of CD4 and CD8 positive CD3 cells within the tumour. The increase in CD4 and CD8 T-
cells is promising and indicates an active immune cell infiltration in the brain tumours of immunised 
mice. 
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Figure 54. Percentage of A) CD3,CD4 and B) CD3,CD8 positive cells obtained from B16HHDII/DR1 
brain tumour TILs. Group 1= Dual vaccination + PD-1 isotype control, Group 2= Dual vaccination + 
anti-PD1, Group 3= Untreated controls. N= 5-10. * = P ≤ 0.05 as deemed by one way ANOVA followed 
by Tukey’s ad hoc test. 
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When further studying the CD8 T-cell TIL population it can be seen that dual ImmunoBody® 
vaccination (with and without anti-PD-1) leads to an increased percentage of CD25 and CD69 
positive CD8 T-cells (see Figure 55). CD25 and CD69 are T-cell activation markers indicating that the 
TIL populations from the vaccinated mice are actively responding to tumours. However there is also 
a high level of PD-1. This PD-1 expression is also indicative of activation, however the interaction of 
this PD-1 with PD-L1 on tumour cells can abrogate the anti-tumour response.  
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Figure 55. Flow cytometric analysis of CD3,CD8 positive cells obtained from B16HHDII/DR1 brain 
tumour TILs. A) CD62L and CD44 double positive cells (memory cells) B) CD69 positive cells C) PD-1 
positive cells D) CD25 positive cells. Group 1= Dual vaccination + PD-1 isotype control, Group 2= Dual 
vaccination + anti-PD1, Group 3= Untreated controls.  N = 5-10. ** = P ≤ 0.01 as deemed by one way 
ANOVA followed by Tukey’s ad hoc test. 
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When the CD4 T-cell population was further probed mice given the dual SCIB1 and WT-1 
ImmunoBody® with anti-PD-1 blockade had increases in the number of CD25, CD69 and PD-1 CD4 
T-cells. These markers indicate that there is also an active response from the CD4 T-cells as well as 
the CD8 T-cells in mice given ImmunoBody® vaccination and anti-PD-1. Unfortunately, these 
changes are not observed in mice given dual vaccination with the PD-1 isotype control (see Figure 
56). 
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Figure 56. Flow cytometric analysis of CD3,CD4 positive cells obtained from B16HHDII/DR1 brain 
tumour TILs. A) CD62L and CD44 double positive cells (memory cells) B) CD69 positive cells C) PD-1 
positive cells D) CD25 positive cells. Group 1= Dual vaccination + PD-1 isotype control, Group 2= Dual 
vaccination + anti-PD1, Group 3= Untreated controls.  N = 5-10. 
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When looking at the regulatory T-cell populations, dual vaccination in conjunction with anti-PD-1 
antibody leads to a marginally higher CD8 T-reg infiltrate into tumours compared to the dually 
vaccinated and untreated control groups (see Figure 57). Dual vaccination with PD-1 isotype control 
also appears to lead to an increase in the percentage of CD4 regulatory T-cells in the TIL population. 
The mice given anti-PD-1 in combination with dual vaccination did not seem to have the same CD4 
T-reg cell infiltrate. Combination of vaccination with anti-PD-1 therapy has previously been shown 
to decrease the number of regulatory T-cells within B16 tumours (Curran, Montalvo et al. 2010). 
Whilst an increase in regulatory T-cells is undesirable it does indicate an active immune response 
within the TIL population.  
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Figure 57. Flow cytometric analysis of regulatory T-cells obtained from B16HHDII/DR1 brain tumour 
TILs. A) Percentage of CD4 regulatory T cells B) Percentage of CD8 regulatory T cells. Group 1= Dual 
vaccination + PD-1 isotype control, Group 2= Dual vaccination + anti-PD1, Group 3= Untreated 
controls. N = 5-10. 
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6.4. Discussion 
Whilst the survival of intracranial B16 HHDII/DR1 tumour bearing mice is not significantly improved 
by ImmunoBody® vaccine in combination with PD-1 blockade (when compared to unvaccinated 
mice) there is an increase in tumour infiltrating CD8 and CD4 cells. This increased immune infiltrate 
is promising and highlights that T-cells are actively entering the brain and accessing the tumour. 
What is even more promising is that since there is increased immune cell infiltration into the 
tumour there are ways of potentially boosting the anti-tumour immune effect. Tumours are highly 
immunosuppressive hence these infiltrating immune cells are not increasing the survival of tumour 
bearing mice. Whilst PD-1 blockade aims to improve the activity of these tumour cells there are a 
few limitations to this modality when treating tumours located within the brain. Previous research 
has found anti-PD-1 therapy to be ineffective at treating recurrent GBM (Filley, Henriquez et al. 
2017). Failure may be due to the relative impairment that the blood brain barrier puts upon 
antibody penetration. The blood brain barrier usually prohibits entry of compounds that are larger 
than 400-600 Da, in the case of anti-PD-1 antibodies these are over 100 KDa in size so are excluded 
by the blood brain barrier. As a result, these anti-PD-1 antibodies bind to T-cells in the periphery, 
not those located within the tumour, this means that the majority of T-cells targeted by PD-1 
blockade are not tumour specific (Filley, Henriquez et al. 2017). Antibody penetration into the brain 
is very low with only around 0.1% of peripherally administered antibodies entering the brain under 
normal conditions (Thom, Hatcher et al. 2018). As a result of this poor brain penetrance the blood 
brain barrier’s effects need to be taken into account. The blood brain barrier functions to prevent 
the passage of large molecules into the brain parenchyma. Systemically administered antibodies 
have been shown to be present at much lower levels in the cerebrospinal fluid than the serum (the 
cerebrospinal fluid is a surrogate indicator of brain penetration by antibodies) (Wang, Q., Delva et 
al. 2018). The delivery of immune checkpoint blockade to the tumour may help to improve objective 
responses. One main advantage of locally delivering checkpoint blockade is that it can help 
minimise the off-target side effects sometimes observed. In a pre-clinical murine melanoma model 
localised delivery of anti-PD-1 using a locally applied biodegradable microneedle system was shown 
to be more efficient than systemically administered anti-PD-1 (Wang, C., Ye et al. 2017). In the GBM 
settings tumours are not as accessible as in the melanoma setting so as a result an alternative 
method for accessing these tumours needs to be considered. One highly invasive method that could 
potentially be utilised is an Ommaya reservoir, this is a catheter system that can be implanted 
within the brain with a subcutaneous injection site under the scalp that can be used to inject 
therapeutics down the catheter positioned within the brain. Unfortunately, the Ommaya reservoir 
creates some complications; improper placement of the catheter can cause serious damage to the 
brain and can even result in death of the patient. Due to the nature of the Ommaya reservoir 
patients are also at risk of developing infections, and in some cases these infections can also be 
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fatal due to the location of the reservoir within the brain (Mechleb, Khater et al. 2003, Perrin, 
Lishner et al. 1990). Another alternative method for delivering antibodies directly to the tumour is 
to simply administer anti-PD-1 into the surgical cavity of patients after tumour removal, one 
problem with this method is that only one dose can be given and therefore the anti-PD-1 may only 
have a short-term effect. Biodegradable wafers impregnated with anti-PD-1 could also be utilised 
to gradually dose the tumour bed post-surgically. Gliadel wafers are one such example of slow 
release biodegradable polymers used to directly deliver drugs into the surgical resection cavity of 
GBM tumours. Gliadel wafers are comprised of a polymer known as polifeproan20 combined with 
carmustine chemotherapy. This chemotherapy can access the brain when administered 
systemically however much like antibody therapy accumulation within the brain is fairly low. As a 
result biodegradable wafers were developed to directly deliver therapy to the tumour site 
(Kleinberg 2016). It would be of great interest to try and develop a biodegradable wafer that can 
slowly release IgG antibodies in the tumour resection cavity. An alternative less invasive method to 
improve antibody brain penetrance is to engineer antibodies so that they can cross the blood brain 
barrier. The ultimate aim is to get antibodies to penetrate the blood brain barrier without altering 
the structural integrity of the blood brain barrier. One such method may be to develop molecular 
Trojan horses; these are antibodies that are linked to protein ligands for receptors on the blood 
brain barrier. One such example of a receptor that can be used to cross the blood brain barrier is 
the transferrin receptor; OX26 is an antibody that binds to the rat transferrin receptor without 
affecting its ligand binding. Conjugation of peptides with this antibody has allowed for their 
therapeutic delivery to the brain (Neves, Aires-da-Silva et al. 2016). The affinity of these anti-
transferrin receptor antibodies was altered via genetic engineering and antibodies with a lower 
binding affinity demonstrated better brain distribution due to their improved detachment from the 
transferrin receptors (Neves, Aires-da-Silva et al. 2016). The anti-transferrin antibodies are an 
effective way to deliver conjugated therapeutics across the blood brain barrier, but the interest of 
this project is to deliver therapeutic antibodies to the brain. This can be done by engineering bi-
specific antibodies, so that one arm of the antibody is specific for the transferrin receptor, enabling 
antibody crossing and the other arm can be specific for PD-1 in this case (Neves, Aires-da-Silva et 
al. 2016).  
It is also worth considering the application of neoadjuvant therapy, this is the administration of 
vaccination and anti-PD-1 prior to the surgical removal of the GBM tumour. Previous research 
indicates that neoadjuvant therapy may be the optimal way of utilising immunotherapy in the GBM 
setting. In an early phase clinical trial utilising the anti-PD-1 antibody Pemrolizumab in the 
neoadjuvant setting for patients with recurrent GBM Pemrolizumab therapy was found to lead to 
a significant increase in overall survival when compared to adjuvant Pemrolizumab therapy 
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(Cloughesy, Mochizuki et al. 2019). Neoadjuvant therapy is believed to lead to an expansion of 
tumour specific T-cells that can target any tumour cells that may have spread from the primary 
tumour site. The presence of the tumour also leads to up-regulation of PD-1 by the immune cells, 
making anti-PD-1 more effective (Melero, Berraondo et al. 2016). 
One key factor that needs to be taken into account is the aggressiveness and rapid growth rate of 
the B16 melanoma cell line compared to other cell lines used to test GBM immunotherapy such as 
the GL261 cell line. Previous research has found that intracranial B16 tumours are more lethal than 
intracranial GL261 with mice dying at a much faster rate (Wainwright, Chang et al. 2014). PD-1 
blockade has previously been paired with active immunotherapy in pre-clinical murine models to 
great effect. Antonios et al. (2016) demonstrated that vaccination with dendritic cells pulsed with 
GL261 lysate, in the established GL261 murine model of GBM increased the infiltration of T-cells 
into the brain tumour, however there was no significant increase in survival of these mice with 
established tumours. Tumour infiltrating lymphocytes appeared to express PD-1 on their surface to 
a much higher level than splenic lymphocytes as a result anti-PD-1 antibody therapy was combined 
with dendritic cell vaccination for the treatment of established GL261 tumours. This combination 
resulted in significant survival improvement, however 100% long term survival was not achieved. 
Both dendritic cell vaccination and anti-PD-1 alone did not improve the survival of mice with 
established tumours (Antonios, Soto et al. 2016). Part of the issues observed with animal survival 
in this thesis may be due to the tumour burden being too large to effectively target with dual 
ImmunoBody® and anti-PD-1 therapy, this may be remedied by injecting fewer tumour cells 
intracranially. Previous research has found that combinatorial immunotherapy combining CTLA-4, 
IDO and PD-L1 blockade is effective at treating the intracranial murine GBM cell line GL261 however 
this same efficacy was not observed when this regime is used to treat intracranial B16 melanoma 
(Wainwright, Chang et al. 2014). These tumours are highly aggressive and as a result therapy was 
commenced rapidly in these studies, with treatment being given three days after implantation of 
tumours. This triple therapy did expand the survival of mice, but this survival benefit was minimal 
compared to that witnessed in intracranial GL261. These differences are thought to be due to the 
presence of regulatory T cells within the tumours. Intracranial GL261 tumours were found to 
contain over ten times the amount of regulatory T-cells as intracranial B16 tumours (Wainwright, 
Chang et al. 2014). 
This study utilised gene gun administration of the ImmunoBody® vaccination to the stomach of 
experimental animals. Whilst this location is fairly central with regards to the anatomy of the mouse, 
this is not the ideal location for targeting tumours located within the brain of these mice. Pre-clinical 
assessment of vaccine therapy for intracranial murine GBM has revealed that the vaccination site 
can affect the efficacy of the vaccine (Ohlfest, Andersen et al. 2013). Utilising an autologous tumour 
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lysate vaccine, mice were either vaccinated in the scruff of the neck, the foreleg and the hind leg; 
mice vaccinated in the hind leg were shown to have significantly increased long-term survival 
compared to mice vaccinated in the neck and foreleg. When staining for antigen specific T-cells with 
a dextramer, the frequency of dextramer positive CD8 T-cells decreased when T-cells were analysed 
from lymph nodes closest to the tumour. There was a threefold increase in dextramer staining when 
the TILs were analysed from mice vaccinated in the hind leg vs those in the neck. Vaccination closer 
to the tumour site resulted in suppressed effector function, with cytotoxic T-lymphocytes isolated 
from mice vaccinated the neck showing less ex vivo tumour cell killing than cytotoxic lymphocytes 
taken from mice vaccinated in the hind leg. These results indicate that immunosuppressive 
cells/cytokines drain from the tumours to their closest local lymph nodes impairing the function of 
immune cells within the vicinity of the tumour (Ohlfest, Andersen et al. 2013).  
It is of importance to use a multi-faceted approach when tackling cancer, even pre-clinical animal 
models have shown that combination of vaccine therapy with checkpoint blockade does not lead 
to 100% survival. This indicates there are probably other factors worthy of consideration when 
treating cancers with combinatorial immunotherapy (Ali, Lewin et al. 2016, Xue, W., Brentville, 
Symonds, Cook, Yagita, Metheringham, and Durrant 2016). One issue with combining multiple 
immunotherapeutic modalities is the potential for immune over-activation, as a result it is worth 
looking at combining other treatment methods with immunotherapy to enhance the anti-tumour 
immune response. This may simply be in the form of dietary and lifestyle changes, or even by 
supplementation with natural anti-cancer therapeutics that are well tolerated and relatively cancer 
specific, one such example is the dipeptide carnosine. 
6.5. Conclusion 
Dual ImmunoBody® vaccination generates an anti-tumour effect that leads to a modest increase in 
T-cell infiltration into the intracranial tumours. This increased infiltrate unfortunately does not 
improve survival of mice with established tumours. Previous research has found that addition of 
immune checkpoint blockade with vaccination can help these infiltrating TILs overcome the 
immunosuppressive effects within the tumour microenvironment and generate and efficient anti-
tumour response. Unfortunately combination of dual ImmunoBody® vaccination with anti-PD-1 
antibody therapy did not increase the survival of these mice when compared to untreated mice. 
This failure of anti-PD-1 to rescue the anti-tumour immune response may be due to the intracranial 
location of these tumours. As a result it would be of great interest in future to look at local 
administration of checkpoint blockade or it would be useful to explore other potential combinations 
of therapy. 
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CHAPTER 7: CARNOSINE AS A NATURAL THERAPY FOR GLIOBLASTOMA 
MULTIFORME 
 
7.1. Introduction 
Carnosine is a dipeptide composed of β-alanine and L-histidine; it is a pleiotropic compound in that 
it has varying effects on different cell types. Carnosine increases the longevity of human fibroblast 
cells whereas on the other hand it seems to inhibit tumour cell growth. This tumour specificity is 
thought to be due to the metabolic changes that occur in tumour cells, with most cancers relying 
on glycolysis for their energy rather than oxidative phosphorylation (a phenomenon known as the 
Warburg effect) (Gaunitz, Hipkiss 2012). Carnosine has previously been shown to have anti-GBM 
properties, with carnosine treatment being shown to inhibit the growth of patient derived GBM 
tumour cells (Renner, Asperger et al. 2010). Numerous studies have revealed that carnosine has 
effects on many different cancer cell types and these effects are attributed to numerous different 
cell-signalling pathways and functions. These varied effects contribute to carnosine’s enigmatic 
nature. Carnosine has numerous properties such as reactive oxygen species (ROS) scavenging and 
pH buffering. Carnosine has been shown to supress ROS production in activated neurons (Boldyrev, 
Bulygina et al. 2004). Carnosine appears to inhibit anaerobic glycolysis in glioblastoma multiforme 
cells, reducing their levels of ATP production. This reduction in ATP production occurs as soon as 30 
minutes after carnosine addition. Inhibition of mitochondrial oxidative phosphorylation with 
potassium cyanide did not alter GBM cellular ATP production and this did not affect the ability of 
carnosine to reduce ATP levels. However, inhibition of glycolytic activity with oxamate reduced ATP 
production greatly, carnosine had no effect on ATP levels of these cells. These results indicate that 
carnosine is an inhibitor of glycolysis in GBM cells (Renner, Asperger et al. 2010). Carnosine 
treatment of GBM cells appears to induce the expression of pyruvate dehydrogenase 4 (PDK4). 
PDK4 inhibits pyruvate dehydrogenase, this in turn results in reduced conversion of pyruvate into 
acetyl-CoA (Renner, Asperger et al. 2010). 
One of the hallmarks of cancer is altered metabolism, this altered metabolism is acquired via 
numerous mutations and enables cancer cells to survive under the metabolic burden that is put 
upon them by their rapid growth. The Warburg effect is a phenomenon commonly seen in cancer, 
cancer cells prefer to generate their ATP via aerobic glycolysis rather than mitochondrial oxidative 
phosphorylation, and this enables these cells to thrive in a low oxygen environment. Brain tumours 
generate three times the amount of ATP by aerobic glycolysis than normal brain tissue (Wolf, 
Agnihotri et al. 2010). The proliferation of cancer cells requires more than just ATP. As a result 
cancer cells shift their metabolic patterns in order to produce many of the required macromolecules 
required such as nucleotides, lipids, proteins and fatty acids. The favouring or aerobic glycolysis 
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produces the metabolic intermediates required for production of the necessary macromolecules 
(Wolf, Agnihotri et al. 2010). Not only does aerobic glycolysis enable production of vital 
macromolecules it also results in production of lower levels of potentially harmful reactive oxygen 
species. Aerobic glycolysis also produces lactic and carbonic acid that is pumped out of cells into 
the tumour microenvironment, this acidic environment enhances tumour immune escape and 
increases tumour invasion (Wolf, Agnihotri et al. 2010). As mentioned above tumours rely on 
aerobic glycolysis for their energy production, producing lactic acid. Cancer patients have been 
shown to have elevated lactate levels within their serum and the level of lactate increases with 
tumour burden. Incubation of human cytotoxic T-lymphocytes with lactic acid after antigen-specific 
stimulation resulted in reduced proliferation and after long term exposure (24h) lactic acid induced 
CTL death. Lactic acid not only reduced proliferation of these cells it also effected their function, 
with reduced cytolysis observed and impaired IL-2 and IFNγ production observed (Fischer, 
Hoffmann et al. 2007).  
Due to its ability to buffer pH and alter energy production in cancer cells carnosine offers a safe 
method for potentially aiding with the treatment of GBM. Whilst it has been shown that carnosine 
alters the metabolism and growth of GBM it provides an attractive method for making these cells 
easier to target immunotherapeutically. 
 
7.2. Aims and hypothesis 
The aim of this chapter was to discover whether carnosine exerts anti-tumour effects against the 
human GBM cell lines SEBTA-027, SF188, UP-007, UP-019 and UP-029 and the murine GBM cell line 
GL261Luc2 by altering their mitochondrial metabolism, this was assessed via a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Carnosine’s use will then be 
explored in vivo to see if any effects in vitro translate into an anti-tumour effect in vivo. 
 
7.3. Results 
7.3.1. Effects of carnosine on the mitochondrial activity of glioblastoma multiforme cell 
lines 
 
Due to the previously reported activity carnosine has on the metabolic activity of GBM cells it was 
decided to test this activity on several GBM cell lines which have not been previously treated with 
carnosine. An MTT assay was used to measure the mitochondrial activity of carnosine treated GBM 
cells. 
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Figure 58. MTT dose response curves for human GBM cells treated with carnosine. The EC50 for each 
cell line is displayed in the table below the dose response curves, with the value shown representing 
the mM concentration. Carnosine was applied to cells for 24 hours prior to performing the MTT 
assay. N=3. 
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The MTT assay results reveal that carnosine appears to reduce the metabolic activity of human 
GBM cell lines in a dose dependent manner. Dose response curves reveal that the EC50 for all of 
these cell lines is within a similar dose (30-65 mM carnosine) with the SF-188 cell line requiring the 
highest concentration of carnosine (63.63 mM) and the UP-007 cell line requiring the least (31.94 
mM). The effects of carnosine were also tested on the murine GL261 Luc2 cell line to see if the 
metabolic changes observed were ubiquitous across murine and human GBMs, enabling pre clinical 
modelling to be performed. 
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Figure 59. The MTT dose response curve for the murine GBM cell line GL261 treated with carnosine. 
The EC50 value is shown below the dose response curve, with the number being shown representing 
the mM concentration. Carnosine was applied to cells for 24 hours prior to performing the MTT 
assay. N= 3. 
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The MTT assay results reveal that carnosine appears to reduce the metabolic activity of the murine 
GL261 Luc2 GBM cell line with it having an EC50 of 32.72 mM. 
 
7.3.2. Effects of carnosine on the migration of glioblastoma multiforme cells 
 
Due to the invasive nature of GBM it was decided to test how carnosine affects the migration of 
GBM cell lines in order to see if it could be potentially used to prevent the invasion and migration 
of GBM cells post-surgically. In order to test if carnosine affected GBM cell line migration scratch 
assays were performed. In order to do this cells were grown on a 96-well plate to almost 100 % 
confluence, once confluent a scratch was made using an Essen bioscience wound maker. Once the 
scratch was made the media was removed from the cells and they were gently rinsed with PBS 
twice. After rinsing the media was replaced and in the case of carnosine treated cells carnosine 
containing media was added (at a ctrl 0 mM and EC75 dose). The plate containing cells was then 
placed into an IncuCyte machine which took pictures every 2 hours. The IncuCyte foftware was then 
used to measure the relative wound density giving a representation of wound closure. The SF-188 
and SEBTA-027 cell lines were examined due to their antigen expression profile and their potential 
use in future tumour modelling experiments. Below in Figure 60 and 61 are the results from the SF-
188 cell line. 
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Figure 60. Microscope images of SF-188 scratch closure A) 0h control B) 48h Ctrl C) 0h EC75 D) 48h 
EC75. Scale bar = 400 μm. 
 
 
Figure 61. Scratch assay results from SF-188 cells with and without carnosine.Control cells were 
grown in normal media and carnosine treated cells were given the EC75 dosage as calculated by the 
MTT dose response curves. N = 3 **** = P ≤ 0.0001 as deemed by a paired T-test. 
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Carnosine was shown to significantly reduce the migration of SF-188 cells (see Figure 62 and 63) in 
scratch assays. Control untreated cells appear to close the wound after around 40 hours, with 
regards to cell treated with the carnosine EC75 they never fully closed the wound after a period of 
96 hours. When studying the wound closure microscopically the SF-188 cells can be seen to migrate 
at a slower rate when treated with carnosine, also of interest was the fact that these cells do not 
appear to be dying (there are very few cells seen floating or rounded). These results taken with the 
MTT results indicate that carnosine’s anti-cancer activity is mediated by its ability to alter the 
metabolic function of these cells and not via the direct induction of cell death.  
It was also decided to see if carnosine had the same effects on the SEBTA-027 cell line since the SF-
188 and SEBTA-027 cell lines are of interest due to their antigen expression profiles. As a result, 
scratch assays were performed in the same manner as they were for the SF-188 cell line. The results 
are shown below in Figure 62 and 63. 
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Figure 62. Microscope images of SEBTA-027 scratch closure A) 0h control B) 48h Ctrl C) 0h EC75 D) 
48h EC75. Scale bar = 400 μm. 
 
Figure 63. Scratch assay results from SEBTA-027 cells with and without carnosine. Control cells were 
grown in normal media and carnosine treated cells were given the EC75 dosage as calculated by the 
MTT dose response curves. N = 3 **** = P ≤ 0.0001 as deemed by a paired T-test. 
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Carnosine appears to have the same effect on wound closure for the SEBTA-027 cell line as it did 
for the SF-188 cell line. Carnosine treated cells showed a slower wound closure compared to control 
cells grown with normal media (see Figure 62). Microscopic analysis reveals the same trend as that 
seen in the SF-188 cell line with the cells appearing to show reduced migration and very little cell 
death being observed. 
Seeing as the effects of carnosine were studied in human cell lines it was also decided to test the 
effects of carnosine on the murine GBM like cell line GL261 Luc2. Scratch assays were performed in 
exactly the same manner as they were for both of the human cell lines. The results are shown below 
in Figure 64 and 65. 
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Figure 64. Microscope images of GL261 Luc2 scratch closure A) 0h control B) 48h Ctrl C) 0h EC75 D) 
48h EC75. Scale bar = 400 μm. 
 
Figure 65. Scratch assay results from GL261 Luc 2 cells with and without carnosine. Control cells 
were grown in normal media and carnosine treated cells were given the EC75 dosage as calculated 
by the MTT dose response curves. N = 3 **** = P ≤ 0.0001 as deemed by a paired T-test. 
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Carnosine seems to have a much greater effect on the migration of the GL261 Luc2 cell line than 
the human GBM cell lines studied. After 96 hours of carnosine treatment the wound density of 
carnosine treated GL261 Luc2 cells was never higher than 40%. When looking at the GL261 Luc2 
cells microscopically carnosine appears to have a marked effect with a large number of cells 
appearing rounded. The murine GL261 Luc2 cell line appears to have a more visible response to 
carnosine therapy than the human cell lines studied. Previous research and the MTT results reveal 
that carnosine has an effect on the metabolism of GBM cells (Renner, Asperger et al. 2010, 
Oppermann, Faust et al. 2019). The differences observed between the human and murine GBM cell 
lines may be due to the metabolic differences between the two species that these cells originate 
from. Mice have a higher metabolic rate than humans due to their smaller size and greater surface 
area to volume ratio (Demetrius 2005). Because carnosine effects mitochondrial metabolism its 
effects would be expected to be heightened in a murine cell line due to the increased metabolism, 
these results support this hypothesis. 
 
7.3.3. In vivo effects of carnosine GL261 Luc2 bearing NOD-SCID mice 
 
After studying the effects of carnosine in vitro it was decided to see what effects carnosine could 
have on the in vivo growth of GL261 Luc2 tumours. A single 20L of 1M dose of carnosine dissolved 
in PBS was injected intratumourally into subcutaneous GL261 Luc2 cells grown in the flank of NOD-
SCID mice. A control group of mice received the same volume (20 μL) of PBS without carnosine. 
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Figure 66. A) Tumour surface area measurements of GL261 Luc2 tumours taken from carnosine and 
PBS treated mice. B) Weights of tumours excised 16 days after carnosine treatment. C) In vivo 
bioluminescent images taken on day 16 post carnosine therapy, the left 4 mice are control mice and 
the 5 on the right are carnosine treated. D) Close up of an in vivo image of a carnosine treated 
tumour, the red arrow highlights an area of reduced tumour growth at the site of injection. Red 
indicates high luciferase activity (indicative of greater tumour size), and blue represents areas of 
less luminescence.  
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Intratumoural injection of a single dose of 1M carnosine reduces the size of GL261 Luc2 tumours 
implanted in the flank of NOD-SCID mice (See Figure 66. A) and B)), what is also of interest is that 
there appears to be an area of specific tumour reduction in the area of injection (see Figure 66. D)). 
These results indicate that a single intratumoural dose of carnosine can reduce the size of GL261 
Luc2 tumours.  
 
7.4. Discussion 
The MTT assay results reveal that carnosine has anti-metabolic activity on the GBM cells studied, 
and this anti-metabolic activity is also evident in the murine GL261 Luc2 GBM cell line. The MTT 
assay relies on mitochondria converting MTT into formazan resulting in a colour change that is a 
surrogate marker for mitochondrial activity. Not only does carnosine appear to alter the 
metabolism of these cells it also appears to alter their motility with the scratch assay revealing that 
carnosine slowed down scratch closure in both a human and murine GBM cell lines. This result is 
highly promising for the prospect of carnosine as a GBM therapeutic, as these tumours are 
renowned for their migration and invasion within the brain with recurrence being inevitable after 
roughly 32 – 36 weeks (Hou, Veeravagu et al. 2006). Carnosine also appears to reduce tumour 
growth in a NOD-SCID GL261 Luc2 subcutaneous model. This in vivo action of carnosine can be 
attributed to the direct activity of carnosine on the cells seeing as the NOD-SCID mouse is an 
immunocompromised mouse, ruling out the contribution of the immune compartment in the anti-
tumour activity of carnosine. 
Previous research has shown that in an in vitro co-culture system with T98G GBM cells and normal 
fibroblast cells, T98G cells were grown within a cloning ring and fibroblasts were grown outside of 
the cloning ring, addition of carnosine to this co-culture system was then studied. When the cloning 
ring is removed T98G cells invade the fibroblast layer and form multiple colonies, when carnosine 
was added to the co-culture system the T98G cells formed less colonies and had a reduced invasion 
of the surrounding fibroblast layer (Oppermann, Dietterle et al. 2018). This selective inhibition of 
the GBM cells whilst the surrounding normal fibroblast cells are left intact is what makes carnosine 
such an attractive therapy. These findings clearly indicate that carnosine has a cancer specific effect. 
Furthermore, carnosine could also be of use for its protective effects especially when combined 
with radiotherapy and chemotherapy by reducing the bystander effects that these therapies have 
on normal cells within the body, especially when dealing with a sensitive organ such as the brain. 
Radiotherapy results in the generation of radical species and the release of pro-inflammatory 
cytokines that result in cellular death (Alan Mitteer, Wang et al. 2015, Tabatabaei, Visse et al. 2017). 
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Due to the reactive species scavenging and anti-oxidant effects of carnosine it can protect tissues 
from the deleterious effects that reactive species and inflammation can have. Carnosine has been 
shown to improve the survival of mice receiving whole body irradiation. One concern may be that 
these protective effects may impede the anti-tumour effect of radiotherapy. In humans the use of 
a carnosine-zinc complex for head and neck cancer patients was shown to reduce oral mucositis 
whilst no negative effects on the radiotherapy were observed (Gaunitz, Hipkiss 2012). 
One key factor to take into account when using carnosine is the presence of the enzyme carnosinase. 
This enzyme actively breaks down carnosine into its constitutive peptides potentially nullifying its 
effects (Sauerhofer, Yuan et al. 2007). If L-carnosine is systemically administered carnosinase breaks 
down carnosine preventing it from reaching tumours and exerting its effects. As a result, it is of 
great interest to synthesise biosimilar chemicals that have the same activity as carnosine but 
overcome the cleavage by carnosinase. In the GBM setting it may be worth examining the use of L-
carnosine in the surgical resection cavity or implanting slow release devices to administer carnosine 
temporally.  Carnosine naturally occurs at a high level in the brain where it is believed to play a 
protective role (Stvolinsky, Kukley et al. 1999). Carnosine is synthesised by the enzyme carnosine 
synthase, this enzyme combines β-alanine and L-histidine to produce carnosine, this enzyme was 
found to be at high levels within the murine brain (Harding, O'Fallon 1979). Carnosine is also 
abundant in skeletal muscle where it has been shown to regulate the intramuscular pH and prevent 
fatigue. Carnosine synthase is responsible for the synthesis of carnosine within the muscle and β-
alanine has been shown to be the limiting factor with regards to carnosine synthesis. As a result, -
alanine supplementation is utilised to improve exercise performance and reduce muscular fatigue 
via an increase in intramuscular carnosine concentration and therefore lactic acid buffering capacity 
(Artioli, Gualano et al. 2010). Due to the presence of carnosine synthase in the brain and 
carnosinase in the serum it may be worth considering systemic administration of β-alanine as 
opposed to carnosine as a method for increasing levels of intracerebral carnosine in GBM patients.  
The clear anti-migratory effects that carnosine has on GBM cells would make it a useful first line 
therapeutic, it would be of great benefit to administer carnosine to the resection cavity of GBM 
tumours post-surgery, prior to the potential application of immunotherapy; this carnosine would 
act to prevent the invasion of any residual cells into the surrounding brain. Seeing as the focus of 
this thesis is on immunotherapy it would be of great interest to study the effects of carnosine on 
the immune cells. Previously carnosine has been shown to extend the in vitro lifespan of CD4 T-
cells. This longevity was attributed to the reactive species scavenging properties of carnosine 
reducing levels of oxidative DNA damage within these cells  (Hyland, Duggan et al. 2000). This 
provides great promise for combining carnosine therapy with immunotherapy. The in vivo data 
presented here reveals that intratumoural carnosine slows the growth of GBM tumours, this effect 
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was studied in NOD-SCID mice so the effects seen can be attributed to carnosine’s direct activity on 
tumour cells. It would be of great interest to see how carnosine effects tumours in 
immunocompetent mice, this would reveal the potential interaction between the immune 
compartment and carnosine. 
 
7.5. Conclusion 
Carnosine was shown to alter the mitochondrial metabolism of GBM cells, and to reduce the growth 
and migration of these cells. Intratumoural delivery of carnosine was also able to slow tumour 
growth in vivo as well as in vitro. As a result of these findings carnosine shows great promise as an 
adjunct therapy for GBM. Whilst carnosine does not appear to kill GBM cells it does slow their 
migration which is of great therapeutic benefit in the GBM setting, especially when considering the 
combination of immunotherapy with carnosine therapy. The tumour specificity and lack of serious 
side effects make carnosine a treatment worth considering in the GBM setting. 
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CHAPTER 8: DISCUSSION AND FUTURE WORK 
 
Glioblastoma multiforme remains one of the cancers with the worst prognosis and poorest patient 
survival. Despite decades of research very little has changed with regards to the therapeutic 
landscape of GBM. Radiotherapy, temozolomide chemotherapy and surgical interventions remain 
the current ‘gold standard’ for GBM therapy. Immunotherapy provides an attractive therapy 
modality for this type of cancer due to its high specificity and the ability of activated immune cells 
to activate the brain parenchyma, traversing the blood brain barrier (a hindrance for many 
molecular therapies). Whilst immunotherapy has garnered significant interest for the treatment of 
GBM many immunotherapeutic approaches have failed during clinical trial testing (Weller, 
Butowski et al. 2017, Filley, Henriquez et al. 2017). As a result, alternative immunotherapeutic 
approaches need to be explored in order to discover an effective therapy. Glioblastoma multiforme 
is also known to be highly immunosuppressive and this may be a reason for the failure of 
immunotherapeutic modalities, therefore future clinical trials using immunotherapeutic 
approaches will need to take this into consideration, combining active immunotherapy with 
checkpoint blockade.  
The aim of this thesis was to try and develop a new immunotherapeutic approach for the treatment 
of glioblastoma multiforme tumours. This involved the identification and targeting of 
immunotherapeutic antigens expressed by GBM. In order to try and overcome the 
immunosuppressive nature of GBM a novel vaccine platform known as the ImmunoBody® has been 
utilised to generate an immune response. ImmunoBody® is a DNA plasmid vaccine that encodes an 
IgG molecule with the peptides of interest engrafted into its complementarity determining regions. 
This method of vaccination has shown great pre-clinical promise and can generate a strong anti-
tumour immune response that has shown efficacy as a monotherapy for the treatment of pre-
clinical melanoma (Pudney, Metheringham et al. 2010). GBM is notoriously immunosuppressive 
with GBM cancers being shown to express immunosuppressive cytokines such as TGFβ and IL-10, 
not only do GBMS secrete immunosuppressive cytokines they have also been shown to express the 
immunosuppressive ligand PD-L1 on their surface (Nduom, Weller et al. 2015). PD-L1 on GBM cells 
binds to the PD-1 receptor on activated T-cells, this binding leads to inhibition of T-cell activity. 
What is also of great importance is that the pro-inflammatory cytokine IFNγ leads to induction of 
PD-L1 on tumour cells meaning that activated immune cells releasing IFNγ within the tumour 
microenvironment can cause cancers to actively adapt to the immune pressure put upon them 
(Topalian, Drake et al. 2012). This PD-1/PD-L1 interaction has been blocked in the clinical setting 
with the aim of boosting the anti-tumour response. Due to the immunosuppressive nature of GBM 
it would be of great interest to combine ImmunoBody® vaccination with PD-1/PD-L1 blockade. The 
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rationale for combining these two treatment modalities is to generate an anti-tumour immune 
response via vaccination and then boost this response by preventing the immune dampening PD-
1/PD-L1 interaction. 
 
8.1. GBM tumours express immunogenic antigens that make them targetable 
with immunotherapy however they also have an immunosuppressive phenotype 
Analysis of GBM cell lines and tumours tissue sections form GBM patients revealed that these 
tumours express a variety of antigens that could targeted with immunotherapeutic approaches. 
The WT-1 and TRP-2 antigens were identified as potential immunotherapeutic targets worth further 
study due to their prevalence in both tumour tissues and cell lines. TRP-2 is a well-known 
immunogenic antigen commonly targeted in the melanoma setting (Patel, P. M., Ottensmeier et al. 
2018, Bronte, Apolloni et al. 2000). Melanocytes in the skin and glial cells within the brain are both 
derived from the nueroectoderm during embryogenesis, as a result tumours of the brain and 
tumours of the skin express many of the same antigens. As a result of this shared lineage the 
expression of many melanoma antigens has been explored in GBM tumours. TRP-2 expression has 
previously been shown to be in a relatively high percentage of GBM cases (62- 34%), however its 
expression is not ubiquitous across all GBM cases (Chi, Merchant et al. 1997, Saikali, Avril et al. 2007, 
Liu, G., Khong et al. 2003). In addition, in order to avoid the risk of seeing the emergence of a clone 
of cells resistant to the vaccine due to antigen loss (immune escape variant), it was thought wise to 
target two independent antigens. The WT-1 antigen was chosen due to its known immunogenicity 
and due to its previously reported expression in GBM tumours (Rushing, Sandberg et al. 2010, Chiba, 
Hashimoto et al. 2010). An ideal vaccine should target antigens that are expressed primarily by 
cancer cells or at least expressed in significantly higher quantity compared to healthy tissues. It 
would also be of great benefit to target antigens that are expressed by many different tumours so 
that the vaccine could be applicable to other cancer types broadening the scope for the therapy. 
An ideal target antigen should be immunogenic and if it is required for tumour cell survival and 
tumorigenicity it makes an even more attractive target (Cheever, Allison et al. 2009). This last 
characteristic reduces the chances for the antigen to be silenced by the tumour under 
immunological pressure as it is essential for the cancer’s survival. An analysis of 75 cancer antigens 
revealed that WT-1 was the top antigen to target in the pancreatic cancer setting. The WT-1 antigen 
was the top antigen due to its importance in proliferation, invasion and metastases (Koido, 
Okamoto et al. 2017), previous research has shown that knockdown of the WT-1 gene slowed the 
growth of human GBM cells and slowed their in vivo growth in nude mice (Clark, Ware et al. 2010). 
WT-1 has also been shown to be involved in the regulation of apoptosis of GBM cell lines with WT-
1 silenced GBM cell lines expressing more pro-apoptotic genes than WT-1 expressing GBM cell lines 
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(Kijima, Hosen et al. 2014). Therefore, both TRP2 and WT1 antigens were judged good antigens and 
therefore chosen for the development of a vaccine to treat GBM.  
GBM is also renowned for its immunosuppressive phenotype, GBM is primarily a disease associated 
with old age with the majority of cases occurring in patients aged between 55 and 60 years of age 
(Hanif, Muzaffar et al. 2017). It has been shown that the increasing age of GBM patients is 
associated with an increased immunosuppressive gene expression profile. PD-L1 and IDO mRNA 
expression is increased in the GBM tumours of older patients (aged 60-69) (Ladomersky, Scholtens 
et al. 2019). It was decided to analyse the immune phenotype of several GBM cell lines using flow 
cytometry. This technique was used to look at the cell surface expression of several immune 
activating and inhibiting ligands. These analyses revealed that there were high levels of the immune 
inhibitory ligand PD-L1 on the surface of cultured GBM cell lines. PD-L1 is an immunosuppressive 
ligand for the PD-1 receptor expressed by T-cells. Ligation of PD-1 on T-cells with PD-L1 results in a 
reduction in the activity of T-cells and an increase in immunosuppression (Ohaegbulam, Assal et al. 
2015). PD-L1 expression is usually restricted to immune privileged tissues however numerous 
cancers have co-opted this inhibitory ligand as a means to prevent immune attack. PTEN loss is 
frequent in many cancers, with GBM being no exception, this loss of PTEN results in expression of 
PD-L1 by GBM cancers (Parsa, Waldron et al. 2007). Whilst this expression of PD-L1 enhances the 
immune escape of tumours it can also be targeted using antibodies to try and prevent the immune 
escape of tumours enabling their immune recognition. Interestingly the non-classical MHC class I 
molecule HLA-G was also discovered on the surface of cultured GBM cells. HLA-G expression is 
usually restricted to the trophoblasts protecting the embryo from immune attack (Kovats, Main et 
al. 1990). HLA-G has previously been shown to prevent cytotoxic CD8 T-cell lysis of HLA-G expressing 
cells (Le Gal, Riteau et al. 1999). HLA-G has also previously been shown to protect GBM cells from 
lysis by alloreactive PBMCs, blockade of HLA-G using antibodies was shown to rescue the lysis of 
tumour cells by alloreactive PBMCs (Wiendl, Mitsdoerffer et al. 2002).  
Whilst the cell lines studied appeared to express immunosuppressive proteins, they also appear to 
express some immune activating proteins. The GBM cells studied all appear to express the MHC 
class I antigen (HLA-A, B, C) on their surface. These MHC class I molecules are responsible for 
presenting immunogenic peptides to cytotoxic T-cells, these MHC class I molecules also protect 
tumour cells from NK cell mediated lysis however this antigen presentation via MHC class I targets 
cells for killing by CD8 T-cells (Garcia-Lora, Algarra et al. 2003). Tumour cells sometimes down 
regulate MHC class I expression to prevent immune cell recognition, this loss of MHC class I 
therefore makes them susceptible to NK cell mediated lysis, however it would appear that whilst 
tumour cells down regulate classical MHC class I they also appear to upregulate non-classical class 
I molecules such as HLA-G that protect them from NK cells. Fortunately, the cell lines studied appear 
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to express HLA-A, B, C so they are susceptible to cytotoxic T-cell attack. The GBM cell lines studied 
also appear to express CD40 on their surface. CD40L is expressed by activated T-cells and it binds 
to CD40, a costimulatory receptor contributing to cell-mediated immunity (Elgueta, Benson et al. 
2009). CD40 ligation on B cells and dendritic cells results in an upregulation of MHC molecules on 
their surfaces and improved antigen presentation. CD40 ligation on tumours has been shown to 
result in the direct death of tumour cells independent of the immune compartment, this CD40 also 
leads to CD8 T-cell activation (Vonderheide 2007). 
These results taken together indicate that GBM expresses immunogenic antigens that can be 
targeted via immunotherapy however the immune profile of these tumours needs to be accounted 
for, such as the apparent expression of the anti-immune PD-L1 and expression of MHC class I. Once 
these antigens were discovered it was decided to utilise a WT-1 and TRP-2 directed ImmunoBody® 
vaccine to generate an anti-tumour immune response in a pre-clinical murine model of GBM. 
 
8.2. ImmunoBody® vaccination generates a strong anti-tumour immune 
response and the addition of checkpoint blockade appears to help tumour 
infiltrating immune cells overcome intratumoural immunosuppression 
The ImmunoBody® vaccination provides an exciting new immunotherapeutic approach for the 
treatment of intracranial tumours. The ability of ImmunoBody® to generate a strong immune 
response and its ability to prophylactically prevent tumour occurrence make it a viable therapy for 
the treatment of brain tumours. The ImmunoBody® vaccine platform provides an attractive method 
for generating an anti-tumour immune response due to its ability to generate an immune response 
via direct and cross presentation of tumour antigens using an IgG antibody as a carrier protein. As 
previously mentioned, it was decided to target the WT-1 and TRP-2 antigens 
immunotherapeutically due to their prevalence and importance in GBM. Targeting multiple 
antigens prevents immune escape from occurring, this is the phenomenon where cancers will adapt 
their antigen expression profile to enable them to evade immune eradication (Dunn, G. P., Old et 
al. 2004). One issue to consider when vaccinating against multiple antigens is the presence of 
epitope dominance, this is where the response to one immunogenic antigen overrides the response 
to the co-administered antigen. Due to the desire to target both the WT-1 and TRP-2 antigens it 
was decided to see if there was any immunodominance to either of these antigens when both TRP-
2 and WT-1 ImmunoBody® vaccines were given simultaneously. When given together the SCIB1 
(TRP-2 directed) and WT-1 ImmunoBody® vaccines did not display any immunodominance with the 
TRP-2 and WT-1 immune response being of similar frequency and avidity when the vaccines were 
given alone and simultaneously. Due to these findings it was decided to test this dual ImmunoBody® 
regime in a prophylactic setting with the dual vaccination regime being administered followed by 
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intracranial tumour implantation. In the prophylactic setting dual WT-1 and SCIB-1 ImmunoBody® 
vaccination resulted in a significant improvement of survival when compared to sham vaccinated 
mice, confirming the anti-tumour activity of dual ImmunoBody® vaccination. When treating 
established intracranial tumours ImmunoBody® vaccination failed to significantly improve the 
survival of tumour bearing mice, however ImmunoBody® vaccination lead to an increased cytotoxic 
T-cell infiltrate into brain tumours. It was hypothesised that adding immune checkpoint blockade 
to the ImmunoBody® vaccination schedule would boost the anti-tumour immune response and 
improve survival of tumour bearing mice, when anti-PD-1 antibody was added to dual WT-1 and 
SCIB1 ImmunoBody® vaccination it lead to a significant improvement in survival compared to mice 
given dual ImmunoBody® vaccination with PD-1 isotype control however this treatment was not 
curative.  Established intracranial tumours are notoriously difficult to treat and there are several 
methods that could be employed to try and improve the response to combinatorial therapy. Whilst 
there appears to be some promise for the use of immunotherapy in the GBM setting there are 
several issues that need to be addressed in order to achieve a robust anti-tumour response. The 
preclinical data presented within this thesis reveals that ImmunoBody® vaccination generates an 
increase in the number or T-cells infiltrating intracranial tumours however this increase was not 
linked to an increased in survival, similar findings have been found using a dendritic cell vaccine 
(Antonios, Soto et al. 2016). Previous research has found that addition of anti-PD-1 to vaccine 
therapy boosted the anti-tumour response of these TILs resulting in improved survival (Antonios, 
Soto et al. 2016). As mentioned previously GBM cells respond to IFNγ in their microenvironment 
therefore it was decided to analyse the response of GBM cells to IFNγ. 
 
8.3. GBM cells can respond to IFNγ in their local environment and adapt their 
immune-related antigen expression profile 
ELISpot results reveal that ImmunoBody® vaccination generates IFNγ release from splenocytes 
when exposed to the target peptides. As a result, it was of great interest to see how GBM cells react 
to IFNγ in their environment. In vitro analyses reveal that GBM cells appear to actively alter their 
phenotype when in the presence of IFNγ indicating that activated immune cells within the tumour 
may alter the tumour’s phenotype and alter its immune profile altering the anti-tumour efficacy of 
these cells. Tumours are known to escape the immune pressures put upon them, so antigens that 
can enhance their immune escape are likely to be upregulated. In a late stage aggressive cancer like 
GBM the tumour mass is likely to be comprised of cells that have escaped the immune pressures 
put upon them and therefore these tumours are highly likely to be immune evasive and suppressive.  
IFNγ is a pleiotropic cytokine that acts on both innate and adaptive immune regulation. IFNγ is 
known to lead to increased MHC expression and therefore antigen presentation. IFNγ has been 
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utilised as a therapeutic in the cancer setting (Zaidi, Merlino 2011). IFNγ has been shown to inhibit 
GBM cell growth in vitro as a result its direct administration intratumourally has been studied as a 
therapy for GBM. Recombinant IFNγ was given in conjunction with radiotherapy for newly 
diagnosed GBM patients, this therapy was well tolerated with the only side effect observed being 
a raised body temperature post injection. Whilst this therapy was well tolerated it failed to result 
in a survival benefit when compared to radiation alone (Farkkila, Jaaskelainen et al. 1994). IFNγ is 
known to induce IL-6 expression in GBM (Iwami, Natsume et al. 2011) IL-6 is associated with 
invasion of GBM cells and as tumour grade increases so does the level of IL-6 (Shan, He et al. 2015). 
Due to the pleiotropic nature of IFNγ its role in the immune response needs to be considered as 
part of a combinatorial approach. 
In vitro analyses conducted for this thesis revealed that when GBM cells were exposed to IFNγ they 
upregulate several immune related cell surface antigens. IFNγ treatment led to an increase of the 
immunosuppressive non-classical class I MHC molecules HLA-G and -E. Expression of these 
molecules on the surface of tumour cells will potentially prevent lysis of tumour cells by T-cells and 
NK cells, providing them with a means by which to circumvent the immune system (Le Gal, Riteau 
et al. 1999, Wischhusen, Friese et al. 2005). The GBM cells studied also appear to upregulate the 
expression of PD-L1 on their surface after IFN treatment which would also contribute towards their 
immune escape via ligation to PD-1 on the surface of activated T-cells. The expression of PD-L1 by 
GBM tumours has been linked to shorter survival times with high PD-L1 expression leading to a 
significant reduction in patient survival times (Nduom, Wei et al. 2016). The upregulation of these 
molecules presents a significant challenge to the success of any vaccine used to treat GBM, however 
the identification of their presence provides further molecules to target when utilising 
immunotherapy.  
However, the cell lines studied also upregulated classical MHC class I (HLA-A, B, C) on their surface 
when exposed to IFNγ. The upregulation of MHC class I is known to improve antigen presentation 
and T-cell recognition of tumours making them more susceptible to cytotoxic T-cell killing. Cancers 
can lose expression of MHC class I and this is a method that enables them to escape immune 
recognition, the loss of MHC class I prevents recognition of tumour cells by cytotoxic T-cells and 
leads to the development of immune escape variants (Garrido, Aptsiauri et al. 2016). Moreover, 
the expression of immune stimulatory CD40 on the surface of the cell lines studied was also 
upregulated after IFNγ exposure. CD40 is an important regulator of the immune response, binding 
of CD40 to its ligand (CD40L) leads to amplification of the immune response via the upregulation of 
costimulatory molecules and MHC class I (Costello, Gastaut et al. 1999). 
IFNγ also increased the level of immune inhibitory enzyme IDO in the GBM cell lines studied. IDO is 
a well-known immune inhibitor and its expression in GBM has been linked to worsened survival 
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(Wainwright, Balyasnikova et al. 2012). The expression of IDO by cancer cells implanted into 
immunocompetent mice prevents their rejection when prophylactically vaccinated, the rejection 
of these tumours could be rescued by inhibiting IDO with 1MT. These findings point to IDO being 
an important modulator of the anti-tumour immune response (Munn, Mellor 2004). IDO expression 
within tumours is linked with an increase in the presence of immune inhibitory regulatory T-cells. 
IDO also leads to depletion of tryptophan, a critical amino-acid for the survival of T-cells, in the 
tumour microenvironment, resulting in the reduction of T-cell growth and thereby contributing to 
an immunosuppressive environment (Zhai, Lauing et al. 2015). 
GBM cell lines adapt to the presence of IFNγ in their environment and this can help reveal the 
response of these cells to immunotherapy. GBM is highly immunosuppressive as evidenced by PD-
L1, GLA-E and HLA-G expression, this immunosuppression is exacerbated when these cells are 
exposed to IFNγ. It is also important to note that these cells also upregulate some immune 
stimulatory molecules such as MHC class I and CD40, so IFNγ represents a potential ‘double-edged 
sword’ for immunotherapy. These findings provide a rationale for combining immune checkpoint 
blockade with active immunotherapy.  
 
8.4. Carnosine represents an attractive natural therapy for GBM 
Long term survival in GBM is extremely rare and despite aggressive surgery and radio chemo 
therapy tumours nearly always recur. GBM cells are highly invasive and have been shown to 
penetrate brain tissue and travel along the vasculature, this makes complete surgical resection of 
these tumours almost impossible (Paw, Carpenter et al. 2015). Upon recurrence the prognosis of 
GBM patients is extremely poor with median survival only being just under 7 months (van Linde, 
Brahm et al. 2017). Due to the highly invasive nature of GBM it would be of great benefit to try and 
prevent the proliferation and migration of any cells that remain post-surgery providing a window 
of opportunity for vaccine induced immune cells to target this reduced number of tumour cells 
before they can spread and grow. 
Carnosine a di-peptide composed of β-alanine and L-histidine has been shown to significantly 
inhibit colony formation and migration of GBM cells co-cultured with normal fibroblast cells, 
without affecting the fibroblasts. This tumour specificity and ability of carnosine to prevent colony 
formation make it an attractive therapeutic option (Oppermann, Dietterle et al. 2018). The effects 
of carnosine on GBM cells was studied in this thesis, with carnosine being shown to reduce the 
migration of GBM cells. Carnosine also alters the mitochondrial activity of all of the GBM cell lines 
studied (as indicated by an MTT assay). This ability of carnosine to reduce the migration of GBM 
cells in a selective manner make it an attractive therapeutic option in combination with 
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immunotherapy. Carnosine has been shown to increase the longevity of CD4+ T-cells in vitro  (Hyland, 
Duggan et al. 2000), carnosine is also a pH buffer which would be beneficial when combined with 
immunotherapy. Tumours frequently have an acidic microenvironment due to increased glycolysis 
within the tumour producing lactic acid, this acidic pH inhibits immune cell function and reduces 
immune cell killing of tumour cells (Lardner 2001). The prospect of delivering carnosine directly into 
the post-surgical cavity of GBM patients (either directly or by using carnosine impregnated 
biodegradable wafers) provides great promise, this therapy would reduce migration of any 
remaining tumour cells whilst buffering the local pH enabling efficient anti-tumour immune cell 
activity. Due to the pH buffering capabilities of carnosine it would be of great benefit to combine it 
with immunotherapy for the aforementioned reasons. 
 
8.5. Issues with brain tumour immunotherapy 
Unfortunately, as evidenced by our findings and those of others GBM tumours are highly 
immunosuppressive and adapt to immune pressures put upon them. What further impedes the 
efficacy of immunotherapy in the GBM context is the unique interaction between the brain and the 
immune system and the unusual immune environment of the brain. Even though the brain is unique 
in immunological terms it is not devoid of an active immune response and activated immune cells 
can access tumours within the brain (Prins, Shu et al. 2008). Results obtained in this study have 
revealed that ImmunoBody® vaccination did generate an antigen-specific immune response that 
provided tumour protection in a prophylactic brain tumour model. When ImmunoBody® 
vaccination was used to treat established intracranial tumours, it didn’t convey a survival advantage 
for mice bearing intracranial tumours. Combination of anti-PD-1 with ImmunoBody® vaccination 
did appear to result in a significant survival advantage however all mice still succumb quickly to the 
disease. There are many reasons for why therapy may have failed to completely cure the mice. Flow 
cytometric analysis of TILs did indicate an increased T-cell infiltrate after vaccination. However, the 
immune cells penetrating the tumour may have been locally suppressed, as a result combination of 
PD-1 blockade with vaccination helped to rescue this immune response. The addition of PD-1 
seemed to improve survival of mice harbouring intracranial tumours when compared to mice 
receiving dual vaccination with isotype control. However the fact that mice die in a short period of 
time indicates that perhaps the ability of anti-PD-1 to penetrate the tumour and the blood brain 
barrier is limited. It would be of great interest to used labelled anti-PD-1 antibody to examine its 
trafficking throughout the body, when injected intra venously and when administered intra-nasally. 
Whilst the antibody can still exert its effects extracranially it would be most beneficial if it were 
delivered to the tumour so that it can boost the immune cells within the tumour. This may be 
improved by directly delivering the antibody using an Ommaya reservoir or gliadel wafers 
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impregnated with anti-PD-1 into the tumour resection cavity. Previous research has shown that 
only around 0.1% of peripherally administered IgG antibodies penetrate the brain under normal 
conditions (Thom, Hatcher et al. 2018). In GBM cases the blood brain barrier is compromised and 
‘leakier’ than that of a healthy brain however antibody penetrance isn’t increased due to the large 
size of antibodies (Razpotnik, Novak et al. 2017).  Interestingly, a small clinical trial found that it was 
better for the patients to receive anti-PD-1 before surgery rather than after surgery probably due 
to the fact that most anti-GBM T-cells were already inside the tumour at the time of surgery and 
therefore adding anti-PD-1 did very little to relieve the break of T-cells that were no longer there 
(Cloughesy, Mochizuki et al. 2019).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
The blood brain barrier (BBB) is a significant obstacle to overcome with regards to treating brain 
diseases with GBM being no exception. Many drugs and molecules that show promise in vitro often 
fail to have the same effects in vivo due their inability to penetrate the blood brain barrier and 
access the brain parenchyma. There are numerous reasons for the highly selective nature of the 
BBB and it works to prevent entry and exit of undesirable substances that could affect the highly 
sensitive brain. The BBB helps to maintain an ideal environment for brain function by regulating ion, 
nutrient, macromolecule and neurotransmitter levels whilst also excluding harmful toxins (Abbott, 
Patabendige et al. 2010). IgG penetration into the brain parenchyma is relatively low and there is 
active efflux of IgG molecules from the brain via the Fc region of these antibodies when they are 
introduced intracerebrally (Zhang, Y., Pardridge 2001). In the cancer setting the blood-tumour 
barrier is far more disorganised than the intact blood brain barrier, this enables larger molecules to 
penetrate the tumour than would be permitted by the blood brain barrier, however this 
permeability is not homogeneous with high amounts of tumour variation observed. Native lung 
cancer has been seen to have a higher level of T-cell infiltrate compared to brain metastases, 
indicating that the intracerebral location of these tumours impedes T-cell penetration (Berghoff, 
Preusser 2018). Systemically administered antibodies can access the brain parenchyma however 
the brain accumulation is dismally low, with only around 0.1 % of the serum concentration being 
detected in the brain. This low accumulation has been attributed to the blood brain barrier and the 
rapid clearance of antibodies from the CSF (Iwasaki 2017). Mouse studies have shown that the site 
of vaccination can alter the immune response to glioblastoma multiforme tumours, mice 
vaccinated in regions further from the site of the tumour displayed a stronger anti-tumour response. 
This indicates that the lymph nodes located closest to the tumour are being altered by factors that 
are draining from the tumour, T-cell priming appears to be impaired in the cervical lymph nodes 
(located within the neck) (Ohlfest, Andersen et al. 2013).  
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8.6. Improving future immune therapy for glioblastoma multiforme 
Due to the issues with antibody penetrance of brain tumours several avenues can be utilised to 
improve blood brain barrier crossing and brain penetrance of therapeutic antibodies. One of the 
most basic methods for enabling antibody penetration into the brain is to utilise focused ultrasound, 
this relies on high frequency ultrasonic waves to disrupt the tight junctions within the blood brain 
barrier allowing molecules otherwise not permitted to cross the blood brain barrier. Previous 
research has shown that the application of focused ultrasound with gas-filled microbubbles can 
permit the entrance of therapeutic antibodies into the brain without any damage to the brain 
parenchyma (Kinoshita, McDannold et al. 2006). One concern may be that ultrasound may affect 
gap junctions within the brain altering cell-cell communication, fortunately gap junctions are not 
destroyed it is their assembly that is affected, however these changes were reversed 24 hours after 
ultrasound exposure (Alonso, Reinz et al. 2010).  
There are two main methods that molecules use to cross the blood brain barrier: adsorption-
mediated transcytosis and receptor-mediated transcytosis. Adsorption-mediated transcytosis 
simply relies on positively charged molecules interacting with the negatively charged phospholipids 
within the membrane of endothelial cells, this then results in internalisation of the positively 
charged molecules and their shuttling across the membrane into the brain parenchyma (Razpotnik, 
Novak et al. 2017). Receptor-mediated transcytosis relies on the binding of molecules to their 
specific receptor on the endothelium of the BBB, resulting in their internalisation and shuttling 
across the endothelial cells. There are several receptors that mediate this form of transcytosis 
across the BBB, these are the insulin, LDL-related protein type I and transferrin receptors. These 
receptors can be targeted to improve the delivery of antibodies across the BBB (Razpotnik, Novak 
et al. 2017). Unfortunately, due to the presence of neonatal Fc receptors on the blood brain barrier 
antibodies are actively removed from the brain via reverse transcytosis.  
Altering the structure of antibodies can afford the opportunity to overcome the active efflux of 
antibodies from the brain parenchyma by these neonatal Fc receptors (Razpotnik, Novak et al. 
2017). Antibodies can be engineered to improve their crossing of the blood brain barrier and this 
can be done by piggybacking on the receptors that allow receptor mediated transcytosis. The 
transferrin receptor was an early target for receptor mediated delivery across the BBB, it is highly 
expressed in the brain vasculature and functions to shuttle iron into the brain. A mouse anti-rat 
transferrin receptor antibody known as OX26 was developed with the aim of crossing the BBB, this 
antibody binds to the receptor without altering its ability to bind iron, allowing it to perform its 
normal function. Conjugation of this antibody with therapeutic peptides was shown to improve 
their delivery to the brain (Jones, Shusta 2007). One issue that arose when using antibodies to 
target the transferrin receptor is the affinity of these antibodies for the receptor prevented their 
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release from the receptor preventing therapeutic delivery to the brain. In order to improve the 
delivery of potential payloads attached to the transferrin antibody the antibody affinity was altered 
by genetic engineering, reducing the affinity of these antibodies improved their delivery throughout 
the brain. These antibodies can be engineered to have one arm specific for the transferrin receptor 
and the other arm can be specific for an antigenic target of choice, creating a bispecific antibody 
(Watts, Dennis 2013). The insulin receptor is also a viable target for crossing the blood brain barrier, 
a bispecific antibody targeting amyloid beta and the human insulin receptor has previously been 
developed and tested in monkeys (Stanimirovic, Kemmerich et al. 2014). This method would be of 
great use to shuttle an antibody specific for PD-1/PD-L1 directly into the brain allowing it to improve 
its tumour penetration and activity. Single chain variable fragments (scFvs) are fusion proteins 
composed of the variable regions of the heavy and light chains of immunoglobulins joined by a 
peptide linker. Previously a scFvs has been developed with a cell penetrating peptide (CPP) as the 
linker between the light and heavy variable regions. These scFv-CPP molecules were shown to cross 
the blood brain barrier and penetrate the brain parenchyma in mice given I.V. doses of scFv-CPP 
(Skrlj, Drevensek et al. 2013). 
Another alternative way to deliver therapeutic antibodies across the blood brain barrier is the 
utilisation of nanoparticles or liposomes. These liposomes and nanoparticles can be altered to 
improve their blood brain barrier crossing, this can be done by giving the nanoparticles a positive 
charge increasing their adsorption mediated transcytosis. These nanoparticles can also be 
synthesised to hijack the receptor mediated transcytosis systems, either by incorporating 
antibodies directed against the receptors, or ligands for these receptors on the surface of these 
nanoparticles. Liposomes can be used to encapsulate and deliver antibodies, this encapsulation 
prevents the enclosed antibodies binding to their targets outside of the tumour location, preventing 
potential off target effects and enhancing tumour delivery (Razpotnik, Novak et al. 2017). 
Magnetoliposomes are magnetic nanoparticles that can be physically directed using magnetic fields, 
this can enable specific delivery to the brain and even aid tumour targeting of the therapeutic 
payload (Razpotnik, Novak et al. 2017). It is also important to note that not just antibodies can be 
loaded into these nanoparticles, other therapeutics such as carnosine can be loaded preventing 
their degradation and enhancing their tumour delivery.  
Stem cells can also be used to deliver therapeutic antibodies to tumours located within the brain. 
Stem cells display a tropism towards tumour sites, stem cells can actively penetrate tumours and 
can inhabit hypoxic regions within tumours even crossing the blood brain barrier to access 
intracranial tumours. Stem cells can be genetically modified to express antibodies or scFvs, previous 
research has found that these stem cells can penetrate tumours and locally deliver therapeutic 
antibodies. Whilst these stem cells show promise they also have some down sides; stem cells have 
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been shown to produce anti-inflammatory cytokines which aren’t conducive for their use in the 
immunotherapy setting (Frank, Najbauer et al. 2010). One major concern associated with the use 
of stem cells is the potential of stem cells to become tumorigenic exacerbating the problem they 
are designed to remedy. It has been shown that mixing bone marrow derived stem cells with breast 
cancer cells leads to induction of xenografts with increased metastatic potential, this was attributed 
to secretion of the chemokine CCL5 by the stem cells. Bone marrow derived stem cells have also 
been shown to spontaneously transform into cells with a malignant phenotype when cultured in 
vitro, however these results have been refuted and transformation has been attributed to culture 
environments (Zhang, C. L., Huang et al. 2017). Despite the fear of tumorigenesis steps can be taken 
to prevent this being a concern and a rigorous stem cell selection process can stop potentially 
tumorigenic stem cells being administered (Zhang, C. L., Huang et al. 2017). 
 
8.7. Improving immune cell transit into the brain of vaccinated mice 
Much like antibody therapies; focused ultrasound can be used to improve immune cell entry into 
tumours located within the brain. NK-92 is a human NK cell line that can be transduced with 
chimeric antigen receptors enabling it to specifically target tumours. In a pre-clinical model of 
breast cancer brain metastases NK-92 cells were transduced with a HER2 receptor enabling them 
to target MB-231-HER2 cells located within the brains of athymic nude mice. Focused ultrasound 
was applied to the brain of tumour bearing mice injected with these HER2 specific NK-92 cells. 
Focused ultrasound was shown to result in a 5-fold increase in the number of NK-92 cells within the 
tumour, these NK-92 cells maintain their function and these cells cause the apoptosis of tumour 
cells, meaning that ultrasound does not appear to affect their activity (Alkins, Burgess et al. 2013). 
Unlike NK cells, T-cells can actively cross the blood brain barrier however this entry is tightly 
controlled. In order for T-cells to traverse the blood brain barrier they need to make direct contact 
with it, resulting in the ‘capture’ of the T-cell. The ligand P-selectin glycoprotein ligand-1 on the 
surface of T-cells binds to selectins on the surface of the blood brain barrier endothelial cells 
alternatively α4-integrins on the surface of T-cells can bind vascular cell adhesion molecule (VCAM) 
and mucosal addressin cell adhesion molecule (MAdCAM-1). Once T-cells are ‘captured’ they roll 
along the blood brain barrier endothelial cells at a slowed rate, resulting in increased cell adhesion 
to the endothelial cells. Once T-cells have been sufficiently slowed they start to protrude into the 
endothelium. Cells can then migrate across the endothelium in two distinct manners: transcellular 
diapedesis where immune cells travel through the endothelial cells directly and paracellular 
diapedesis where cells pass through the junctions between the endothelial cells (Banks, Erickson 
2010, Engelhardt, Ransohoff 2012). Once T-cells have penetrated the endothelial layer they need 
to breach the underlying glia limitans in order to reach the brain parenchyma. Matrix 
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metalloproteinases (MMPs) regulate the crossing of T-cells across the glia limitans, MMP-2 and 
MMP-9 activity is necessary for this to occur. MMP2 and MMP-9 cleave β-dystroglycan on astrocyte 
end feet enabling immune cell penetration of the parenchyma (Engelhardt, Ransohoff 2012). 
Antigen specific CD8 T-cells have been shown to specifically shuttle across the blood brain barrier 
to access peptides located within the brain. The presence of immunogenic peptide in the brain 
results in up regulation of MHC class I on the luminal side of endothelial cells within blood vessels. 
This increased MHC class I expression results in increased peptide specific CD8 T-cell crossing of the 
blood brain barrier (Galea, Bernardes-Silva et al. 2007). The presence of the blood brain barrier 
protects the brain from unnecessary T-cell infiltration and potential inflammation of the brain. In 
GBM the blood brain barrier is compromised and is ‘leaky’ compared to the healthy blood brain 
barrier, there are high levels of heterogeneity of this disruption and it varies from case to case. Not 
only does the blood brain barrier pose a challenge for immunotherapy there is also the blood 
tumour barrier to consider. Blood vessels associated with glioblastoma upregulate the adhesion 
molecule tenascin C (TNC), this captures T-cells and prevents their crossing of the blood vessels 
(Quail, Joyce 2017). Previous research has shown that T-cells can be engineered to express ligands 
for adhesion molecules on endothelial cells improving their capture and crossing of the blood brain 
barrier, enabling more efficient tumour targeting (Platten 2018). One of the oldest methods used 
for increasing penetration of the blood brain barrier is osmotic disruption using mannitol. Infusion 
of hyperosmotic mannitol results in endothelial cell shrinking and the subsequent opening of the 
gap junctions. Unfortunately, osmotic disruption of the blood brain barrier is non-specific and as a 
result a variety of molecules can leave and enter the brain resulting in potentially fatal oedema and 
toxicity (van Tellingen, Yetkin-Arik et al. 2015).  
It is important to note that there is dysfunction of the blood brain barrier in GBM with down 
regulation of the proteins that form the tight junctions in the BBB (Wolburg, Wolburg-Buchholz et 
al. 2003). This dysfunction of the blood brain barrier explains the cerebral oedema frequently 
observed in GBM patients. In vitro experiments have revealed that GBM cells secrete factors that 
lead to the increase in the leakiness of an in vitro model of the BBB as indicated by transepithelial 
electrical resistance (Schneider, Ludwig et al. 2004). Invading glioblastoma cells can also lead to a 
physical disruption of the architecture of the blood brain and blood tumour barriers. GBM cells 
utilise blood vessels as a route for invasion and they co-opt blood vessels to aid their growth. These 
GBM cells displace astrocyte end feet from their perivascular location, the presence of just a small 
number of cells in these perivascular locations is enough to increase the permeability of the blood 
brain barrier. This finding was confirmed to be due to the tumour implanted within the brains of 
mice and not due to the surgical procedure used to implant tumours, control mice underwent the 
same surgical procedure but rather than having GBM cells injected into their brains non-malignant 
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glial cells were implanted. These animals didn't have the same leakiness as that observed in GBM 
harbouring mice (as indicated by Evans blue dye exclusion) (Watkins, Robel et al. 2014).  
 
8.8. Incorporation of immunotherapy into standard therapy 
When utilising immunotherapy for the treatment of GBM it would be of great benefit to combine 
immunotherapy with standard therapy. Unfortunately, some of the therapeutics utilised for GBM 
are known to have immunosuppressive properties. Dexamethosone is a steroidal anti-inflammatory 
drug that is used to control oedema in GBM patients. Due to its anti-inflammatory properties 
dexamethasone is immunosuppressive, it is quite common for dexamethasone to be utilised to 
control adverse responses to immunotherapy dampening potentially deleterious immune over 
activation. Dexamethasone is a well-known immunosuppressor and as a result if patients receive 
immunotherapy they should cease dexamethasone therapy (Platten 2019). In vitro experiments 
have shown that dexamethasone inhibits healthy CD8 and CD4 T-cell division (Giles, Hutchinson et 
al. 2018). Dexamethasone also appears to alter the maturation of dendritic cells in vitro; these 
dendritic cells also seem to secrete higher levels of anti-inflammatory cytokines whereas dendritic 
cells that weren’t exposed to dexamethasone secreted more pro-inflammatory cytokines. 
Dexamethasone also seems to decrease the CD4 T-cell priming by dendritic cells (Falcon-Beas, 
Tittarelli et al. 2019). Seeing as dexamethasone has immunosuppressive effects an alternative 
method for reducing oedema in GBM patients’ needs to be explored. Bevacizumab is an anti-VEGF 
antibody that can potentially be used to reduce oedema in GBM patients without generating any 
immunosuppressive side effects. However as mentioned previously antibodies aren’t very good at 
penetrating intracranial tumours therefore their penetrance would need to be improved using the 
aforementioned methods. Studies using Bevacizumab for GBM patients have revealed that it 
reduces oedema in a durable manner (Ananthnarayan, Bahng et al. 2008, Ellingson, Cloughesy et 
al. 2012). 
GBM patients are also treated with radiotherapy and temozolomide chemotherapy, the current 
‘gold standard’ for GBM therapy. Temzolomide and radiotherapy can have both immune 
suppressive and immune activating effects and when utilising immunotherapy an optimum dosing 
schedule needs to be used when combining standard therapy with immunotherapy. When studying 
patients receiving standard radiotherapy and TMZ chemotherapy their CD4 T-cell count can be seen 
to reduce post therapy and this reduced CD4 count was shown to be linked with reduced survival 
(Grossman, Ye et al. 2011). Whilst CD4 T-cell count is seen to go down it is important to note that 
some of these CD4 cells may potentially be CD4 regulatory T-cells, these can be negative regulators 
of the anti-tumour immune response. In a pre-clinical rat model harbouring subcutaneous GBM 
cells it was shown that low dose metronomic (frequent low doses) temozolomide chemotherapy 
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results in a decrease in the number of regulatory T-cells located within the spleens and tumours of 
these rats (Banissi, Ghiringhelli et al. 2009). Pre-clinical murine work has revealed that when the 
standard temozolomide dosing regime is employed, the anti-tumour effects of PD-1 blockade are 
abrogated, however when utilising metronomic dosing (frequent low doses) of temozolomide the 
anti-tumour effects of anti-PD-1 therapy remain (Platten 2019).  Radiotherapy appears to enhance 
anti-tumour immunity so its combination with immunotherapy is very enticing. Radiotherapy can 
increase tumour immune recognition by increasing the expression of MHC class I, irradiation also 
leads to increased immune cell infiltrate into tumours and increased antigen recognition (Chow, 
Hara et al. 2015). Another important phenomenon to take into account is the abscopal effect, this 
is when radiation applied to one tumour site leads to regression of tumours at a distal site, and this 
indicates that the irradiation of the tumours results in increased T-cell activation that can result in 
eradication of tumours located throughout the body (Chow, Hara et al. 2015). Combination of 
radiotherapy with anti-PD-1 immune checkpoint blockade has been shown to improve long term 
survival in an orthotopic mouse model of GBM. This combinatorial therapy resulted in a reduced 
number of regulatory T-cells and an increase in the number of CD8 effector cells within the brain 
tumours (Zeng, See et al. 2013). Radiotherapy combined with IDO blockade and anti-PD-1 therapy 
has been shown to have a similar synergistic effect with mice given combinatorial IDO blockade, 
anti-PD-1 and radiotherapy resulted in long term survival, the addition of temozolomide to this 
treatment regime reduced the number of long term survivors to a third of that when utilising the 
treatments without chemotherapy (Ladomersky, Zhai et al. 2018). Radiotherapy leads to an 
increase in IFNγ secretion by tumour cells and this may help to explain why PD-1 blockade and anti-
IDO therapy combine so well with this method of therapy. Combined chemotherapy and 
radiotherapy has been shown to lead to an upregulation of IFNγ by murine melanoma (B16-F10) 
and GBM (GL261 Luc2) cell lines, this was linked to increased PD-L1 expression on the surface of 
these cell lines (Derer, Spiljar et al. 2016). The effects of standard radio-chemotherapy were studied 
by analysing the PBMCs of GBM patients before and after therapy. Standard therapy resulted in a 
significant decrease in the white blood cell count of patients, decreases were observed in the CD3 
and CD4 cell count however there was no significant decrease in the number of CD8 cells. 
Treatment was also shown to lead to a significant increase in the number of regulatory T-cells within 
the PBMCs of GBM patients (Fadul, Fisher et al. 2011). 
These data indicate that there needs to be an optimisation of the usage of standard therapy when 
combining it with immunotherapy, simple adjustments can help the two modalities work in a 
beneficial manner, however this will need further research. It is also important to take into account 
the fact that some patients are resistant to temozolomide chemotherapy due to expression of the 
MGMT protein.  
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8.9. Concluding remarks 
In order to develop an effective therapy for glioblastoma multiforme numerous factors need to be 
taken into account. Just in the context of immune evasion GBM cells adaptively upregulate immune 
escape ligands and cytokines. It is also important to take into account other factors that affect the 
immune system, a patient’s mental status can affect the efficacy of immune therapies. A diagnosis 
of cancer can be highly stressful especially with a terminal cancer such as glioblastoma multiforme. 
The hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic–adrenal medullary (SAM) axis 
are two major neuronal-hormonal axes that can affect the immune system; these axes lead to 
secretion of cortisol and catecholamine that can interact with immune cells and alter their activity. 
Stress can lead to a shift from a Th1 CD4 T-cell profile to a Th2 CD4 T-cell profile, result in a reduced 
antibody response to vaccination and lead to increased incidence of illness (Padgett, Glaser 2003). 
Immunotherapy definitely represents an attractive therapeutic option for the treatment of GBM, 
and the ImmunoBody® vaccine represents an attractive method of generating tumour specific T-
cells. In order to treat established tumours the combination of ImmunoBody® vaccination with 
other treatment modalities needs to be explored. The addition of an anti-PD-1 antibody to the 
ImmunoBody® vaccination schedule resulted in a marginal increase in the survival of intracranial 
tumour bearing mice however this was not deemed significant. One issue that needs to be taken 
into account is the ability of the anti-PD-1 antibody to access the tumour as a result it would be of 
great interest to examine methods for improving antibody penetrance of the blood brain barrier. 
Addition of this therapy to standard therapy is also worthy of further investigation, it may be worth 
considering the combination of this approach with radiotherapy. It is also worth considering 
cessation of TMZ and dexamethasone therapy due to their immunosuppressive nature. It is also 
worth noting that TMZ is not efficacious in all cases due to the presence of the MGMT protein in 
some patients’ tumours.  
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APPENDICES 
 
Appendix 1. IHC staining breakdown of GBM tissues 
 
 Antigen  
HAGE  TRP-2  WT-1  gp100 MGMT HLA-ABC HLA-E HLA-G PD-L1 
Case 1 
Male 38 
GBM  
         
Case 2 
Male 31 
GBM  
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Case 3 
Male 20 
GBM  
         
Case 4 
Female 
19 GBM 
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Case 5 
Male 43 
AA  
         
Case 6 
Female 
59 GBM  
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Case 7 
Male 40 
GBM 
         
Case 8 
Male 24 
GBM 
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Case 9 
Male 1 
GBM  
         
Case 10 
Male 75 
GBM 
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Case 11 
Female 
41 GBM  
         
Case 12 
Male 51 
GBM 
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Case 13 
Female 
58 GBM  
         
Case 14 
Female 
31 GBM 
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Case 15 
Female 
11 GBM  
         
Case 16 
Female 
51 GBM 
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Case 17 
Female 
22 GBM  
         
Case 18 
Male 33 
GBM 
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Case 19 
Male 73 
GBM  
         
Case 20 
Male 43 
GBM  
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Case 21 
Female 
61 GBM  
         
Case 22 
Male 26 
GBM  
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Case 23 
Male 59 
GBM  
         
Case 24 
Female 
40 AA  
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Case 25 
Male 34 
GBM 
         
Case 26 
Female 
33 AA  
         
279 
 
Case 27 
Male 40 
GBM  
         
Case 28 
Female 
58 GBM 
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Case 29 
Female 
33 GBM 
         
Case 30 
Female 
44 GBM  
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Case 31 
Male 26 
GBM 
         
Case 32 
Female 
48 GBM 
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Case 33 
Male 43 
GBM  
         
Case 34 
Female 
30 GBM  
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Case 35 
Female 
42 GBM 
         
Normal 
brain 
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Appendix 2. Break down of the flow cytometry histograms for each GBM cell line 
 
Appendix 2 Figure 1. SEBTA-025 the green peaks represent unstained cells whereas the red peaks 
represent stained cells 
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Appendix 2 Figure 2. SEBTA-027 the green peaks represent unstained cells whereas the red peaks 
represent stained cells 
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Appendix 2 Figure 3. SF-188 the green peaks represent unstained cells whereas the red peaks 
represent stained cells 
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Appendix 2 Figure 4. UP-007 the green peaks represent unstained cells whereas the red peaks 
represent stained cells 
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Appendix 2 Figure 5. UP-019 the green peaks represent unstained cells whereas the red peaks 
represent stained cells 
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Appendix 3. An example flow cytometry plot obtained from B16HHDII intracranial tumour 
infiltrating lymphocytes 
Appendix 3 Figure 1. Breakdown of flow cytometry staining of CD8+ TILs. A) Live CD3+ cells were 
gated out of the TIL population and then in B) CD3+ cells were then split into CD4+ and CD8+ cells 
which were then further probed. C) Dot plot of CD69 and PD-1 stained CD8+ cells D) Dot plot of CD44  
and CD62L stained CD8+ cells E) Dot plot of CD25 and FoxP3 stained CD8+ cells. 
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Appendix 3 Figure 2. Breakdown of flow cytometry staining of CD4+ TILs. A) Live CD3+ cells were 
gated out of the TIL population and then in B) CD3+ cells were then split into CD4+ and CD8+ cells 
which were then further probed. C) Dot plot of CD69 and PD-1 stained CD4+ cells D) Dot plot of CD44 
and CD62L stained CD4+ cells E) Dot plot of CD25 and FoxP3 stained CD4+ cells. 
 
